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DENDRITIC CELLS AS CANCER VACCINES
Dendritic cells (DCs) are antigen-presenting cells that initiate and direct adaptive 
immune responses. Upon activation, they show a burst of antigen uptake, mature and 
travel to lymph nodes where they can drive naïve T cell activation and polarization. 
As such, they are considered excellent candidates for therapeutic cancer vaccines, 
which holds the great promise for re-calibration of the existing host-tumor interaction, 
tipping the balance from tumor tolerance towards tumor control. The goal of cancer 
immunotherapy is to elicit cytotoxic antigen-specific CD8+ T cell responses and thereby 
eliminate cancer cells via cellular immunity. Although numerous vaccination studies 
showed the immunogenicity of tumor-associated antigens introduced by dendritic cells 
[1–3], limited clinical success has been achieved with these vaccines. Likely, this is 
at least partially attributable to the local suppressive environment at the tumor site. 
Optimal DC maturation may help overcome the local suppression. Due to limited access 
to human tissue and blood DCs, much of our knowledge has come from mouse models 
and monocyte-derived DCs (moDCs). Thus far, virtually all clinical trials were based on 
ex vivo generated DCs, either derived from monocytes or CD34+ progenitor-cells. More 
recently, the understanding and the use of primary human DCs in cancer vaccination 
strategies has become within reach through efficient isolation techniques. Primary DCs 
are hypothesized to be stronger inducers of anti-cancer responses than monocyte-
derived DCs since they differentiate in vivo and require only short ex vivo handling. 
Optimal stimulation of DCs used for cancer immunotherapy is essential to mediate 
immune responses that will be sufficiently robust and long-lasting to induce tumor 
regression and/or eradication and overcome the suppressive tumor microenvironment. 
In order to manipulate T cell responses in DC-based therapeutic strategies, a better 
understanding of the primary human DC subsets and their functional specialization is 
needed.
THE ROLE OF DC MATURATION 
The rationale behind DC-based cancer vaccines is the unique capacity of DCs to activate 
naïve and memory T cells and orchestrate an immune response. In the last two decades, 
we became to understand the life-cycle of a DC and how maturation primes them for 
induction of immune stimulatory responses. Immature DCs reside in peripheral tissues, 
where they can recognize and capture antigens. Upon activation, the DCs migrate to 
lymph nodes and other lymphoid tissues where they can initiate cellular responses. 
They present the captured antigens to CD4+ T cells via major histocompatibility complex 
(MHC) class II. Furthermore, DCs excel at cross-presentation, in which extracellular 
antigens are presented in MHC class I to CD8+ T cells and therefore allows cross-
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priming. The immune response initiated by the DCs depends on the signal that the 
DC receives upon encounter of the antigen. DCs can induce and regulate immunity 
against pathogens and tolerance against self-antigens and commensal microorganisms 
[4–6]. When no inflammatory or infection signal is sensed by the DC in the context of 
the antigen uptake, the DC will generally induce tolerance to what probably represents 
a self-antigen. On the other hand, DCs undergo a maturation process when - during 
antigen uptake - they are stimulated by pathogen-associated molecular patterns 
(PAMPs) via pattern-recognition receptors (PRRs) that are abundantly expressed on 
DCs [20]. Also proinflammatory cytokines such as interleukin (IL)-1, IL-6, IL-8 or 
TNF-α and damage-associated molecular pattern molecules (DAMPs) such as nuclear 
or cytosolic proteins can trigger specialized receptors or PRRs, respectively. PRRs on 
DCs include C-type lectin receptors, NOD-like receptors, RIG-I-like receptors and DNA 
receptors. These receptors detect pathogen specific proteins, lipids, carbohydrates and 
nucleic acids. A widely studied class of PRRs is the Toll-like receptor (TLR) family. To 
date, 10 different TLRs have been identified in humans that are either expressed on the 
surface (TLRs 1, 2, 4-6) or in endocytic compartments (TLRs 3, 7-10) and all recognize 
different molecular patterns (summarized in [7]). To induce maturation of DCs for 
cancer vaccines, agonists of TLRs are frequently used to imitate the encounter with a 
virus or bacterium. Dendritic cell maturation involves drastic phenotypical and functional 
changes which include an increase in the surface expression of MHC, migratory as 
well as co-stimulatory molecules, a burst in antigen-uptake and processing, and the 
induction of cytokine production. The term mature is often used not only functionally 
to designate immunogenic DCs but also to describe this phenotypic transformation. 
These changes in the DC prepare it for traveling to lymphoid organs where they prime 
antigen-specific T cells to become effector T cells. 
The education of T cells by DCs is based on three fundamental signals (figure 1). 
The first signal is the recognition of antigen by the TCR on T cells presented in the 
context of MHC molecules on DCs. This interaction mediates antigen specificity and T 
cell activation by downstream signaling of the TCR. The second signal is mediated by 
co-stimulatory and co-inhibitory molecules on DCs which further activate T cells and 
induce expansion or attenuate the T cell response, respectively [8]. The third signal 
determines the polarization of the T cells and is mediated by DC-derived cytokines. 
Dendritic cells are capable of educating naïve T cells into a range of effector cells 
including immunogenic CD4+ Th cells, cytotoxic CD8+ T cells as well as tolerogenic 
regulatory T cells (Tregs). Regulatory T cells cannot only be induced by cytokines, but 
also by an enzyme named indoleamine 2,3-dioxygenase 1 (IDO). IDO enzymatically 
converts L-tryptophan in L-kynurenine and therefore marks the first and rate-limiting 
step in tryptophan catabolism. Decreases in tryptophan and increases of tryptophan 
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metabolites inhibit T cell proliferation [9–11], induce anergy and apoptosis [11–13] 
and drive naïve CD4 T cells towards differentiation into regulatory T cells [14,15].
DC
T cell
Signal I
Signal II
Signal III
TCRMHC 
Figure 1 | Signals from dendritic cell to T cell. The cues a T cell receives from a DC can be of 
differing nature depending on the intensity and type of signal. Besides TCR engagement by antigen 
in MHC molecules (Signal I), there is a variety of co-stimulatory and co-inhibitory signals provided via 
ligand-receptor interactions (Signal II) and polarizing signals in the form of soluble factors (Signal III). 
All together decide the response of the T cell. 
In order for DC-based immunotherapy to elicit potent anti-tumor T cell responses, 
the administered DCs need to raise an immune stimulatory rather than tolerogenic T 
cell response. For example, the presence of interleukin (IL)-12 and type I interferons 
(IFNs) promotes the induction of Th1 cells, whereas IL-10 or expression of IDO inhibits 
induction of Th1 cells and promotes the differentiation of Tregs [14–17]. In anti-viral 
responses, Th1 cells and antigen-specific cytotoxic CD8+ T cells are elicited to eradicate 
cells infected by the virus. This type of immune response is also highly desirable in 
anti-tumor strategies, in which the aim is to eradicate tumorous cells by cytotoxic CD8+ 
T cells.
MONOCYTE DERIVED DC MATURATION FOR CANCER 
IMMUNOTHERAPY
To date, mainly ex vivo generated moDCs have found application in the clinic. MoDCs 
are DCs differentiated ex vivo from monocytes. In about 6 days, the addition of the 
cytokines GM-CSF and IL-4 allows generation of a large number of moDCs [18,19] 
Several clinical studies comparing immature and mature moDCs proved that mature 
moDCs induced significantly better T cell and clinical responses than their immature 
counterparts. Jonuleit et al. compared mature (maturation with PGE2, TNF-α, IL-1β and 
IL-6) and immature moDCs and found that only mature moDCs induced the expansion 
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of syngeneic tumor peptide-specific CD8+ T cells that showed strong antigen-specific 
cytotoxicity [20]. They also showed that while mature moDCs induced increased recall 
antigen-specific CD4+ T-cell responses in 87,5% of patients, immature moDCs did so in 
only 37,5% [21]. Superior immunological responses induced by matured moDCs were 
shown by a several studies performed by different groups and in different cancer types 
[22,23].
We know today that maturation is key to immunogenic DC activity and that steady-state 
DCs can induce tolerance [24,25] or T cell anergy or deletion [26,27]. Different ways to 
mature moDCs have been investigated with the goal to induce cellular immunity. Since 
IL-12 is a key driver of cellular immunity, different maturation cocktails were developed 
with a special attention to induce IL-12 secreting DCs. Factors used to mature moDCs 
include CD40 ligand (CD40L), tumor necrosis factor-α (TNF-α), IFN-α and IFN-γ. Direct 
activation by PAMPs can be mimicked using agonists for PRRs such as TLR3 ligand 
polyinosinic:polycytidylic acid (polyI:C), TLR4 ligand LPS,  TLR7/8 ligand imiquimod 
(R848) and oligodeoxynucleotides (CpG) binding TLR9. 
To better imitate an inflammatory environment, cocktails combining several factors 
have also been used. These factors include prostaglandin E2 (PGE2), IL-1β and IL-
6. PGE2 induces maturation and strong CCR7 expression and migration capacity in 
moDCs and was widely used in initial maturation cocktails. However, encounter with 
CD40L-expressing cells following PGE2 stimulation limits the production of IL-12 and 
CCL19, a T cell attractant [28–30]. Furthermore, PGE2 induces the production of IL-
12p40, but inhibits the active IL-12p70 heterodimer [31]. PGE2 also primes DCs for 
preferential interaction with Tregs; Tregs are attracted through elevated production 
of CCL22 even after the removal of PGE2 [32]. The addition of poyI:C and R848 to 
PGE2 resulted in potent IL-12 production and Th1 polarization while also maintaining 
CCL21-directed migration [33]. The advantage of combining PGE2 and TLR ligands has 
been supported by another study with the TLR7/8 ligand CL075 [34], but also partially 
challenged in a study where the presence of PGE2 during TLR ligation fully restored 
migratory capacity of moDCs, but left IL-12p70 production and activation of tumor 
antigen-specific cytotoxic T cells unaffected [35]. 
IFNs play a central role in the initiation of innate and adaptive immune responses and 
can be used alone or in combination with other factors to mature moDCs. Several 
studies show that IFN-α induces the differentiation and maturation of moDCs and also 
IFN-γ can be used to mature moDCs, leading to the secretion of large quantities of IL-
12 and induction of Th1 cells [36–40].
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HUMAN BLOOD DC SUBSETS
Although, due to practical reasons, most clinical DC vaccination trials have been 
performed with monocyte-derived DCs, primary DCs may be more potent inducers of 
anti-cancer responses since they differentiate in vivo and require only short ex vivo 
handling. In peripheral blood, at least two major types of DCs can be distinguished, 
namely myeloid DCs (mDC) and plasmacytoid DCs (pDCs) [41,42] (figure 2). 
Myeloid DCs express high levels of CD11c and can further be subdivided based on 
the differential expression of either CD1c (blood dendritic cell antigen 1 = BDCA1) or 
CD141 (BDCA3). While CD1c+ mDCs and pDCs constitute a mere ~0,6% and ~0,3% of 
peripheral blood mononuclear cells (PBMCs), respectively, CD141+ mDCs are extremely 
scarce and represent only about 0,03% of PBMCs. Differences in their transcriptional 
profile, their repertoire of Toll-like receptors and cytokines produced upon stimulation 
suggest specialized functions [43–47]. Plasmacytoid DCs express mainly TLR7 and 
TLR9. Both mDC subsets express TLR3 and TLR8 among others, although expression 
levels of TLR3 are much higher in CD141+ mDCs [47]. 
TLRs
type I IFNs
TLRs
IL-12
CD141+mDC
TLRs
CD1c+mDC
IL-12
PlasmacytoidDendritic Cells Myeloid Dendritic Cells
IFN-λ
Figure 2 | Human blood DC types. In peripheral blood, two major types of DCs can be distinguished, 
namely myeloid DCs (mDC) and plasmacytoid DCs (pDCs). Myeloid DCs can be subdivided based on 
the differential expression of either CD1c or CD141. Differences in their transcriptional profile, their 
repertoire of Toll-like receptors (TLRs) and cytokines produced upon stimulation suggest specialized 
functions. 
The large amounts of type I IFNs that are produced by pDC upon activation, have 
pleiotropic effects on the immune system and initiate and facilitate innate immune 
responses and an anti-viral state, but also support adaptive anti-tumor responses [48]. 
Plasmacytoid DCs also participate in priming T helper (Th) cells, depending on the 
stimulus they receive (summarized in [49]). Steady-state pDCs can induce tolerance 
rather than an immune stimulatory response (summarized in [50]). To prevent tolerance, 
it is therefore important to induce maturation of pDCs in DC-based cancer vaccination 
|  Chapter 1
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strategies. For both pDCs and mDCs it has been shown that they induce proliferation 
in an allogeneic setting and that they can cross-present exogenous antigens to prime 
CD8+ T cells [51–56]. Upon TLR ligation, CD1c+ mDCs can produce a variety of cyto- 
and chemokines that attract T cells or act pro-inflammatory [42,45,57]. CD141+ mDCs 
possess a more limited repertoire of TLRs as well as cyto- and chemokines compared 
to CD1c+ mDCs [43,45,54,58–61] and especially TLR3 is uniquely highly expressed as 
compared to CD1c+ mDCs and pDCs. TLR3 recognizes retroviral double-stranded RNA, 
which points to an anti-viral function of CD141+ mDCs. Importantly, both mDC subsets 
have the capacity to produce the Th1-skewing cytokine IL-12. 
To date, our knowledge of the functional differentiation of the blood DC subsets is 
limited. However, the transcriptional and functional differences between blood DC 
subsets suggest they may also differ in their capacity to induce anti-tumor immunity.
SCOPE OF THIS THESIS
In this thesis, we examined and compared human blood pDC, CD1c+ mDCs and CD141+ 
mDCs with regard to different functions important for their use as cancer vaccines. 
Optimal stimulation of DCs used for cancer immunotherapy is essential to mediate 
immune responses that will be sufficiently robust and long-lasting to induce tumor 
regression and/or eradication and overcome the suppressive tumor microenvironment. 
Throughout this thesis we have used different strategies to stimulate the DCs and 
have compared the differing outcomes. Dendritic cells communicate in many ways 
with T cells. In chapter 2 we introduce and discuss the nature of activatory and 
tolerogenic dendritic cell-derived signal II, i.e. co-stimulatory and co-inhibitory 
molecules expressed on DCs. We functionally assessed each subset with regard to 
its T cell polarizing capacities in chapter 3. We compared the induction of T cell 
proliferation, the induction of Tregs and importantly the cytokine profile of naïve CD4+ 
T cells after co-culture with the different subsets (signal III). In chapter 4 we analyzed 
the capacities of the subsets to take up, process and present antigens to T cells. We 
studied whether the functional differentiation of the subsets extents to the capacity to 
cross-present antigens and therefore the cross-priming of CD8+ T cells, an important 
function in the context of cancer therapy. An interesting difference appeared to exist 
between the human blood DCs in the expression of the immune-inhibitory enzyme 
IDO. The functional role of IDO with respect to T cell proliferation and antigen cross-
presentation was assessed in chapter 5.
To avoid extensive ex vivo handling and to move towards an off-the-shelf approach 
for immune-stimulatory anti-tumor immunotherapy, we pursued the idea to target 
DCs with nanocarriers that could induce maturation while at the same time delivering 
General introduction  | 
17
1
tumor antigen. In chapter 6 we describe several possible targets on pDCs that can 
be targeted for this goal and could help advance this approach to in vivo application.
This thesis therefore provides extensive new insights into the functional specialization 
of human blood DCs which will help designing the next generation of DC-based cancer 
vaccines.
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ABSTRACT
Dendritic cells (DCs) are central in maintaining the intricate balance between immunity 
and tolerance by orchestrating adaptive immune responses. Being the most potent 
antigen presenting cells, DCs are capable of educating naïve T cells into a wide variety of 
effector cells ranging from immunogenic CD4+ T helper cells and ctyotoxic CD8+ T cells 
to tolerogenic regulatory T cells (Treg). This education is based on three fundamental 
signals. Signal I, which is mediated by antigen/MHC complexes binding to antigen-
specific T cell receptors, guarantees antigen specificity. The co-stimulatory signal II, 
mediated by B7 family molecules, is crucial for the expansion of the antigen-specific T 
cells. The final step is T cell polarization by signal III, which is conveyed by DC-derived 
cytokines and determines the effector functions of the emerging T cell. Although co-
stimulation is widely recognized to result from the engagement of T cell-derived CD28 
with DC-expressed B7 molecules (CD80/CD86), other co-stimulatory pathways have 
been identified. These pathways can be divided into two groups based on their impact 
on primed T cells. Whereas pathways delivering activatory signals to T cells are termed 
co-stimulatory pathways, pathways delivering tolerogenic signals to T cells are termed 
co-inhibitory pathways. In this review, we discuss how the nature of DC-derived signal 
II determines the quality of ensuing T cell responses and eventually promoting either 
immunity or tolerance. A thorough understanding of this process is instrumental in 
determining the underlying mechanism of disorders demonstrating distorted immunity/
tolerance balance, and would help innovating new therapeutic approaches for such 
disorders. 
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1. INTRODUCTION
The immune system is endowed with the unique capacity to protect against invading 
pathogens, yet not react to self. Among the different constituents of the immune 
system, dendritic cells (DCs) play a central role in drawing the thin line between 
immunity and tolerance. Discovered in 1973 [1], DCs are recognized as the most 
potent antigen presenting cells (APCs). Their ability to initiate and modulate various 
forms of T cell responses, earned them the position of being master orchestrators 
of adaptive immunity [2]. DCs are spread throughout the body, residing in different 
tissues as sentinels, monitoring their surrounding environment for any signs of danger. 
Equipped with pathogen recognition receptors (PRRs), DCs are capable of sensing 
pathogenic invasion [3] and self structures associated with cellular stress [4]. Upon 
danger sensing, DCs will undergo functional changes, also known as maturation, 
crucial for the ensuing induction of T cell responses [5]. A hallmark of DC maturation is 
the expression of the chemokine receptor CCR7 that allows mature DCs to migrate to 
draining lymphoid tissues where they activate naïve T cells in a process based on three 
signals. The first signal results from the ligation of T cell receptors (TCRs) to pathogen-
derived peptide antigens that are presented by major histocompatibility complex (MHC) 
molecules of DCs, which are upregulated upon maturation. This principal stimulation 
signal is important to assure antigen specificity of the immune response. Although 
TCR triggering is crucial for naïve T cell activation, it is not sufficient by itself to initiate 
an efficacious immune response. The concept of a second co-stimulatory signal was 
first introduced by Lafferty and colleagues. They deduced from organ transplantation 
studies that alloantigens presented by transplanted tissues failed to elicit any immune 
responses unless accompanied by hematopoietic stimulator cells [6]. This concept was 
corroborated by seminal observations by the group of Schwartz, implying that T cells 
activated solely by TCR engagement were rendered unresponsive and anergic [7]. This 
was followed by the discovery of the main elements of co-stimulation: CD28 [8] and 
CD80 [9], the latter being initially identified as a B cell activation marker and eventually 
recognized as the ligand of CD28 [10]. Subsequently, more pathways contributing 
to signal II were identified. Based on the nature of their signal, these molecules can 
be divided into co-stimulatory molecules that promote T cell proliferation, and co-
inhibitory molecules that attenuate T cell responses. The nature of signal II is vital in 
determining the T cell response, which is further defined by a third polarizing signal. 
This third signal promotes the selective development of naïve T cells into one of the 
identified types of effector or tolerogenic T cells [11]. Although signal III is generally 
recognized to be mediated by soluble DC-derived cytokines, there are indications that 
signal II may also contribute to T cell polarization. A final putative DC-derived signal 
is suggested to provide polarized T cells with homing directions to the site of infection 
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or injury [12]. Thus, DCs control the delicate balance between immunity and tolerance 
through the signals they convey to T cells. 
Although the combined effect of all DC-derived signals is important for full blown T cell 
responses, signal II is key for allowing these responses and licensing them to become 
either immunogenic or tolerogenic. Here, we shed light on the multifaceted signal II 
by reviewing current knowledge of to date identified co-stimulatory and co-inhibitory 
pathways (Fig. 1), their mode of action, relation to disease and any possible clinical 
applications based on utilizing these pathways.   
2. CO-STIMULATORY MOLECULES
2.1. CD80/CD86/CD28 pathway
Following the discovery of the CD80/CD28 interaction, B7-2 (CD86) was identified as a 
second ligand for CD28 [13]. The CD80/CD86/CD28 pathway was suggested to deliver 
the strongest co-stimulatory pathway as CD28 deficient cells failed to proliferate in the 
presence of APCs [14]. The consequences of CD28 engagement by its ligands comprise 
stimulation of T cell proliferation, dramatic upregulation of IL-2 [15], promotion of T 
cell survival by enhancing Bcl-XL expression [16] and enhanced glycolytic flux to meet 
energetic requirements associated with a sustained response [17]. Those effects were 
shown to be dependent on activating the signaling cascades of phosphoinositide-3 
kinase (PI3K), protein kinase B (PKB, also known as Akt) and nuclear factor kappaB 
(NF-κB) [18].
Several reports pointed out a possible role for CD28 signaling in T cell polarization. 
Murine T cells were shown to produce enhanced levels of IL-4 and IL-5, characteristic 
for T helper (Th) 2, upon strong CD28 stimulation [19]. Strong CD28 signaling was 
also demonstrated to inhibit Th17 responses [20]. Although it is generally accepted 
that memory T cells, unlike naives, are less dependent on co-stimulation via CD28, 
it was shown that this co-stimulatory pathway is important in controlling T cell recall 
responses [21]. 
In addition to its key role in initiating and sustaining efficient T cell responses, the CD28 
pathway is also involved in controlling immune tolerance. Co-stimulation of developing 
thymocytes by CD28 was shown to induce the expression of Foxp3 and promote the 
differentiation of Treg cells [22]. Furthermore, T cell activation in the absence of 
CD28 co-stimulation leads to a state of anergy characterized by dramatically reduced 
production of IL-2 and other effector cytokines upon subsequent TCR triggering [23]. 
There is ample evidence that DCs utilize this mechanism to maintain tolerance to self. 
At steady state conditions, immature DCs present self-derived antigens accompanied 
by low levels of CD80/CD86 and therefore fail to supply specific T cells with adequate 
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signal II, leading eventually to the deletion, anergy or regulation of auto-reactive T 
cells that escaped thymic selection [24]. Thus, the CD80/CD86/CD28 pathway is as 
involved in promoting tolerance as in mediating immunity.
Since many immunogenic tumors lack expression of CD80 and CD86, it was postulated 
that tumor-infiltrating T cells would receive chronic TCR stimulation without co-
stimulation leading to T cell anergy. This hypothesis was tested by inducing the 
expression of CD80/CD86 molecules on tumor cells prior to injection into mice. Forced 
expression of CD80/CD86 in tumor cells resulted into CD8+ T cell-dependent tumor 
rejection [25]. However, this method had barely any effect on pre-established tumors 
[26], implying that other pathways promoting immune tolerance towards established 
tumors are involved.
2.2. CD40/CD40L pathway
CD40 was the first co-stimulatory molecules to be identified from the TNF receptor 
(TNFR) family. First discovered as B cell receptor, CD40 is also expressed by DCs, 
macrophages, epithelial cells and even activated T cells. Its ligand (CD40L or CD154), 
a member of the TNF family, is expressed not only by activated T cells, but also 
by NK cells and plasmacytoid DCs (pDC) [27]. In addition to promoting humoral 
immunity by activating B cells, the CD40/CD40L pair is pivotal for cellular immunity as 
it mediates a dialogue between T cells and DCs. Indeed, CD40 engagement on DCs 
was shown to activate NF-κB pathway [27] and consequently inducing DC maturation 
[28] and enhancing DC longevity [29]. Initially, CD40-induced maturation of DCs was 
suggested to be sufficient in licensing CD8+ ctyotoxic responses  [30]. However, further 
investigation in the CD40 pathway revealed that additional signals are necessary for 
optimal DC activation. CD40 cross-linking alone is not enough to induce IL-12 production, 
necessary for cytotoxic and Th1 responses, but DC pre-activation by microbial products 
followed by CD40 ligation dramatically increased IL-12 production [31]. This finding 
indicates that combined triggering of CD40 and PRRs, like toll-like receptors (TLRs), is 
critical for DC licensing. The CD40-induced IL-12 also implies a central role for CD40/
CD40L pathway in T cell differentiation, by favoring Th1 polarization. Blocking CD40/
CD40L interactions lead to abrogated Th1 responses with reciprocal upregulation of 
Th2 cytokines [32].
The adjuvant effect of CD40 ligation, reflected by DC activation, prompted the 
application of agonistic anti-CD40 antibodies for cancer therapy. Injecting agonistic 
anti-CD40 antibodies evoked ctyotoxic T cell responses and eradicated the tumor in 
a mouse model of lymphoma [33]. Furthermore, application of fully humanized anti-
CD40 agonistic antibody resulted in objective partial responses in 14% of advanced 
solid tumor patients [34]. A similar approach was based on the administration of soluble 
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CD40L, which was less efficient as it lead to partial responses in 6% of treated tumor 
patients [35]. More clinical trials applying CD40 ligation, singularly or in conjunction 
with other therapeutic modalities, were carried out and showed promising results [36]. 
Due to its activatory nature, the CD40/CD40L is decisive in regulating tolerance. It 
was shown that DCs derived from CD40 deficient mice conferred tolerance by priming 
IL-10 secreting Treg cells [37]. This effect on tolerance prompted investigating the 
possibility of exploiting CD40 blocking to enhance allograft survival. Although applying 
anti-CD40L antibodies as a monotherapy was able to block many effector mechanisms, 
it failed to induce sufficient allograft tolerance [38]. However, combinations with other 
immunosuppressive therapies such as CTLA-4-Ig [39] and Rapamycin [40] were shown 
to result in long term graft survival. Collectively, CD40/CD40L pathway, in conjunction 
with other pathways, is vital for initiating active immunity and regulating tolerance. 
    
2.3. ICOSL/ICOS pathway
The inducible T cell co-stimulator, abbreviated ICOS, was identified as the third member 
of the CD28/CTLA-4 family of co-stimulatory molecules [41]. ICOS expression by T 
cells requires prior TCR activation and CD28 co-stimulation [42]. The ligand (ICOSL) 
is expressed by DCs [43], B cells and a variety of non hematopoietic tissues [44]. 
ICOSL/ICOS pathway exerts its co-stimulatory effects on already activated T cells by 
supporting proliferation and cytokine production [41]. Additionally, ICOS is proposed 
to play an important role in T cell polarization. Initially, ICOSL/ICOS was suggested to 
support Th2 responses. Blocking ICOSL/ICOS interactions was shown to block Th2-
lead airway responses without influencing Th1-mediated inflammation [45]. Similarly, 
another study showed that the majority of T cells expressing ICOS in vivo coproduced 
Th2-type cytokines [46]. In contrast, disrupting ICOSL/ICOS pathway was found to 
inhibit Th1-mediated disorders like allograft rejection [47] and experimental allergic 
encephalomyelitis (EAE) [48]. ICOS was shown to be involved driving Th17 responses 
[49], further complicating the role of ICOSL/ICOS in T cell polarization. An attempt 
to resolve this controversy was by showing that engaging ICOS on activated T cells 
amplified the effector responses of these cells regardless of their polarized state [50].
Benefiting of the activatory effect of ICOSL/ICOS pathway in the context of cancer 
therapy was evaluated. Induced ICOSL expression on tumor cells was demonstrated to 
promote tumor regression by inducing CD8 cytotoxicity [51]. Nevertheless, this strategy 
was ineffective in case of weakly immunogenic tumors [52]. Surprisingly, it was recently 
revealed that tumor cell-expressed ICOSL augments Treg activation and expansion 
within the tumor local environment [53]. This suggests that triggering ICOSL/ICOS 
pathway may not be the most optimal option for cancer treatment. On the contrary, 
blocking its ICOSL/ICOS mediated suppression may be beneficial in cancer therapy. 
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The tolerogenic effect of ICOSL/ICOS pathway is not restricted to tumors, as there 
are indications of its involvement in maintaining immune tolerance. ICOS deficient 
mice displayed reduced numbers of natural Tregs (nTregs), which may be owed to a 
decrease in survival and/or proliferation of these cells [54]. Another indication of ICOS 
involvement in tolerance is the finding that ICOS triggering on T cells dramatically 
increased the production of the anti-inflammatory cytokine IL-10 [41]. Consistently, 
high ICOS expression by T cells was selectively associated with the anti-inflammatory 
IL-10 [46]. These findings argue for targeting ICOSL/ICOS pathway to induce tolerance 
for therapeutic purposes. However, it is very important to clearly dissect the conditions 
under which this pathway induces activation or tolerance. 
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Figure 2: Signal II - co-stimulatory & co-inhibitory
molecules on DCs and T cells. A variety of ligands
and receptors on DCs and T cells induce signaling that
either promote or inhibit T cell proliferation, survival and
expression of cytokines.
Figure 1 | Co-stimulatory and co-inhibitory molecules and their cognate ligands. DC-derived 
signal II can promote T cell activation when conveyed by co-stimulatory molecules, or can attenuate T 
cell responses when onveyed by co-inhibitory molecules.  
2.4. CD70/CD27 pathway
CD70 is another member of the TNF family of co-stimulatory molecules. Its ligand CD27 
was identified first as a novel T cell differentiation antigen [55]. The contribution of 
CD27 to immunity was later recognized to be dependent on its binding partner CD70, 
which is expressed under the control of antigen receptors and TLRs in lymphocytes 
and DCs respectively [56]. Similar to CD40, engaging CD27 induced the activation of 
NF-κB pathway [57]. The first indication of the co-stimulatory properties of the CD70/
CD27 pathway was provided by triggering CD27, which augmented CD3-induced T 
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cell proliferation [55]. This effect was later explained by promoting survival of newly 
stimulated T cells, in contrast to CD28 that prompts cell cycle entry and induces 
proliferation [58]. This survival effect relies completely on IL-2 receptor signaling and 
the autocrine production of IL-2 [59].
The contribution of CD70/CD27 pathway to T cell polarization is debatable. CD8+ 
T cells from CD27 knockout mice maintained the capacity of differentiation into 
cytotoxic T lymphocytes and IFN-γ production, implying that CD27 is not involved 
in the development of cytotoxic CD8 responses [60]. On the other hand, transgenic 
expression of CD70 on steady state immature DCs was found to break CD8+ tolerance 
and permit the differentiation of effector CD4+ and CD8+ cells from naïve precursors 
[61]. Moreover, the murine CD8α+ DC subset was revealed to favor the differentiation 
of Th1 cells in a CD70-depndent and IL-12-independent mechanism [62]. This is further 
supported by showing that human Langerhans cells (LC), an epidermal subset of DCs, 
are capable of inducing CD8+ anti-viral responses in a CD70-dependent manner [63]. A 
recent study also demonstrated that CD70/CD27 pathway impedes the differentiation 
of Th17 effector cells and attenuates accompanying autoimmunity in a mouse model of 
multiple sclerosis [64]. These findings imply that CD70 involvement in T cell polarization 
may depend on the type of DCs expressing CD70 and the type of stimuli to which these 
DCs are exposed.
The activatory effect of CD70/CD27 pathway can be exploited for anti-tumor therapy. 
Induced expression of both CD70 and CD40L by tumor cells was shown to impede tumor 
growth and initiate anti-tumor immunity [65]. Furthermore, the application of CD70, 
encoded in a vaccinia virus, was shown to confer protection against introduced tumors 
[66]. Evidence for possible clinical benefit from mobilizing the CD70/CD27 pathway 
was provided by a recent clinical trial utilizing DCs expressing with CD70, CD40L 
and constitutively active TLR4 (TriMix-DC) in the treatment of metastatic melanoma 
patients. These TriMix-DCs were able to initiate a broad anti-tumor T cell response, 
resulting in prolonged progression-free survival [67]. This paves the way for a novel 
strategy in cancer immunotherapy based on mobilizing the CD70/CD27 pathway.
Several reports have implicated CD70/CD27 pathway in autoimmunity. Elevated 
expression of CD70 by pathogenic T cells was observed in rheumatoid arthritis [68] 
and lupus erythematosus patients [69]. Moreover, blocking CD70/CD27 pathway seems 
to help ameliorating inflammation in mouse models of arthritis [70] and colitis [71]. 
However, the study reporting Th17 inhibiting effects of CD70 signaling [64] may argue 
against the blockade of CD70/CD27 pathway, especially since Th17 effector cells are 
involved in various auto-inflammatory diseases.   
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2.5. OX-40L/OX-40 pathway
OX-40L and OX-40 belong to the TNF family and TNFR family respectively. OX-40, also 
known as CD134, was first described on activated CD4+ T cells [72]. The expression 
of OX-40 is in fact restricted to recently antigen-activated T cells and not naïve or 
memory T cells, implying that it is specialized in delivering co-stimulation to activated 
T cells [73]. The ligand, OX-40L (CD252), is expressed on DCs and macrophages, 
especially after TLR or CD40 ligation [74]. Additionally, responding T cells express 
OX-40L themselves [75]. Engagement of OX-40 on T cells promotes long term survival 
by inducing the expression of the anti-apoptotic molecules Bcl-2 and Bcl-xL [76]. This 
study suggests that the differential expression kinetics of OX-40 and CD28, the latter 
being constitutively expressed by T cells, bares functional specialization. Whereas 
CD28 is essential for the initial priming of naïve T cells into effector T cells, OX-40 is 
crucial for the expansion (later proliferation) and survival of these effector cells. 
Several studies have pointed out a central role for OX-40 in regulating the balance 
between Th1 and Th2 responses. Co-stimulating T cells through OX-40 was shown to 
induce IL-4 expression and inhibited IFN-γ production [77]. Furthermore, DC treatment 
with thymic stromal lymphopoietin (TSLP), known for its Th2 skewing properties, leads 
to the expression of OX-40L and the subsequent priming of Th2 cells [78]. OX-40-
favored Th2 response was proposed to be mediated by an initial induction of nuclear 
factor of activated T cells c1 in an IL-4 receptor independent manner, followed by an 
IL-4 receptor dependent effect on GATA-3 [79]. However, it was shown later that DC-
derived OX-40L maintained both Th2 and Th1 responses, owed to OX-40-enhanced 
survival of effector T cells regardless of their polarization [80].  Thus, it seems that the 
role of OX-40/OX-40L in the differentiation of Th2 cells is restricted to promoting the 
survival of already established Th2 cells that differentiated under the effect of other 
DC-derived factors. 
OX-40/OX-40L is also involved in controlling immune tolerance. The first evidence 
of this role is the expression of significant amounts of OX-40 on naturally occurring 
Foxp3+ Treg cells. OX40 signaling appears to be dispensable for the development 
of nTreg cells, since this population exists in OX-40 deficient mice. However, OX-40 
signaling is important for the survival of nTreg cells as OX-40 deficient mice displayed 
lower counts of this population of Treg cells [81]. The effect of OX-40 triggering on 
the functions of nTreg cells remains controversial. Whereas one study showed that OX-
40 signaling in CD4+ T cells render them resistant to suppression by nTreg cells [81], 
another study reported abrogated suppression following OX-40 triggering on nTreg 
cells [82]. Another mechanism by which OX-40L/OX-40 is assumed to contribute to 
tolerance regulation is by influencing the development of induced Treg cells (iTreg). 
Under conditions promoting iTreg differentiation, OX-40 engagement on T cells was 
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shown to inhibit Foxp3 expression by these T cells [83]. Nevertheless, the surrounding 
environment during iTreg differentiation seems to determine the outcome of OX-40 
signaling, which was reported to promote the expansion of iTreg cells if IL-4 and IFN-γ 
were absent from the milieu [84]. In conclusion, OX-40L/OX-40 appears to be central 
in maintaining the survival of T cells in general, but its influence on T cell functions 
requires further elucidation.   
2.6. 4-1BBL/4-1BB pathway
4-1BB (CD137) is yet another member of the TNFR family. Its expression is induced 
on T cells following TCR activation [85]. The ligand, 4-1BBL of the TNF family, is 
expressed on activated APCs [86]. Engagement of T cell 4-1BB was reported to induce 
IL-2 production independently of CD28, when accompanied by strong TCR signaling 
[87]. Furthermore, 4-1BB interaction with its ligand was demonstrated to provide a co-
stimulatory signal particularly to CD8+ T cells, enhancing proliferation, ctyotoxicity [88] 
and survival [89]. Similar to other TNFR family members, 4-1BB enhanced survival is 
dependent on NF-κB activation, which in turn induces the two pro-survival molecules: 
Bcl-xL and Bfl-1 [89]. When compared to co-stimulation with CD80/CD86, 4-1BBL 
appears to be more effective in driving CD8+ memory T cells into a fully differentiated 
effector state [90]. Furthermore, 4-1BB ligation was also shown to augment Th1 
cytokines and suppress Th2 cytokines, implying a possible role for 4-1BB in T cell 
polarization [91]. Collectively, these properties raised the interest in 4-1BBL/4-1BB 
pathway as potential therapeutic target especially in cancer therapy. Several studies 
demonstrated a beneficial effect of activating 4-1BB in inducing anti-tumor immunity 
and tumor regression thereafter [92]. Nevertheless, great caution should be taken 
before transferring these observations into clinical applications especially after 
reporting possible tolerogenic effects following 4-1BB triggering. Engaging 4-1BB by 
agonist antibodies was reported to ameliorate the severity of autoimmunity in murine 
models of experimental autoimmune encephalomyelitis (EAE) [93] and systemic lupus 
erythematosus [94], and to inhibit rejections of intestinal allografts in mice [95]. These 
findings imply a link between 4-1BBL/4-1BB pathway and tolerance. Indeed, 4-1BB co-
stimulation was shown to synergize with IL-2 in promoting nTreg expansion [96]. In an 
experimental model of rheumatoid arthritis, treatment with 4-1BB agonist antibodies 
inhibited disease progression, which was attributed to the induction of IDO [97]. 
Altogether, 4-1BBL/4-1BB pathway contributes to immunity and tolerance, allowing 
multiple therapeutic applications through this pathway.
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2.7. GITRL/GITR pathway
Glucocorticoid-induced TNFR related gene (GITR) was first discovered as a 
dexamethasone-induced molecule in murine T cell hybridomas [98]. The expression 
of the human ortholog was subsequently identified in human lymphocytes and shown 
to be independent of glucocorticoid treatment. Similar to the TNFR family members 
OX-40 and 4-1BB, GITR is only expressed on recently activated T cells, implying a 
role in promoting effector functions rather than involvement in initial priming of naïve 
T cells [99]. The GITR ligand (GITRL) is expressed by APCs and is upregulated upon 
activation [100]. GITRL/GITR pathway provides co-stimulation to naïve T lymphocytes 
demonstrated by enhanced proliferation and effector functions in the setting of 
suboptimal TCR stimulation [101]. Additionally, GITR triggering promoted naïve 
T cell survival through the activation of NF-κB and MAPK pathways, though it was 
not sufficient to inhibit activation-induced cell death initiated by TCR signaling [102]. 
GITRL/GITR pathway does not seem to have an impact on T cell polarization. Although 
applying an agonist antibody against GITR initially enhanced Th2 responses in a mouse 
model of helminth infection, this effect was short lived and GITR-independent [103]. 
A role for GITRL/GITR pathway in immune tolerance was initially demonstrated by 
the constitutive expression of GITR on Treg cells [104]. Factually, Treg cells isolated 
based on the expression of GITR could prevent the development of colitis induced in 
an adoptive transfer model [105]. However, engaging Treg-expressed GITR, by agonist 
antibodies, was shown to abrogate their suppressive capacity [104]. In the beginning, 
this effect was interpreted by mere activation of Treg cells upon GITR stimulation, 
but this explanation was underscored by the fact that Treg cell preincubation with 
anti-GITR did not cause the subsequent loss of suppression [104]. Eventually, it was 
revealed that triggering GITR on effector T cells rendered them resistant to suppression 
by Treg [106], providing a plausible explanation for the anti-tolerogenic effects of GITR 
stimulation. This postulates a model where APC-expressed GITRL would bind GITR on 
recently stimulated T cells allowing them to resist suppression. Simultaneously, GITR 
ligation on Treg cells would allow their expansion and their subsequent domination at 
later stages of the immune response [106].
Based on the activatory nature of GITRL/GITR pathway and its characteristic inhibition of 
tolerance, employing this pathway in cancer therapy was evaluated. The administration 
of an agonistic antibody against GITR has been shown to augment CD8 anti-tumor 
immunity [107]. In addition to mobilizing anti-tumor responses, triggering GITR was 
also shown to attenuate Treg-mediated suppression within the tumor [108], making 
GITRL/GITR a promising target for cancer therapy.           
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2.8. LIGHT/HVEM pathway
The TNFR family member herpes virus entry mediator (HVEM) was initially discovered as 
a receptor for herpes simplex virus [109]. It is expressed on resting T cells, monocytes 
and immature DCs. HVEM has multiple binding partners: LIGHT and lymphotoxin-α 
(LTα) from the TNF superfamily; and CD160 and B and T lymphocyte attenuator (BTLA) 
from the Ig superfamily. HVEM interaction with these ligands creates a complex network 
of pathways, which collectively regulates adaptive immune responses [110]. In this 
section we will only focus on the co-stimulatory pathway resulting from LIGTH/HVEM 
interactions. LIGHT is expressed by immature DCs [111] and is induced upon activation 
on T cells, in contrast to HVEM [112]. LIGTH/HVEM interaction was revealed to be 
required for DC-mediated allogenic T cell responses. Indeed, activating T cell HVEM 
enhanced T cell proliferation at suboptimal TCR stimulation conditions [111]. Disrupted 
LIGHT/HVEM interaction was shown to result in inhibited T cell proliferation, further 
supporting the importance of this pathway in co-stimulation [113]. Similar to other 
TNFR family members, HVEM mediates its effects by activating NF-κB pathway [114]. 
Interestingly, LIGHT/HVEM pathway can also contribute to T cell activation indirectly 
by inducing DC maturation, reminiscent of the role of CD40 in inducing DC maturation 
[115]. LIGHT/HVEM pathway is also suggested to contribute to T cell polarization. T 
cells co-stimulated through HVEM displayed enhanced production of Th1 cytokines 
[116]. Accordingly, LIGHT deficient mice showed reduced IFN-γ levels, prolonging 
allograft survival in these mice [117]. Due to the complexity of the signaling network 
of HVEM and LIGHT, reported findings should be interpreted as these observations may 
involve other pathways.   
2.9. TIM family
In addition to the CD28/B7 and TNFR/TNF co-stimulatory families, the recently identified 
TIM (T cell immunoglobulin domain and mucin domain) family is a new contributor to 
signal II. This family of genes was initially identified while searching for Th1-specific 
markers [118]. In humans, three TIM family members: TIM1, TIM3 and TIM4 have 
been identified thus far. Mice posses an additional member: TIM2 [119]. In this section 
we will only focus on TIM3 and TIM4, which were reported to be expressed by DCs. 
TIM3 was first discovered as a specific marker for Th1 cells [118], and was shown to 
induce the death of these cells by binding to its ligand galectin-9 [120]. TIM3 expression 
was also detected on DCs, and its ligation by galectin-9 induced the production of the 
inflammatory cytokine TNF-α. The absence of TIM3 signaling was shown to result in 
impaired TLR responsiveness, implying a synergistic relation between TIM3 and TLR 
signaling pathways [121]. Although TIM3 triggering on T cells and DCs leads to ERK 
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phosphorylation and IκBα degradation, different tyrosine phosphorylation patterns in 
T cells and DCs were detected, providing a plausible explanation for the differential 
effects of TIM3 between different cell types [121]. Thus far, interactions between DC-
expressed TIM3 and T cell-expressed galectin-9 have not been investigated. However, 
previous findings prompt a model where DC-expressed TIM3 promotes inflammation 
and the differentiation of TIM3-expressing Th1 cells. IFN-γ-induced galectin-9 would 
interact with TIM3 from other T cells, inducing cell death and thereby self-limiting 
the immune response. Additionally, TIM3 is suggested to contribute to tolerance. A 
crucial role for TIM3 in clearing apoptotic cells by phagocytosis was recently revealed. 
Blocking this function resulted in inhibited cross-presentation of self-antigens and the 
development of auto-antibodies [122]. In a completely different mechanism, TIM3 
expressed by tumor infiltrating DCs was shown to interact with the alarmin HMGB1, 
disturbing the recruitment of tumor cell-derived nucleic acids into DC endosomes, 
attenuating immune responses to these tumors [123].
In contrast to the other members of the TIM family, TIM4 is exclusively expressed by 
APCs and not by T cells [124]. Through binding to TIM1 on T cells, TIM4 was shown 
to provide T cells with a co-stimulatory signal promoting T cell expansion, cytokine 
production and survival. These effects were mediated by induced phosphorylation of 
the signaling molecules LAT, Akt and ERK1/2 in stimulated T cells [125]. Notably, the 
strength of TIM4 signal is decisive in determining the stimulatory effect, as weak TIM4 
signaling inhibits T cell proliferation instead of potentiating it [124]. Similarly, TIM4 was 
shown to inhibit the proliferation of naïve T cells, which lack the expression of TIM1 
[126]. These data imply that TIM4 has at least two binding partners: an activating 
ligand (TIM1) and an inhibitory one to be identified. Through these ligands, TIM4 
exerts bimodal regulation of immune responses. Analogous to TIM3, the role of TIM4 
in regulating immunity is also evident through mediating the engulfment of apoptotic 
cells. In vivo blocking of TIM4 resulted in the development of auto-antibodies [127].
2.10. Adhesion molecules providing co-stimulatory signals
Leukocyte adhesion and detachment from other cells is tightly regulated by adhesion 
molecules. A specific set of these molecules is involved in regulating DC/T cell interactions. 
This set includes the following molecules: ICAM-1 and LFA-3, expressed by DCs, and 
their respective ligands LFA-1 and CD2, expressed by T cells. The seminal discovery 
of the involvement of LFA-1 in mediating T cell functions prompted a hypothesis that 
LFA-1 would act by enhancing adhesion and thereby increasing the range of avidities 
that can promote antigen recognition [128]. Subsequently, ICAM-1 was identified as 
the ligand of LFA-1 [129]. LFA-1 ligation by ICAM-1 was shown to induce proliferation 
of TCR-stimulated T cells in an IL-2 dependent mechanism, proposing that ICAM-1/
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LFA-1 interaction as a co-stimulatory pathway [130]. In addition to co-stimulation, 
ICAM-1/LFA-1 interaction stabilizes the immunological junction [131] and the ICAM-
1/LFA-1 pathway appears to contribute to T cell differentiation as repeated T cell 
stimulation with ICAM-1 promoted IFN-γ production by these cells [132]. the ICAM-1/
LFA-1 pathway also 
 Moreover, blocking ICAM-1/LFA-1 interactions during T cell stimulation drastically 
increased Th2 cytokines [133]. More recently, ICAM-1/LFA-1 interaction during CD8+ T 
cell priming was demonstrated to be essential for the establishment of effective T cell 
memory [134]. The effects of the ICAM-1/LFA-1 pathway are believed to result from 
influencing multiple cellular signaling cascades. LFA-1 was found to interact with the 
transcriptional co-activator JAB1, implying an influence on c-Jun-driven transcription 
[135]. 
In parallel, T cell CD2 interaction with its ligand LFA-3 was recognized for contributing 
to T cell activation by strengthening the adhesion between T cells and APCs and 
thereby enforcing TCR contact with its ligands [136]. Moreover, CD2 signaling was 
also shown to restore responsiveness in anergized human T cells [137]. CD2 blocking 
in vivo was revealed to induce T cell unresponsiveness, further supporting the notion 
that LFA-3/CD2 pathway contributes to immune activation [138]. Conversely, specific 
mobilization of LFA-3/CD2 interactions was demonstrated to induce, single handedly, 
nonproliferating Treg cells secreting high amounts of IL-10 [139]. In light of these 
contradictions, further characterization of the role of LFA-3/CD2 co-stimulatory pathway 
is required.   
3. CO-INHIBITORY MOLECULES 
3.1 CD80/CD86/CTLA-4 pathway
 CTLA-4 (ctyotoxic T-lymphocyte antigen-4) (CD152) is a CD28 homologue that was 
discovered in 1987 [140]. The closely related structures of these two molecules 
suggest overlapping functional qualities. Indeed, CTLA-4 binds to CD80 and CD86, 
though at greater affinities. However, CTLA-4 was the first described co-stimulatory 
molecule with inhibitory effects in a stark contrast to the activatory properties of CD28 
[141]. The effects of CTLA-4 include inhibition of proliferation, cell cycle progression 
and IL-2 synthesis [142]. Additionally, CTLA-4 seems to have an influence on T cell 
polarization. T cells lacking CTLA-4 expression were shown to adopt a Th2 phenotype 
[143]. Furthermore, neutralizing CTLA-4 signaling in T cells was recently shown to 
enhance IL-17 production and promote the differentiation of Th17 cells [144].  
The prominent role of CTLA-4 in tolerance is clearly demonstrated by CTLA-4 deficient 
mice, which succumb at 3-4 weeks of age to massive lymphoproliferative disease 
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[145]. Furthermore, the suppressive functions of  naturally occurring Treg cells, 
which constitutively express CTLA-4, were dependent on CTLA-4 signaling [146], 
corroborating its role in tolerance. CTLA-4 contribution to tolerance is postulated 
to arise from controlling T cell responses in an intrinsic or extrinsic manner [147]. 
First, CTLA-4 antagonizes the CD28 stimulatory signaling by competing with CD28 on 
binding to CD80/CD86. Interestingly, CTLA-4 expression on cells is induced in a CD28-
dependent mechanism [148], implying that CTLA-4 serves as an internal checkpoint 
that prohibits excessive stimulation by CD28. Extrinsic inhibitory effects of CTLA-4 are 
suggested to be exerted through different mechanisms. CTLA-4 molecules expressed 
by Treg cells were shown to engage CD80/CD86, expressed by DCs, promoting the 
activity of Indoleamine 2,3-dioxygenase (IDO). The modified catabolic properties of 
DCs lead to localized deprivation of tryptophan and thereby reduced T stimulatory 
capacity of these DCs [149]. Another suggested mechanism for the extrinsic effects of 
CTLA-4 was demonstrated by the capacity of CTLA-4 to capture CD86, expressed by 
APCs, internalize it for ensuing degradation in a process called trans-endocytosis [150]. 
Treg cells were also observed to suppress T cells by establishing a direct interaction 
through CTLA-4, which binds to CD80 and CD86 expressed by those T cells [151]. 
Finally, unstimulated T cells were revealed to produce a soluble form of CTLA-4, which 
may possibly convey the inhibitory effects to other cells [152]. Collectively, CTLA-4 is 
unequivocally vital for tolerance. 
Due to its role in maintaining tolerance, blocking CTLA-4 interaction with CD80 and 
CD86 was postulated to promote anti-tumor immunity. Indeed, in vivo administration 
of blocking antibodies against CTLA-4 resulted into effective anti-tumor immunity and 
tumor rejection [153]. Nevertheless, CTLA-4 blockade efficacy in tumor therapy was 
correlated with the stage and immunogenicity of the tumor. At early stages small 
tumors were sensitive to the effects of CLTA-4 blockade [154], whereas advanced 
tumors were resistant due to the strongly tumor-induced T cell tolerance [155]. In 
an attempt to circumvent this hurdle, anti-CTLA-4 blocking antibodies were tested 
in combination with other therapeutic modalities. Combined anti-CTLA-4 application 
and Treg depletion resulted in maximal tumor rejection, which was dependent on 
the expansion of tumor-specific CD8+ T cells [156]. Those promising experimental 
observations lead to the development of two fully human anti-CLTA-4 antibodies: 
ipilimumab (Bristol-Myres Squibb, New York, NY, USA) and tremelimumab (Pfizer, New 
York, NY, USA). Early clinical trials in metastatic melanoma and ovarian carcinoma 
patients demonstrated that blocking CTLA-4 resulted in extensive tumor necrosis with 
lymphocyte and granulocyte infiltrates in a large number of patients [157]. Further 
large scale clinical trials have shown irrefutable evidence of the efficacy of anti-CTLA-4 
antibodies, leading eventually to FDA approval of these antibodies [158]. Despite its 
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novelty, this therapeutic strategy is challenged by auto-immune complications resulting 
from the administration of anti-CTLA-4 antibodies [159]. 
The tolerogenic effects arising from CTLA-4 engagement with CD80/CD86 can also 
be utilized for inducing tolerance towards transplanted tissues. This notion has 
been supported by observations in animal experimental models. Administration of 
recombinant CTLA-4-Ig fusion protein after renal or cardiac transplantation enhanced 
allograft acceptance and reduced inflammatory responses [160]. This led to the 
development of humanized CTLA-4-Ig (Belatacept). Kidney transplantation patients 
receiving Belatacept showed reduced allograft rejection and maintained better renal 
functions, compared to patients receiving cyclosporine. These findings resulted in 
gaining FDA approval for using Belatacept for the prevention of acute rejection post 
renal transplant [161].  
3.2 PD-L1/PD-L2/PD-1 pathway
Programmed cell death-1 (PD-1) is another member of the CD28 family that is expressed 
by activated T and B cells [162]. Two ligands were identified to interact with PD-1: PD-
L1 [163] and PD-L2 [164]. Those ligands are characterized by differential expression 
patterns. PD-L1 is constitutively expressed and further enhanced on activated 
lymphocytes, including Treg cells, and DCs. It is also expressed by a wide variety 
of non-hematopoietic cell types including the vascular endothelial cells, neurons and 
pancreatic islet cells. In contrast, PD-L2 expression is restricted to DCs and macrophages 
under certain conditions [165]. Interestingly, PD-L2 displays three times higher binding 
affinity to PD-1 in comparison to PD-L1, which on the other hand was also identified 
to bind to CD80 [166]. The varying binding and expression properties of PD-L1 and 
PD-L2 suggest distinct functions in regulating T cell responses. Along with its ligands 
PD-1, is recognized for its vital role in regulating adaptive immune responses [167]. 
Indeed, triggering of PD-1 by one of its ligands during TCR signaling can block T cell 
proliferation, cytokine production and cytolytic activity and impair T cell survival [168]. 
The intracellular domain of PD-1 contains an immunoreceptor tyrosine-based inhibitory 
motif (ITIM) as well as an immunoreceptor tyrosine-based switch motif (ITSM), which 
are phosphorylated upon ligand engagement. Subsequently protein phosphatases, 
such as SHP-1 and SHP-2, are recruited to TSM where they are activated and inhibit 
proximal TCR signaling events by dephosphorylating key intermediates in the TCR 
signaling cascade [169]. Similar to CLTA-4, triggering PD-1 limits glucose metabolism 
and Akt activation, albeit through different mechanisms [169]. Consistently, a recent 
study also demonstrated that PD-1 exerted its inhibitory effects by affecting Akt and 
Ras pathways and thereby inhibiting cell cycle progression and T cell proliferation 
[170]. 
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 The first indication of the importance of PD-1 in immune tolerance came from PD-1 
deficient mice, which developed strain-specific autoimmunity. The absence of PD-1 
caused the development of cardiomyopathy secondary to the production of auto-
antibodies against cardiac troponin in BALB/c mice [171], while C57BL/6 developed 
a lupus-like autoimmune disease [172]. In humans, polymorphisms in the PD-1 gene 
were also associated with susceptibility to several autoimmune diseases including 
systemic lupus erythematosus [173], type I diabetes [174] and multiple sclerosis 
[175]. These observations were supported by functional studies demonstrating the 
contribution of the PD-L1/PD-L2/ PD-1 pathway to central tolerance. In the thymus, 
interactions between PD-1, expressed by CD4-CD8- thymocytes, and PD-L1 broadly 
expressed in the thymic cortex, were deemed crucial in regulating positive selection 
[176].  PD-1 was also shown to participate in thymic negative selection [177]. Gene 
expression profiling studies of central tolerance in nonobese diabetic (NOD) mice also 
implicated PD-1 and PD-L1 in central tolerance [178]. PD-L1/PD-L2/ PD-1 pathway 
also contributes to peripheral tolerance through multiple mechanisms. Self-reactive 
CD8+ T cells lacking PD-1 display increased responsiveness to self antigens presented 
by resting DCs, suggesting that DC-expressed PD-L1 and PD-L2 may control T cell 
activation [179]. PD-L1/PD-L2/ PD-1 pathway can also regulate reactivation, expansion 
and functions of effector T cells [180]. Additionally, PD-1 triggering of TCR-stimulated, 
TGF-β-treated T cells profoundly enhanced the de novo generation of Foxp3+ Treg cells 
from CD4+ naïve precursors. Further engagement of PD-L1 on the induced Treg cells 
sustained Foxp3 expression and enhanced the suppressive capacity of these cells [181]. 
Consistently, PD-L1 was shown to mediate the effects of the immune suppressant 
vitamin D (VitD). DCs treated with VitD were shown to induce IL-10 producing Treg 
cells in a PD-L1 dependent mechanism [182]. Interactions between PD-1 and PD-L1 
are also proposed to maintain tolerance by modifying DC-T cell contact. PD-1 ligation 
was shown to inhibit the TCR-induced stop signals, disrupting the stable DC-T cell 
contact and subsequently allowing tolerized T cells to move freely and prohibiting 
clustering around antigen-bearing DCs [183]. Another plausible mechanism for PD-L1/
PD-L2/ PD-1 pathway-induced tolerance is that PD-L1 expressed by Treg cells would 
engage PD-1 expressed by DCs and modulate DC function and thereby impeding 
immune responses [184]. 
The inhibitory effects of PD-L1/PD-L2/PD-1 pathway can be hijacked by tumors to 
evade anti-tumor immune responses. PD-L1 expression has been confirmed on many 
tumors including glioblastoma and melanoma as well as cancers of the head and neck, 
lung, ovary, colon, stomach, kidney and breast. High expression PD-L1 levels by tumor 
cells, tumor infiltrating lymphocytes or both associated with aggressive tumor behavior, 
poor prognosis and elevated risk of mortality [185]. Moreover, DCs generated from 
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peripheral blood of ovarian cancer patients displayed high levels of PD-L1, prompting 
impaired T cells responses, which were restored by blocking PD-L1/PD-1 interactions 
[186]. In vivo, forced PD-L1 expression by squamous cancer cells rendered them 
resistant to T cell-mediated immunity. This resistance however was broken upon 
treatment with anti-PD-L1 blocking antibodies [187]. A recent study also revealed that 
platinum based chemotherapeutics enhanced anti-tumor T cell responses by disrupting 
PD-L2/PD-1 interactions through reducing PD-L2 levels on both DCs and tumor cells 
[188]. These experimental observations prompted the development of humanized anti-
PD-1and anti-PD-L1 antibodies for clinical application. Early stage clinical trials with 
these antibodies demonstrated clinical activity, which was characterized by durability 
accompanied with minimal side effects [189]. 
There is also evidence that viral infections can make use of PD-L1/PD-L2/PD-1 pathway. 
Animal models of chronic viral infections had elevated PD-1 expression on exhausted 
viral antigen-specific T cells. The activity of these T cells was restored following PD-L1 
blocking, suggesting a novel strategy for combating chronic viral infections [190]. 
In line with its inhibitory role, PD-L1/PD-L2/PD-1 pathway can be harnessed for the 
induction of tolerance when needed. Administration of recombinant PD-L1-Ig, with 
agonistic effect for PD-1, prolonged the survival of cardiac allografts in mice [191]. 
Furthermore, PD-L1 expression on murine liver allografts is central for spontaneous 
tolerance [192]. 
3.3 B7-H3 pathway
B7-H3 belongs to the B7 family of co-stimulatory molecules. Similar to other 
immunoglobulin superfamily members, B7-H3 is a transmembrane molecule. It 
possesses a short cytoplasmic tail with no known signaling domain. B7-H3 is expressed 
on a wide a variety of tissues and tumor cell lines. However, its expression on leukocytes 
is only detectable following stimulation. B7-H3 expression can be induced on DCs and 
monocytes by inflammatory cytokines, whereas a combination of phorbol myristate 
acetate and ionomycin can induce it on T cells. B7-H3 was shown to bind a receptor 
expressed by activated T cells. This receptor is distinct from CD28, CTLA-4, ICOS 
and PD-1 and yet to be identified [193]. Triggering receptor expressed on myeloid 
cells (TREM)-like transcript 2 (TLT-2), constitutively expressed by CD8+ T cells and 
activation-induced on CD4+ T cells, was proposed to be the binding partner of B7-H3 
[194]. However, this was strongly refuted by another study providing evidence of non-
existing interaction between B7-H3 and TLT-2 [195].  Initially, B7-H3 was suggested to 
be a positive co-stimulatory molecule that induces T cell proliferation, IFN-γ production 
and CTL generation in humans [193]. Nevertheless, this was contradicted by another 
study demonstrating that B7-H3 is a potently inhibited T cell stimulation under different 
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conditions and regardless of the stimulation status of the T cells in question [195]. 
This is corroborated by data from murine studies where applying an agonistic fusion 
protein, B7-H3-Ig, was shown to inhibit proliferation, IL-2 and IFN-γ production of 
TCR-stimulated T cells. This inhibitory effect was demonstrated by exacerbated airway 
inflammation in B7-H3 deficient mice compared to wild type counterparts [196]. 
Moreover, blocking B7-H3 caused enhanced T cell proliferation in vitro and worsened 
EAE in vivo. This effect may be explained by the inhibitory influence of B7-H3 signaling 
over NF-κB, NFAT and AP-1 that are involved in regulating T cell activation [197]. 
Notably, the effects of B7-H3 were overridden by CD28 co-stimulation, implying 
that B7-H3 functions optimally in the absence of co-stimulation [196]. Of interest, 
tumors are suggested to hijack the B7-H3 to evade anti-tumor immune responses. 
This is demonstrated by increased disease severity when cancer cells upregulated 
B7-H3 expression [198]. Collectively, further characterization of the B7-H3 pathway is 
required to resolve functional discrepancies, which may be explained by the existence 
of two receptors for B7-H3 with opposite functions, yet to be identified.  
3.4 B7-H4 pathway
B7-H4 is the last among the B7 family members that was identified. Unlike other B7 family 
members, which are type I membrane molecules, B7-H4 is characterized by a glycosyl 
phosphatidylinositol (GPI) domain that links to the cell membrane [199]. In humans, 
B7-H4 mRNA was detected in a variety of tissues. However, immunohistochemical 
analysis did not reveal any B7-H4 protein expression by these tissues. Likewise, no 
B7-H4 expression could be detected on freshly isolated T cells, B cells, monocytes and 
DCs, but it was induced after activating these cells in vitro. The ligand of B7-H4 has 
not been identified yet, but it is suggested to be expressed by stimulated T cells and 
to be distinct from other CD28 family members [200]. B7-H4 is widely regarded as a 
co-inhibitory molecule. Indeed, treatment of TCR-stimulated T cells by a fusion B7-H4-
Ig protein resulted in inhibited T cell proliferation and cytokine production, an effect 
that required B7-H4 cross-linking [200]. The inhibitory effects of B7-H4 are proposed 
to arise from arrested cell cycle progression in T cells [200], and impaired induction of 
JunB, known for its role in inducing IL-2 production in activated T cells [199]. A recent 
study also showed that B7-H4 signaling inhibits phosphorylation of MAP kinases, ERK, 
p38, JNK and Akt, usually elicited upon TCR triggering of T cells [201]. 
In line with in vitro findings, mice suffering from graft versus host disease demonstrated 
prolonged survival upon the in vivo application of B7-H4-Ig [200]. Expectedly, in vivo 
administration of an antagonizing antibody against B7-H4 blocked the inhibitory effect 
of B7-H4 pathway and led to accelerated disease development in a mouse model of EAE 
[199]. Furthermore, B7-H4 deficient mice showed better control of Leishmania major 
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infection as Th1 responses were augmented in these mice [202]. B7-H4 deficiency 
also enhanced neutrophils-mediated immunity, implying that B7-H4 may have a role 
in regulating innate immunity too [203]. In addition to its role as a co-inhibitory 
molecule, B7-H4 seems to mediate the effect of Treg cells. It was shown that Treg 
cells, but not conventional T cells, induce high levels of IL-10 production by APCs and 
consequently trigger B7-H4 expression that renders these APCs immunosuppressive 
[204]. The overall tolerogenic effect of B7-H4 can be exploited by tumors to evade 
immune responses. B7-H4 expression was reported for several tumors including lung 
cancer, ovarian cancer [205], gastric cancer [206] and tumor-associated macrophages 
[207]. Blockade of B7-H4 on these macrophages was actually effective in reversing 
their suppressive effect and restored anti-tumor T cell immunity [207]. Additionally, 
manipulating B7-H4 pathway has potential in the field of transplantation. A recent 
study showed that B7-H4 expression was shown to prolong islet allograft survival in 
mice [208]. Thus, the B7-H4 pathway serves as an interesting therapeutic target in 
different diseases, though several aspects of this pathway remain elusive.     
3.5 HVEM/BTLA/CD160 pathway
As mentioned earlier, the molecules HVEM, BTLA, CD160 and LIGHT interact directly 
with each other forming a complex pathway network regulating adaptive immune 
responses. HVEM, expressed by immature DCs, can provide negative co-stimulatory 
signals through binding to its ligands BTLA and CD160 on T cells [110]. BTLA belongs 
to the Ig superfamily and is a structural homologue of CTLA-4 and PD-1. It is also 
a transmembrane glycoprotein that can be phosphorylated on tyrosines located in 
conserved cytoplasmic ITIM motif [209]. T cell expression of BTLA was shown to be 
very low on naïve cells. However, it is upregulated upon antigen-stimulation peaking 
at day 2 and declining around day 7 post-stimulation. This expression can be retrieved 
upon secondary stimulation of activated T cells. Interestingly, anergic T cells and Th1 
cells demonstrated high BTLA expression unlike Th2 cells and Treg cells that have low 
BTLA expression [210]. The unique BTLA expression pattern and expression kinetics 
indicate that BTLA may interfere at certain stages of T cell activation with specificity to 
certain types of effector T cells.
 HVEM delivers its inhibitory signal to T cells by binding to BTLA, which induces the 
phosphorylation of its ITIM domain and the recruitment of SHP-2, leading to attenuated 
antigen-driven T cell activation [211]. In addition to inhibiting T cell responses, there is 
evidence that HVEM/BTLA pathway promotes T cell survival in a mechanism dependent 
on NF-κB activation [212]. Interestingly, BTLA was also shown to mediate Treg cell 
suppression by interacting with HVEM expressed by Treg cells. This was supported 
by showing that Treg cells from HVEM deficient mice had lower suppressor activity 
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and that wild type Treg cells failed to suppress effector T cells from BTLA deficient 
mice [213]. The inhibitory effects of BTLA are also observed in vivo. In an EAE 
model, BTLA deficient mice displayed increased severity and persistence of disease 
when compared with wild type controls [209]. BTLA deficiency was also reported to 
exacerbate allergic airway inflammation [214] and to cause the development of auto-
antibodies leading to a hepatitis-like syndrome with advancing age [215]. Moreover, 
a single nucleotide polymorphism (SNP) in the ITIM region of BTLA was reported to 
associate with increased susceptibility to rheumatoid arthritis [216]. Another study also 
revealed an association between another BTLA SNP and rheumatoid arthritis, but not 
with systemic lupus erythematosus or Sjogren’s syndrome [217]. Similar to B7-H3 and 
B7-H4, the inhibitory effects of BTLA can be exploited by tumors to evade immunity. 
Melanoma-specific CD8+ T cells were shown to persistently express BTLA. Interrupted 
BTLA signaling, achieved by applying CpG oligonocluotide vaccine formulations, lead to 
functional recovery of melanoma-specific CD8+ T cells [218].
HVEM can also interact with CD160, a glycosylphosphatidylinositol anchored membrane 
molecule that is mainly expressed by CD8+ T cells and activated CD4+ T cells. Cross-
linking CD160 with a specific antibody on stimulated T cells was shown to strongly 
inhibit T cell proliferation and cytokine production. Similarly, the inhibitory effect of 
CD160 was also elicited by binding to its ligand HVEM [219]. Although both BTLA 
and CD160 bind to the cysteine-rich domain-1 (CRD-1) of HVEM with comparable 
affinity, CD160 dissociates from HVEM at a slower rate compared to BTLA. Moreover, 
mutagenesis study of HVEM revealed that CD160 has a distinct binding site on HVEM, 
albeit overlapping with BTLA [220]. Those differences between CD160 and BTLA, 
though subtle, suggest that these molecules do not have redundant functions. Further 
delineation of the elusive HVEM/CD160 pathway and its functional implications are 
required to unravel its specific role in regulating immune responses.    
3.6. ILT3 and ILT4/HLA-G pathways
The inhibitory receptor immunoglobulin-like transcript-3 (ILT3) [221] and ILT4 [222], 
both expressed by monocytes, macrophages and DCs, belong to a family of Ig-like 
inhibitory receptors that are closely related to the killer cell inhibitory receptors. Both 
ILT3 and ILT4 were shown to transmit signal through a long cytoplasmic tail containing 
ITIM motifs, which inhibit cell activation by recruiting the protein phosphatase SHP-
1 [221], [222]. In the case of ILT3, the extracellular region consists of two Ig-like 
domains, which are speculated to contain the putative binding site of the yet to be 
identified ILT3 ligand [221]. On the other hand, the binding partner of ILT4 was shown 
to be the MHC class I molecule HLA-G [222]. In addition to triggering an inhibitory 
signal, ILT3 cross-linking was shown to lead to its internalization and delivery into an 
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antigen presenting compartment, suggesting a role in antigen processing [221]. DC 
expression of ILT3 and ILT4 was shown to be induced under the effect of CD8+CD28- 
alloantigen-specific T suppressor cells [223]. Immature monocyte-derived DCs (MoDCs) 
also upregulated ILT3 and ILT4 expression upon treatment with either IL-10 or/and 
IFN-α [224]. VitD treatment only induced ILT3 expression in MoDCs [224] and primary 
human blood BDCA1+ DCs [225]. Expectedly, ILT3 expression, by both MoDCs and 
pDCs, was downregulated following activation [226]. 
Tolerogenic DCs over-expressing ILT3 or ILT4 demonstrated impaired NF-κB activation 
and consequently reduced transcription capacity of NF-κB dependent co-stimulatory 
molecules [223]. Those DCs were shown to be capable of transforming allo-reactive 
effector T cells into antigen-specific Treg cells [224]. Similarly, triggering ILT4 by HLA-G 
tetramers was shown to impair maturation and T cell stimulatory capacity of human 
DCs [227]. Interestingly, ILT3 was shown to maintain its T cell inhibitory effect when it 
was expressed as soluble ILT3-Fc that lacks ILT3’s cytoplasmic tail, indicating that ILT3 
delivers its inhibitory signal by binding to its partner on activated T cells [228]. Recently 
it was shown that ILT3 capacity to convert T cells into suppressive cells is dependent on 
BCL6 signaling in these T cells [229]. ILT3 is also proposed to be important for controlling 
inflammation, as silencing ILT3 expression in DCs enhances TLR responsiveness, which 
is reflected by enhanced secretion of inflammatory cytokines such as IL-1α, IL-1β, IL-6 
and IFN-α. ILT3-silenced DCs could also attract more lymphocytes by secreting high 
levels of the chemokines CXCL10 and CXCL11 in response to TLR ligation. Eventually, 
impaired ILT3 expression in DCs rendered them more stimulatory for T cells, which 
also secreted higher levels of cytokines like IFN-γ and IL-17 [230]. Another suggested 
mechanism by which both ILT3 and ILT4 contribute to tolerance is by possibly mediating 
the effects of IDO. DCs cultured in tryptophan-deprived local environment upregulated 
the expression of ILT3 and ILT4, favoring the development of Foxp3+ Treg cells [231]. 
Finally, ILT4 was shown to be central for the development of type 1 regulatory T cells, 
induced by IL-10-treated DCs [232].
The effects of ILT3 and ILT4/HLA-G pathways are also evidenced in vivo. Immune 
modulation exerted by ILT4/HLA-G interactions is believed to mediate maternal 
tolerance towards the semi allogenic fetus [233]. Moreover, in vivo treatment with 
VitD was shown to upregulate the expression of ILT3 on DCs in healing psoriatic 
lesions. Nevertheless, ILT3 was revealed to be dispensable for the induction of Treg 
cells and completely overridden by the inhibitory effects of VitD [234]. Consistently, 
maternal VitD intake during pregnancy was found to enhance ILT3 and ILT4 gene 
expression levels in cord blood, pointing out a plausible mechanism for early induction 
of immune tolerance [235]. Enhanced ILT3 and ILT4 levels were also observed at an 
early stage of venom-specific immunotherapy, implying a possible role in inducing 
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tolerance towards allergic reactions [236]. Owed to its inhibitory effects, ILT3 is 
suggested to be employed by tumors as a mean of evading anti-tumor immunity. 
Indeed, soluble ILT3 protein was found at high levels in the serum of patients with 
melanoma, and carcinomas of the colon, rectum, and pancreas produce. This soluble 
ILT3 was active in inducing suppressor CD8+ T cells that block anti-tumor immunity, 
which was restored upon blocking or depleting ILT3 [237]. A similar mechanism is also 
utilized by viruses, as demonstrated by a point mutation in one of HIV Gag epitopes 
that increased binding to ILT4 and consequently programmed myelomonocytic cells 
to become tolerogenic [238]. The inhibitory effects of ILT3 can also be harnessed for 
allograft acceptance. Indeed, soluble recombinant ILT3-Fc was shown to suppress T 
cell-mediated rejection of allogenic islet transplants in mice [239]. In correlation to 
its inhibitory effect, blood monocytes during multiple sclerosis relapses demonstrated 
lower ILT3 expression, which was restored upon treatment with IFN-β, unraveling a 
plausible therapeutic target in the treatment of multiple sclerosis [240]. Similarly, a 
SNP in the ILT3 extracellular region was correlated with low surface expression and 
increased serum cytokine levels in lupus patients [241]. 
4. CONCLUDING REMARKS AND FUTURE PROSPECTS
Since the identification of the CD80/CD86/CD28 classical co-stimulatory pathway, the 
concept of DC-derived signal II was dramatically expanded to accommodate the ever 
increasing number of newly discovered co-stimulatory and co-inhibitory pathways. An 
increasing body of reports reflects the complexity of these pathways and implies possible 
interactions to form a sophisticated network controlling adaptive immune responses. 
The existence of multiple co-stimulatory and co-inhibitory pathways postulates for 
overlapping functions. Nevertheless, this notion of redundancy should be considered 
carefully. The components of these pathways have distinct expression patterns and 
kinetics, which means that these pathways are not simultaneously operative. In 
addition, mobilizing these pathways can trigger distinct signaling cascades and thereby 
leading to variable outcomes. 
Dendritic cell expression of co-stimulatory and co-inhibitory molecules is dictated by 
several factors. The specific type of DC is a major determinant of this expression. In 
humans, DCs are classified into groups based on origin, specific expression of certain 
surface markers and functional properties. For example, human blood DCs are divided 
into two major subsets: plasmacytoid DCs (pDCs) and myeloid DCs (myDCs). The 
latter can be further divided into three subsets: BDCA1+ DCs, BDCA3+ DCs and CD16+ 
DCs. In parallel, skin DCs are also classified into epidermal Langerhans cells (LCs), 
dermal CD1a+ DCs and dermal CD14+ DCs. Similar classification can be expected in 
other tissue-resident DCs. Most of the findings concerning co-stimulatory and co-
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inhibitory molecules in humans were based on experiments performed on the in 
vitro generated monocyte-derived DCs, which serve as a great tool for delineating 
immunological functions and mechanisms. However, there are strong indications of 
differential expression of co-stimulatory and co-inhibitory molecules among different 
DC subsets. These variations can be partially related to the intrinsic qualities of every 
DC subset. For instance, pDCs and LCs lack the expression of TLR4, and consequently 
they are not able to upregulate CD80 and CD86, observed in other subsets in response 
to lipopolysaccharide (LPS). 
Another central determinant of co-stimulatory and co-inhibitory molecules expression 
by DCs is the type of stimulus, to which DCs are exposed. As mentioned earlier, DCs 
respond to pathogen stimulation by upregulating CD80 and CD86. However, there are 
indications that certain co-stimulatory molecules are strictly expressed upon activation 
with a specific class of pathogens. A clear example is CD70 expression by LCs upon 
TLR3 triggering by double-stranded RNA derived from viruses, granting LCs advantage 
in eliciting strong anti-viral CD8+ T cell responses. Although dermal dendritic cells and 
MoDCs express TLR3, they do not upregulate CD70 in response to double stranded 
RNA, implying a combined effect of the type of stimulus and the type of DC in inducing 
CD70 expression. Similarly, pDC stimulation with CpG B, a TLR9 ligand, induced the 
expression of CD70, which was not observed using another type of stimulation or 
in other DC subsets [242]. Another example demonstrating the effect of pathogenic 
stimulation is the upregulation of OX40L only upon exposure to the soluble egg antigen 
from the parasite Schistosoma mansoni. Furthermore, DC treatment with certain 
immune modulating agents can influence the expression of co-stimulatory and co-
inhibitory molecules. VitD-treated DCs displayed induced expression of PD-L1 and 
ILT3, concurrent with inhibited expression of CD80 and CD86. On the other hand, DCs 
under the influence of IL-10 had normal expression levels of CD80 and CD86 but over-
expressed ILT3 and ILT4. It is also evident that DCs are strongly influenced by cues 
derived from the local environment. The well-documented effect of VitD, the major 
component of local skin milieu, is a clear example. The influence of other known tissue-
related environmental factors on co-stimulation requires further elucidation. Thus, 
optimal understanding of the role of DC-derived signal II requires determining the 
total repertoire of co-stimulatory and co-inhibitory molecules expressed by different DC 
subsets and under different conditions. 
In addition to the differential DC expression of co-stimulatory and co-inhibitory molecules, 
the respective ligands of these molecules are also described to be expressed by T cells 
following different kinetics. Some of these ligands are constitutively expressed, like 
CD28, whereas others are restricted to recently TCR-activated T cells such as 4-1BB 
and GITR. Furthermore, some of these ligands were shown to be exclusively expressed 
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by certain types of effector T cells, like the Th1-specific expression of TIM3. Taken 
together, the different expression modalities of the co-stimulatory and co-inhibitory 
pathway constituents imply that these pathways are mobilized at certain stages of T 
cell priming and under specific conditions.
Despite the stimulatory or inhibitory nature of signal II, there are some indications 
pointing out a role in T cell polarization, typically undertaken by cytokine-based 
signal III. For instance, OX-40L/OX-40 and 4-1BBL/4-1BB pathways are proposed to 
promote the differentiation of Th2 and Th1 effector cells respectively. Nevertheless, 
the observed polarizing effect was in many occasions revealed to be the mere outcome 
of promoted T cell survival rather than active polarization signaling mediated by these 
co-stimulatory or co-inhibitory molecules. Therefore, reported contributions of signal II 
to T cell differentiation should be interpreted carefully and further investigated. 
The vast immunological consequences of signal II have transformed its pathways, both 
stimulatory and inhibitory, into therapeutic targets for the treatment of a wide variety 
of diseases. Mobilizing co-stimulatory pathways and blocking co-inhibitory interactions 
showed promising results in promoting anti-tumor immunity and it is proposed to 
be beneficial for the treatment of chronic viral responses. Assuming that mature 
DCs provide optimal positive co-stimulatory signals while priming anti-tumor T cells, 
blocking co-inhibitory pathways may augment the efficacy of these T cells. In that 
respect, concurrent targeting of multiple co-inhibitory pathways might be necessary. 
Neutralizing the key inhibitory check point CTLA-4 permits extensive primary T cell 
activation, but by itself is not sufficient for driving an anti-tumor immune response, 
especially in the case of advanced tumors. However, the additional circumvention of 
yet another co-inhibitory check point, which is dictated by the tumor itself, may solve 
this problem. Selecting the second inhibitory target would highly depend on the type of 
the treated tumor, as different types of tumors were revealed to preferentially express 
certain co-inhibitory receptors (PD-L1, PD-L2, B7-H3...etc). The synergistic effects of 
such a combinatorial blocking strategy may not only mount efficient anti-tumor T cell 
responses, but also allow the persistence of such responses within the local tumor 
environment.
On the other hand, promoting tolerance by blocking activation and mobilizing co-
inhibitory pathways is a promising strategy for raising allograft tolerance. Similarly, 
immune suppressant agents were also revealed to manipulate these pathways in a 
comparable manner to induce tolerance. Nevertheless, these therapeutic modalities 
should be applied with great care to avoid any possible adverse effects like inducing 
susceptibility to infection or autoimmune reactions. Targeting these therapies to a 
specific pathway or a specific cellular compartment, like a certain DC subset, may be 
an option to bypass any possible complications.
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ABSTRACT 
Dendritic cells (DCs) are central players of immune responses; they become activated 
upon infection or inflammation and migrate to lymph nodes, where they can initiate 
an antigen-specific immune response by activating naive T cells. Two major types of 
naturally occurring DCs circulate in peripheral blood, namely myeloid and plasmacytoid 
DCs (pDCs). Myeloid DCs (mDCs) can be subdivided based on the expression of 
either CD1c or CD141. These human DC subsets differ in surface marker expression, 
Toll-like receptor (TLR)-repertoire and transcriptional profile, suggesting functional 
differences between them. Here, we directly compared the capacity of human blood 
mDCs and pDCs to activate and polarize CD4+ T cells. CD141+ mDCs show an overall 
more mature phenotype over CD1c+ mDC and pDCs; they produce less IL-10 and 
more IL-12 than CD1c+ mDCs. Despite these differences, all subsets can induce 
the production of IFN-γ in naive CD4+ T cells. Especially CD1c+ and CD141+ mDCs 
induce a strong T helper 1 profile. Importantly, naive CD4+ T cells are not polarized 
towards regulatory T cells by any subset. These findings further establish all three 
human blood DCs – despite their differences – as promising candidates for immuno-
stimulatory effectors in cancer immunotherapy.
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INTRODUCTION
Dendritic cells (DCs) are professional antigen-presenting cells that possess the 
unique capacity to activate and prime naive CD4+ and CD8+ T cells [1]. They 
form a heterogeneous population consisting of specialized DC subsets that differ 
in their surface marker expression, molecular phenotype, antigen-processing and 
-presentation capacity [2–4]. In peripheral blood, at least two major types of DCs can 
be distinguished, namely myeloid DCs (mDC) and plasmacytoid DCs (pDCs) [5,6]. 
Myeloid DCs express high levels of CD11c and can further be subdivided based on 
the differential expression of either CD1c (blood dendritic cell antigen 1 = BDCA1) or 
CD141 (BDCA3). Each DC subset has its own repertoire of Toll-like receptors (TLRs), 
underlining their functional specialization [3,7]. Plasmacytoid DCs express mainly 
TLR7 and TLR9. Both mDC subsets express TLR3 and TLR8 among others, although 
expression levels of TLR3 are much higher in CD141+ mDCs [7]. Plasmacytoid DCs 
are key effectors of innate immune responses due to their capacity to produce large 
amounts of type I IFNs in response to bacterial or viral infections; this production 
can also be induced by TLR agonists such as R848 and oligodeoxynucleotides class 
C (CpG) [8,9]. Besides their role in the innate immune system, pDCs also participate 
in priming T helper (Th) cells, depending on the stimulus they receive (summarized 
in [9]). Myeloid DCs, on the other hand, have the capacity to produce the Th1-
skewing cytokine interleukin (IL) 12. For both pDCs and mDCs it has been shown 
that they induce proliferation in an allogeneic setting and that they can cross-present 
exogenous antigens to prime CD8+ T cells [10–16]. 
As a result of their unique capacity to orchestrate adaptive immune responses, DCs 
are being exploited for cancer immunotherapy. Recently, more advanced examination 
of primary blood DCs has come within reach through the availability of efficient 
isolation techniques. Primary DCs are hypothesized to be stronger inducers of anti-
cancer responses than monocyte derived DCs in cell-based vaccination strategies 
since they differentiate in vivo and require only short ex vivo handling. The first 
clinical studies utilizing primary blood DCs have recently been conducted by our 
group, demonstrating the safety and efficacy of CD1c+ mDCs and pDCs in cancer 
immunotherapy [17,18]. 
In order for DC-based immunotherapy to elicit potent anti-tumor T cell responses, the 
administered DCs need to raise an immune-stimulatory rather than tolerogenic T cell 
response [19]. Naive T cells will proliferate upon encounter with antigen presenting 
cells presenting their specific antigen in the presence of co-stimulatory signals. The 
nature of co-stimulation and cytokines from the DC will influence the polarization of 
the T cells into different T helper phenotypes such as Th1, Th2, Th17 or regulatory 
T cells (Tregs). For example, the presence of IL-12 promotes the induction of Th1 
|  Chapter 3  
66
cells, whereas IL-10 inhibits induction of Th1 cells and promotes the differentiation 
of Tregs [20,21]. In anti-viral responses, Th1 cells and antigen-specific cytotoxic 
CD8+ T cells are elicited to eradicate cells infected by the virus. This type of immune 
response is also highly desirable in anti-tumor strategies, in which the aim is to 
eradicate tumor cells. Toll-like receptor ligands such as polyinosinic:polycytidylic acid 
(polyI:C), R848 and CpG have been shown to possess Th1 polarizing capacity when 
used as adjuvants or maturation agents for DCs [22–26].
To be able to successfully manipulate T cell responses for therapeutic strategies, a 
better understanding of the functional specialization of human DC subsets is needed. 
In this study, we compared the CD4+ T cell stimulatory and polarizing capacity of 
human blood mDCs and pDCs side-by-side – especially the capacity to induce Th1 
responses upon differential stimulation. 
MATERIAL AND METHODS
Cells
Human blood DCs were isolated from buffy coats (Sanquin) obtained from healthy 
volunteers after written informed consent and according to institutional guidelines. 
PBMCs were purified via ficoll density gradient centrifugation (Lymphoprep by Axis-
Shield). Monocytes were depleted via plastic adherence. 
DCs were isolated by fluorescence-activated cell sorting (FACS). For this, lineage 
positive cells were depleted from PBMCs either with Dynabeads Human DC 
enrichment kit (Invitrogen by Life Technologies) or with anti-FITC microbeads 
(Miltenyi Biotec) after incubation with FITC-conjugated anti-Lin1 antibody cocktail 
(CD3+CD14+CD16+CD19+CD20+CD56+) (BD Biosciences). The remaining cells were 
labeled with: FITC-conjugated anti-Lin1 antibody cocktail (BD Biosciences), PE-Cy7-
conjugated anti-HLA-DR (BD Biosciences), BV421-conjugated anti-CD1c (Biolegend), 
APC-conjugated anti-CD141 (Miltenyi Biotec), and PE-conjugated anti-BDCA4 
(Miltenyi Biotec). Subsets were sorted to obtain CD1c+ mDCs, CD141+ mDCs or 
pDCs, respectively (purity 98-100%) (Suppl. Fig. 1). In some experiments, CD1c+ 
mDCs were isolated from PBMCs with a CD1c+ DC isolation kit (Miltenyi Biotec). 
CD141+ mDCs and pDCs were isolated from PBLs by positive selection with anti-
CD141 (CD141) and anti-BDCA4 magnetic microbeads, respectively (Miltenyi Biotec). 
Purity was assessed by flow cytometry (85-97%). Naive CD4+ T cells were isolated 
from PBLs by depleting CD4- cells with MACS MultiSort beads and additional use 
of PE-conjugated anti-CD45RO (Dako) and anti-PE beads (Miltenyi Biotec) for the 
depletion of CD45RO+ memory T cells (purity >95 %).
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Figure 1: Phenotype of human blood DCs upon TLR stimulation (a) MHC class I (HLA-ABC) and MHC class II (HLA-DR)
expression was analyzed by flow cytometry of DCs kept at 4°C or DCs stimulated and cultured overnight. Myeloid DCs
were stimulated with R848 and polyI:C (pI:C), whereas pDCs were stimulated with R848 alone. The bar graphs show the
mean  SEM of the mean fluorescent intensity (MFI) (n3) and the histogram shows expression of freshly isolated DC
subsets from a single representative donor (filled histogram: isotype control; grey line: pDCs, black line: CD1c+ mDCs,
dashed line: CD141+ mDCs). (b) The bar graphs (upper panel) show the fold change  SEM of the MFI for surface
expression of the co-stimulatory molecules CD80 and CD86 after overnight stimulation with reference to cells cultured
in medium alone (or IL-3 for pDCs) (n4). The histograms (lower panel) show CD80 and CD86 expression from a single
representative donor (insets: MFI values). Significance was determined by Kruskal-Wallis test followed by Dunns testing
comparing different conditions of the same subset (* P<.05; ** P<.01; *** P<.001).
Figure 1 | Phenotype of human blood DCs upon TLR stimulation (a) MHC class I (HLA-
ABC) and MHC class II (HLA-DR) expression was analyzed by flow cytometry of DCs kept at 4°C or 
DCs stimulated and cultured overnight. Myeloid DCs were stimulated with R848 and polyI:C (pI:C), 
whereas pDCs were stimulated with R848 alone. The bar graphs show the mean ± SEM of the 
mean fluorescent intensity (MFI) (n≤3) and the histogram shows expression of freshly isolated DC 
subsets from a single representative donor (filled histogram: isotype control; grey line: pDCs, black 
line: CD1c+ mDCs, dashed line: CD141+ mDCs). (b) The bar graphs (upper panel) show the fol  
change ± SEM of the MFI for surface expression f the co- timulatory molecules CD80 and CD86 
after overnight stimulation with reference to cells cultured in medium alone (or IL-3 for p Cs) (n≤4). 
The histograms (lower panel) show CD80 and CD86 expression from a single representative donor 
(insets: MFI values). Significance was determined by Kruskal-Wallis test followed by Dunns testing 
comparing different conditions of the same subset (* P<.05; ** P<.01; *** P<.001).
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All cells were cultured in X-VIVO 15 medium (Lonza) supplemented with 2 % human 
serum (Sigma-Aldrich). The DCs were stimulated with the following TLR ligands: 4 
μg/ml R848 (Axxora), 2 μg/ml polyI:C (Sigma) (Figure 1 & 2) or 20 μg/ml polyI:C 
(Enzo Life Sciences) (Figure 3 & 4), 450 U/ml GM-CSF (Cellgenix), or 5 μg/ml CpG-C 
(desigmated CpG throughout text; Enzo Life Sciences). For the control condition 
of pDCs, the medium was supplemented with 10 ng/ml recombinant human IL-3 
(Cellgenix) to ensure pDC survival.
Cell sorting was performed on a BD Aria and flow cytometry on a BD Calibur or BD 
Verse. The flow cytometry data was analyzed by FlowJo software.
Phenotype and cytokine production of TLR activated DCs 
The DC subsets were incubated overnight at 37°C with different stimuli in triplicates 
(CD1c+ mDCs, pDCs) or in duplicate (CD141+ mDCs). The next day, supernatants 
were taken and cells were labeled with PE-conjugated anti-MHC class I and FITC-
conjugated anti-MHC class II (BD), PE-conjugated anti-CD80 (BD Biosciences), PE-
conjugated anti-CD86 (BD Biosciences). Marker expression was determined by flow 
cytometry (BD Calibur and FlowJo software). Supernatants were analyzed for IL-10 
(eBioscience) and IL-12p70 (M122 and M121B by Pierce Endogen, standard by BD 
Biosciences) by standard sandwich ELISA. Depicted in Fig. 2 is the cytokine production 
by 50,000 DCs in a volume of 100 µl. For CD141+ mDCs, in some instances fewer cells 
were cultured. In all instances, cytokine production per cell was calculated.
T cell proliferation with allogeneic naive CD4+ T cells 
CD1c+ mDCs, CD141+ mDCs or pDCs (1x104 cells) were incubated overnight at 37°C 
with different stimuli in triplicate. The next day, allogeneic naive CD4+ T cells were 
added to the DCs at a ratio of 1:5 (DC : T cell). Proliferative responses were determined 
by adding 1 μCi [0.037 MBq]/well of tritiated thymidine (3H) (MP Biomedicals) to the 
cells after three days of co-culture. 3H incorporation over a time course of 16 hours 
was measured with a scintillation counter. 
 
Co-cultures of DCs with naive CD4+ T cells and analysis of the CD4+ T cell 
phenotype
Dendritic cells (1x104) were stimulated overnight with the different stimuli in 100 ml 
medium. Next, allogeneic naive CD4+ T cells (4x104) were added at a ratio of 1:4 
(DC:T cell) in a final volume of 200 µl medium containing 10 pg/ml superantigen 
Staphylococcus aureus enterotoxin B (SEB) (Sigma). At day 5, human rIL-2 (20 
IU/ml, Novartis) was added and the cultures expanded for the next 6-8 days. On 
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day 11-13, resting T cells were counted and analyzed by flow cytometry with three 
panels. Panel 1: anti-CD25-APC (BD Bioscience), anti-CD127-PE (eBioscience), and 
anti-Foxp3-A488 (eBioscience). Panel 2: anti-T-bet-A488, anti-GATA-3-PE and anti-
RORγt-APC (all eBioscience). Panel 3: anti-CD45RO-APC (BD Bioscience), anti-CD197 
(R&D Systems) with goat-anti-mouse IgG2a-A488 (Life Technologies) and anti-
CD62-L (eBioscience) with rat-anti-mouse IgG1-PE (BD Pharmingen). The population 
of Tregs was determined by selecting CD25+ CD127- cells and subsequently gating 
on the FoxP3+ population (Suppl. Fig. 2a). From CD45RO+ cells, TCM were determined 
by further gating on CD197+/CD62-L+ and TEM were determined by further gating 
on CD197- cells. Both populations are shown as percentage of live cells (forward-
sideward scatter) (Suppl. Fig. 2b). 
Furthermore, 5x104 of the T cells of each condition were re-stimulated with 5x104 
anti-CD3/ anti-CD28 beads (Dynabeads Gibco by Life Technologies) in triplicates 
and supernatants from 24-hour-cultures were analyzed for levels of IFN-γ (Pierce 
Endogen), IL-5 and IL-10 (eBioscience) by standard sandwich ELISA.
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Figure 2: TLR ligation induces differential cytokine production by human blood DCs The DCs where stimulated as
indicated and cultured overnight at 37°C. IL-10 and IL-12p70 production was analyzed in supernatants of overnight
cultures by standard sandwich ELISA (n6). Each symbol represents one donor (also across the subsets). Significance was
determined by Kruskal-Wallis test followed by Dunns testing comparing different conditions of the same subset (* P<.05;
** P<.01; *** P<.001).
Figure 3: Human blood DCs induce proliferation of naive CD4+ T cells Human CD1c+ mDCs, CD141+mDCs and pDCs were
cultured overnight with the stimuli as indicated. The next day, allogeneic naive CD4+ T cells were added to the DCs (ratio
5:1). Proliferation was measured at day four of co-culture by determining tritiated thymidine incorporation. The graph
shows the mean proliferation  SEM in counts per minute [cpm] (n4). Each experiment was performed in triplicate for
CD1c+ mDCs and pDCs and in duplicate for CD141+ mDCs. Significance was tested for each subset in comparison with T
cells alone by Kruskal-Wallis test followed by Dunns testing (* P<.05; ** P<.01; *** P<.001).
Figure 2 | TLR ligation induces differential cytokine production by human blood DCs The 
DCs where stimulated as indicated and cultured overnight at 37°C. IL-10 and IL-12p70 production 
was analyzed in supernatants of overnight cultures by standard sandwich ELISA (n≥6). Each symbol 
represents one donor (also across the subsets). Significance was determined by Kruskal-Wallis test 
followed by Dunns testing comparing different conditions of the same subset (* P<.05; ** P<.01; 
*** P<.001). 
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Figure 2: TLR ligation induces differential cytokine production by human blood DCs The DCs where stimulated as
indicated and cultured overnight at 37°C. IL-10 and IL-12p70 production was analyzed in supernatants of overnight
cultures by standard sandwich ELISA (n6). Each symbol represents one donor (also across the subsets). Significance was
determined by Kruskal-Wallis test followed by Dunns testing comparing different conditions of the same subset (* P<.05;
** P<.01; *** P<.001).
Figure 3: Human blood DCs induce proliferation of naive CD4+ T cells Human CD1c+ mDCs, CD141+mDCs and pDCs were
cultured overnight with the stimuli as indicated. The next day, allogeneic naive CD4+ T cells were added to the DCs (ratio
5:1). Proliferation was measured at day four of co-culture by determining tritiated thymidine incorporation. The graph
shows the mean proliferation  SEM in counts per minute [cpm] (n4). Each experiment was performed in triplicate for
CD1c+ mDCs and pDCs and in duplicate for CD141+ mDCs. Significance was tested for each subset in comparison with T
cells alone by Kruskal-Wallis test followed by Dunns testing (* P<.05; ** P<.01; *** P<.001).
Figure 3 | Human blood DCs induce proliferation of naive CD4+ T cells Human CD1c+ 
mDCs, CD141+mDCs and pDCs were cultured overnight with the stimuli as indicated. The next day, 
allogeneic naive CD4+ T cells were added to the DCs (ratio 5:1). Proliferation was measured at 
day four of co-culture by determining tritiated thymidine incorporation. The graph shows the mean 
proliferation ± SEM in cou ts per mi0nute [cpm] (n≥4). Each xperiment was performed in triplicate 
for CD1c+ mDCs and pDCs and in duplicate for CD141+ mDCs. Significance was tested for each subset 
in comparison with T cells alone by Kruskal-Wallis test followed by Dunns testing (* P<.05; ** P<.01; 
*** P<.001).
Statistical analysis
Data were analyzed by Kruskal-Wallis test followed by Dunns testing, by an 1-way-
ANOVA followed by Tukey testing or with paired student t-test using Prism5 
(GraphPad Prism5). Statistical significance was defined as <0.05 (* P<.05; ** P<.01; 
*** P<.001).
RESULTS
TLR ligation increases expression of co-stimulatory molecules by human 
blood DCs
High expression of MHC molecules is a hallmark of DCs, underlining their antigen 
presenting capacities. Accordingly, we found high levels of both MHC class I as well 
as class II molecules on all three DC subsets (Fig. 1a). The levels of both MHC class 
I and class II molecules was highest for CD141+ mDCs and comparable for CD1c+ 
mDCs and pDCs, both on freshly isolated cells as well as after TLR activation. 
The expression of co-stimulatory molecules by DCs is essential to activate T cells 
and can be induced by TLR ligands. Throughout the study, CD1c+ and CD141+ 
mDC maturation was achieved by polyI:C, R848, or a combination of both. CD1c+ 
mDCs were also stimulated with granulocyte-macrophage colony-stimulating factor 
(GM-CSF). Plasmacytoid DCs were stimulated with R848 or CpG and IL-3 used for 
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the control to secure pDC survival. On CD1c+ mDCs, the co-stimulatory molecule 
CD86 was already highly expressed after overnight culture in medium alone; on 
CD141+ mDCs this holds true for the expression of both CD80 and CD86 (Fig. 1b). In 
comparison, CD141+ mDCs showed the highest expression of CD80 and CD86, both 
after culturing in medium alone or after TLR ligation (Fig. 1b). Although CD80 and 
CD86 molecules were expressed already at high levels on immature DCs, expression 
of both molecules was significantly increased upon culture with TLR ligands on all DCs.
TLR ligation induces differential cytokine production by human blood DCs
Dendritic cell-derived IL-10 is known to inhibit Th1 cells and induce type 1 Tregs 
(Tregs producing IL-10), whereas IL-12 is a Th1-inducing cytokine and therefore 
desirable in the context of anti-cancer therapy [20,21]. We directly compared the 
secretion of these cytokines by the differentially stimulated DC subsets. Plasmacytoid 
DCs did not secrete IL-10 or IL-12 at detectable levels, whereas CD1c+ and CD141+ 
mDCs secreted both IL-10 and IL-12 at differential levels depending on the stimulus 
(Fig. 2). R88 and polyI:C, alone or in combination, induced IL-10 production in CD1c+ 
mDCs, while only the combination of both TLR ligands induced a significant increase 
in the secretion of IL-12. CD141+ mDCs secreted low amounts of IL-10, irrespective 
of the stimulus and at lower levels than CD1c+ mDCs. We observed a significant 
increase in IL-12 production by CD141+ mDCs after stimulation with the both polyI:C 
and R848, which is higher than the production by CD1c+ mDCs. We can therefore 
conclude that CD141+ mDCs produce less IL-10 and more IL-12 than CD1c+ mDCs.
Human blood DCs induce proliferation of allogeneic naive CD4+ T cells 
A primary immune response constitutes the activation of naive T cells in response to 
antigen, and their subsequent proliferation and differentiation. Besides recognition 
of their cognate antigen, naive T cells depend on co-stimulation by the antigen-
presenting cell to start such a primary response. The ability of blood DCs to induce 
proliferation of naive T cells was directly compared by co-culturing overnight 
stimulated pDCs, CD1c+ and CD141+ mDCs of the same donors with allogeneic 
naive CD4+ T cells. Proliferation was measured at day four by tritiated thymidine 
incorporation. All primary blood DC subsets showed the ability to induce proliferation 
of naive CD4+ T cells (Fig. 3). Even so, R848-matured mDCs induced the highest 
levels of proliferation, while polyI:C maturation did not further increase proliferation 
as compared to unstimulated mDCs. For pDCs, R848 and IL-3 (control) treatment 
stimulate similar levels of naive CD4+ T cell proliferation, while the levels for CpG-
treated pDCs tends to be lower than for R848 or IL-3.
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Besides providing effector T cells, a primary immune response can generate 
immunological memory in the form of memory T cells. While central memory T cells 
(TCM) are responsible for rapid clonal expansion after re-exposure to antigen and 
localize in lymphoid organs, effector memory T cells (TEM) localize in mucosal tissue 
and mediate rapid effector functions there. Although the formation and longevity of 
such memory cells can only be accurately measured in vivo, we wanted to get an idea 
of the individual capacities of the different DC subsets to induce them. For this, we 
co-cultured naive, allogeneic CD4+ T cells with the differentially activated blood DC 
subsets until the T cells had ceased to proliferate [27]. At this resting state (after ~12 
days), we analyzed their CD45RO, CCR7 (CD197) and L-selectin (CD62L) expression. 
The percentages of CD45RO+ CCR7- (TEM ) and CD45RO
+ L-selectin+ CCR7+ (TCM) 
among the T cells did not differ significantly between the subsets or different stimuli 
(Suppl. Fig. 3 and 2b). At the time point measured, the T cells comprise a larger 
proportion of TEM (mean 47,14 % - 71,51 %) than TCM (mean 13,47 % - 24 %).
Taken together, all subsets can effectively induce proliferation of naive T cells and 
are probably able to induce memory T cells. However, mDCs induce significantly 
higher proliferation when matured with R848 in comparison to polyI:C maturation or 
culturing alone. 
All human blood DCs can drive IFNγ production by naive CD4+ T cells and 
do not induce Tregs
Dendritic cells play a critical role in the polarization of naive CD4+ T cells into different 
T helper phenotypes or Tregs. In a Th1 response, cytotoxic CD8+ T cells that are able 
to kill cells bearing their specific antigen are elicited. Therefore, this type of immune 
response is highly desirable in anti-tumor strategies. To compare the differential 
T cell stimulatory and polarizing capacity – especially the capacity to induce Th1 
responses upon differential stimulation with polyI:C, R848 and CpG – and possible 
Treg induction by human blood mDCs and pDCs, naive CD4+ T cells were co-cultured 
with the DC subsets until they reached resting state. Importantly, analysis of the 
resting T cells did not show a large fraction of Tregs for any DC subset or condition 
(mean 3% - 10%) (Fig. 4a; Suppl. Fig. 2a). Although the differences are small, it is 
interesting to note that the percentages of these cells were lowest for polyI:C and 
R848-matured mDCs and was highest for GM-CSF-stimulated CD1c+ mDCs (mean 
3% and 10%, respectively). For the pDC co-cultures there is a tendency of a higher 
proportion of Tregs being induced after R848 or CpG stimulation compared to the 
control (IL-3-treated cells) (mean 7%, 7% and 4%, respectively). Furthermore, we 
analyzed the induction of Th subset–specifying transcription factors T-bet, GATA-3 
and RORγt (Fig. 4b).
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Figure 4: Mature human DC subsets can skew naive CD4+ T cells towards Th1 phenotype and do not induce a big 
population of Tregs Human blood DCs were incubated with the indicated stimuli. The next day, allogeneic naive CD4+ T 
cells were added to the DCs together with a low concentration of the superantigen SEB (10 pg/ml) and cultured until 
resting (11-13 days). (a) These CD4+ T cells were analyzed by flow cytometry for presence of a Treg population 
(CD25+CD127-FoxP3+ CD4+ T cells) (n5). (b) The cells were also stained for the expression of transcription factors T-bet, 
Gata-3 and RORγt. In the lower panel, all three transcription factors are depicted in a single bar graph (mean value for 
each).  (c) Furthermore, 5x104 of these CD4+ T cells were re-stimulated for 24 hrs with anti-CD3/CD28-beads. 
Supernatants were analyzed for IL-5, IL-10 and IFN-γ by sandwich ELISA (n4). The bar graphs show mean cytokine 
production  SEM. In the lower panel, all three cytokines are depicted in a single bar graph (mean value for each 
cytokine). Significance comparing different conditions of the same subset was determined by Kruskal-Wallis test 
followed by Dunns testing (* P<.05) ((a) and (c)), by an 1-way-ANOVA followed by Turkey testing or a paired T test (b). 
Figure 4 | Mature human DC subsets can skew naive CD4+ T cells towards Th1 phenotype 
and do not induce a big population of Tregs Human blood DCs were incubated with the 
indicated stimuli. The next day, allogeneic naive CD4+ T cells were added to the DCs together with 
a low concentration of the superantigen SEB (10 pg/ml) and cultured until resting (11-13 days). 
(a) These CD4+ T cells were analyzed by flow cytometry for presence of a Treg population 
(CD25+CD127-FoxP3+ CD4+ T cells) (n≥5). (b) The cells were also stained for the expression of 
transcription factors T-bet, Gata-3 and RORγt. In the lower panel, all three transcription factors are 
depicted in a single bar graph (mean value for each). (c) Furthermore, 5x104 of these CD4+ T cells 
were re-stimulated for 24 hrs with anti-CD3/CD28-beads. Supernatants were analyzed for IL-5, IL-10 
and IFN-γ by sandwich ELISA (n≥4). The bar graphs show mean cytokine production ± SEM. In the 
lower panel, all three cytokines are depicted in a single bar graph (mean value for each cytokine). 
Significance comparing different conditions of the same subset was determined by Kruskal-Wallis 
test followed by Dunns testing, by an 1-way-ANOVA followed by Turkey testing or a paired T test (b) 
(* P<.05; ** P<.01).
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We found pronounced populations expressing T-bet across the subsets and stimuli 
(CD1c+ mDCs: 9% - 35%, CD141+ mDCs: 23% - 35%, pDCs: 32% -42%), indicating 
Th1 polarization by all subsets. GATA-3 expression was overall low, indicating little 
Th2 polarization. CD141+ mDCs showed the most pronounced GATA-3 expression 
for control and R848 stimulation (mean 5,1% and 4,25%, respectively), which was 
significantly reduced with polyI:C or combined R848 and polyI:C stimulation of 
CD141+ mDCs (mean 1,87 %for both). Furthermore, RORγt expression was only 
detected in a very small population of CD4+ T cells across the subsets (0,08% - 
0,72%), indicating Th1 rather than Th17 polarization of these cells.
Resting CD4+ T cells were also re-stimulated with anti-CD3/anti-CD28 beads and 
their supernatants analyzed for IL-5, IL-10, IL-17 and IFN-γ production to determine 
the Th1 polarization capacity of the DC subsets. Interleukin 5 is a Th2 cytokine, while 
IL-10 inhibits Th1 polarization and IFN-γ is a strong Th1 inducer [20,21,28]. Notably, 
co-culture with all three blood DC subsets induced T cells with prominent IFN-γ 
production after re-stimulation even without TLR maturation (Fig. 4c). T cells primed 
by CD141+ or CD1c+ mDCs induced prominent populations of T-bet expressing cells 
and secreted high levels of IFN-γ, indicating Th1 skewing (Fig. 4c, lower panel). GM-
CSF-stimulated CD1c+ mDCs, induced smaller populations of T-bet expressing cells 
and lower levels of IFN-γ and similar levels of both IL-5 and IL-10 as the medium 
control or TLR-matured DCs; therefore, GM-CSF maturation of CD1c+ mDCs does not 
induce the most potent Th1 response. Also pDCs induce a prominent population of 
T-bet expressing cells and IFN-γ release from re-stimulated CD4+ T cells, although 
the levels of IFN-γ are lower than for optimally stimulated mDCs. Plasmacytoid DCs 
induce similar levels of IL-5 in co-cultured T cells as mDCs. However, the levels of 
IL-10 are higher, especially for R848 and CpG stimulated pDCs, which coincides with 
a tendency for a bigger proportion of Tregs (CD25+ CD127- FoxP3+) induced in these 
conditions. We measured no IL-17 for pDCs and modest levels for mDCs stimulated 
with R848 or CD1c+ mDCs stimulated with the combination of R848 and polyI:C 
(Suppl. Fig. 4). Together with the RORγt expression data we conclude a Th1 rather 
than Th17 polarization of the naïve CD4+ T cells. In sum, all subsets polarize naive 
CD4+ T cells mainly towards Th1 cells with a strong T-bet signature producing mainly 
IFN-γ after re-stimulation.
T cell stimulatory and polarizing capacity of human primary blood dendritic cell subsets  | 
75
3
DISCUSSION
In order to manipulate T cell responses for DC-based cancer-immunotherapy, a 
better understanding of the functional specialization of human DC subsets is needed. 
In this study, we compared the capacities of primary human blood mDCs and pDCs to 
activate and polarize CD4+ T cells side-by-side. We report that CD1c+ mDCs, CD141+ 
mDCs and pDCs all induce proliferation of naive CD4+ T cells. Importantly, naive CD4+ 
T cells are not skewed towards a regulatory phenotype by co-culture with either 
mature mDCs or pDCs. Despite differences in activation and cytokine profile, both 
CD141+ and CD1c+ mDCs polarize naive CD4+ T cells towards T cells with a strong 
IFN-γ signature; also pDCs induce IFN-γ, although at lower levels and accompanied 
by a higher IL-10 production. 
While all DC subsets mature upon TLR ligation, we observed distinct cytokine 
responses for different subsets and stimuli. CD1c+ mDCs produced only a limited 
amount of IL-12 after maturation with either R848 or polyI:C alone, but production 
was significantly increased with a combination of these TLR ligands. Even higher 
levels of IL-12 are produced by CD141+ mDCs when stimulated with the combination 
of polyI:C and R848. In contrast to our findings, Nizzoli et al. did not find IL-12 
production for CD141+ mDCs after combined polyI:C and R848 stimulation [29]. 
Other studies have shown that in order to induce strong IL-12 responses in human 
and mouse DCs, both an innate trigger such as TLR ligation and a second trigger 
like ligation of CD40 by CD40L on T cells is needed [7,30]. More recently, it has been 
shown for CD1c+ mDCs, that the combination of the TLR ligands R848 and LPS can 
trigger significant IL-12 production [29]. In the case of CD141+ mDCs, a cocktail 
of polyI:C together with the cytokines IFN-γ, TNF-α, IFN-α, and IL-1β was shown 
to induce significant levels of IL-12 [31]. Hémont et al. showed that CD141+ mDCs 
produced less IL-12 as compared to CD1c+ mDCs for single TLR ligation, but that a 
higher proportion produced IL-12 after TLR1/2 or TLR3 ligation in a whole blood assay 
[7]. Our data supports the notion that a single stimulus is not sufficient to induce 
high IL-12 production and with polyI:C and R848 we describe a new combination that 
can trigger substantial IL-12 secretion by both human mDC subsets. 
All DC subsets induced proliferation of naive CD4+ T cells - regardless of the stimulus. 
The level of T cell proliferation induced by polyI:C-matured mDCs is similar to non-
stimulated mDCs. Strikingly, GM-CSF-stimulated CD1c+ mDCs and R848-matured 
CD1c+ and CD141+ mDCs cause an extra boost in proliferation of naive CD4+ T cells. 
This is in accordance with an earlier study by Jongbloed et al., which described 
equally high induction of proliferation of naive CD4+ T cells for non-stimulated or 
polyI:C stimulated CD1c+ and CD141+ mDCs after six days [31]. Because of the up-
regulation of the expression of co-stimulatory molecules with both stimuli compared 
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to untreated DCs, one would expect a higher proliferation rate than with untreated 
DCs. Certainly, other cytokines and immuno-stimulatory, but also immuno-inhibitory 
molecules expressed by cultured DCs are integrated into a single response by the T 
cells and possible differences in these factors might cause the observed differences 
in T cell proliferation. 
Only a minor percentage of CD4+ T cells that grew out of co-cultures with the different 
DC subsets displayed a Treg phenotype. Earlier studies suggest that pDCs can act as 
Th1, Th2, Th17 or even Treg inducers in T cell priming, depending on the stimulus 
they receive (summarized in [9]). One stimulus that can induce this regulatory T cell 
phenotype is CpG and the proposed mechanism is via the expression of inducible co-
stimulator ligand (ICOS-L) [32]. Ito et al. show in their study that pDCs upregulate 
ICOS-L upon CpG maturation, which triggers IL-10 production of T cells, but no 
production of IL-4, IL-5 or IL-13. This is in accordance with our findings, where we 
observed higher levels IL-10 and a tendency of a higher proportion of Tregs for pDCs 
matured with CpG or R848 compared to matured mDCs, but no elevated levels of IL-
5. However, regardless of the stimulus we also found a strong T-bet expression and 
IFN-γ production by CD4+ T cells that had grown out of co-cultures. Plasmacytoid 
DCs secrete large amounts of type I IFNs in response to bacterial or viral stimuli, 
including R848 and CpG [8]. Type I IFNs are not only important in innate responses, 
but can also help to skew T cells towards a Th1 phenotype [33]. Type I IFNs secreted 
by pDCs might play a role in the observed IFN-γ induction.  
Regulatory T cell induction with functional effects on T cells has been described in one 
study for tissue mDCs of the skin [34]. We show here that primary blood mDCs induce 
only a low proportion of Tregs and, importantly, the overall CD4+ T cell population 
displays a Th1 phenotype after co-culture (pronounced T-bet expression and high 
IFN-γ production) and no Th2 or Th17 phenotype. Myeloid DCs induced a strong 
Th1 phenotype in CD4+ T cells. This is in line with the ability of mDCs to produce IL-
12 after combined polyI:C and R848 stimulation. For the other conditions, one can 
speculate whether the addition of the CD4+ T cells and therefore ligation of CD40 
on the DCs gives the needed second signal for IL-12 production and helps the Th1 
skewing. Different groups have shown that blood mDCs can induce IFN-γ production 
in naive CD4+ and CD8+ T cells [7,35,36]. Jongbloed et al. found that CD141+ mDCs 
were more potent than CD1c+ DCs at inducing IFN-γ responses in total CD4+ T cells, 
especially after polyI:C stimulation [31]. We found that, although CD1c+ mDCs show 
a less mature phenotype than CD141+ mDCs including higher IL-10 and lower IL-12 
production, CD1c+ and CD141+ mDCs induce similar IFN-γ responses after co-culture 
with naive CD4+ T cells. However, there is a tendency for CD141+ mDCs to induce 
less IL-5 and IL-10 than CD1c+, also arguing for an overall stronger Th1 skewing by 
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this subset. For CD141+ mDCs, high TLR3 expression and the ability to produce IFN-λ 
and CXCL10, both known to induce antiviral responses, all suggest their capability 
to induce Th1 skewing in T cells [7,37,38]. Certainly, R848 and polyI:C can trigger 
distinct pathways as TLR3 signals through a TRIF-to-IRF3 pathway, rather than an 
MyD88-to-IRF7 pathway that is used by TLR8. It is interesting to note that both mDC 
subsets react strongly and in a similar way to polyI:C, although the expression levels 
of TLR3 are much higher in CD141+ mDCs than in CD1c+ mDCs [7]. Likely, other 
receptors for polyI:C contribute to the response in one or both of the mDC subsets. 
The synthetic dsRNA analog is a ligand for multiple pathogen recognition receptors, 
and besides TLR3 also triggers cytosolic RIG-I-like receptors that are expressed by 
mDCs [39,40]. Perrot et al. suggest in a study on mDCs and NK cells that both TLR3 
stimulation as well as RIG-I-like receptor ligation is needed for IFN-γ induction by 
mDCs [41].
In addition to their CD4+ T cell activating capacities, all three subsets can cross-
present exogenous antigens for cognate re-stimulation of previously activated CD8+ T 
cells [10–14], making them promising candidates for DC-based vaccination strategies 
against cancer. Both CD1c+ mDCs and pDCs have generated promising results in 
first clinical studies utilizing these primary blood DC subsets as vaccines [17,18]. 
These studies support their excellent in vivo functioning and mark them as the next 
generation of cancer vaccines. In this context, we have learned from the current work 
that GM-CSF is not the optimal stimulus for CD1c+ mDCs, since GM-CSF stimulation 
showed an overall lower Th1 skewing capacity and induced more Tregs than other 
stimuli. While maturation with polyI:C or the combination of polyI:C and R848 induce 
the most pronounced Th1 skewing, the number of T cells that grow out with these 
stimuli is lower than for example with R848 stimulation. Considering the proliferation 
data and the similar polarization capacity by all subsets and with all stimuli including 
control DCs, one can only speculate about a recommendation for a suited stimulation 
of DCs for DC-based vaccination strategies. However, TLR maturation probably has 
extra benefits beyond skewing T cell polarization. For example, TLR activation of 
DCs can lead to the up-regulation of otherwise unexpressed TLR ligands in the DCs 
[42], making them sensitive to a broader range of danger signals. Furthermore, 
in an in vivo situation also other cell types might play a crucial role for the overall 
outcome of a therapy. Such cells include NK and CD8+ T cells, for which type I IFNs 
and IL-12 – secreted at higher levels upon TLR maturation - are important [43–46]. 
As discussed above, CD141+ mDCs certainly display promising properties for DC-
based anti-cancer vaccination strategies. Besides their Th1 inducing capacity, human 
CD141+ mDCs are also excellent cross-presenters of exogenous antigens to CD8+ T 
cells. While some publications show superior cross-presentation capacity of CD141+ 
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mDCs [31,47–49] and put them forward as the human counterparts of mouse 
CD8α+ DCs [31,47–50], other studies suggest that the different human DCs subsets 
bear similar cross-presentation capacities at least for soluble antigens delivered 
through early endosomes [14,15,51]. The type and size of the antigen as well as 
the compartments they are targeted to probably underlie these differing outcomes 
(reviewed in [52,53]). In addition of using single subsets for therapeutic approaches, 
we hypothesize that using a combination of several DC subsets could further increase 
T cell activating properties, since earlier studies have shown that cell-cell interactions 
as well as soluble factors can act to cross-activate the different DCs (summarized in 
[54]). With this comparative study, we have reinforced the establishment of human 
circulating CD1c+ mDCs, CD141+ mDCs and pDCs as promising candidates for DC-
based immunotherapy in the context of cancer. 
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Supplementary Figure 1: Gating strategy for the sorting of primary blood DC subsets and purity. Before
fluorescence-activated cell sorting (FACS), lineage (CD3, CD14, CD16, CD19, CD20, CD56) positive cells
were depleted from PBMCs. The remaining cells were incubated with the antibodies recognizing lineage
markers (FITC), HLA-DR (PE-C7), CD1c (BV421), CD141 (APC), and BDCA4 (PE). (a) The cells were sorted
from lineage negative, HLR-DR+/high cells into three different populations, based on the expression of
CD1c, CD141 or BDCA4 to obtain CD1c+ mDCs, CD141+ mDCs or pDCs, respectively. (b) Purity of isolated
cells was assessed by gating on life cells and analyzing expression of HLA-DR and exclusive expression of
CD1c, CD141 or BDCA4 (not shown). Shown is HLA-DR with either CD1c, CD141 or BDCA4.
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Supplementary Figure 1 | Gating strategy for the sorting of primary blood DC subsets and 
purity. Before fluorescence-activated cell sorting (FACS), lineage (CD3, CD14, CD16, CD19, CD20, 
CD56) positive cells were depleted from PBMCs. The remaining cells were incubated with the antibodies 
recognizing lineage marker  (FITC), HLA-DR (PE-C7), CD1c (BV421), CD141 (APC), and BDCA4 (PE). 
(a) The cells were sorted from lineage negative, HLR-DR+/high cells into three different populations, 
based on th  expression of CD1c, CD141 or BDCA4 to obtai  CD1c+ mDCs, CD141+ mDCs or pDCs, 
respectively. (b) Purity of isolated cells was a sessed by gating on life c lls and analyzing expressi n 
of HLA-DR and xclusive expression of" "CD1c, CD141 or BDCA4 (not shown). Shown is HLA-DR with 
either CD1c, CD141 or BDCA4.
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Supplementary Figure 2: Gating strategy for regulatory T cells and effector memory phenotype.
(a) The population of regulatory T cells was determined by selecting CD25+ CD127- cells and
subsequently gating on the FoxP3+ population. The populations are shown as percentage of live cells
in figure 4a. Dead cells were excluded on the basis of the forward-sideward scatter. (b) Central and
effector memory T cells were determined on the basis of surface staining of CD45RO (APC), CD197
(CCR7) (+ A488-conjugated secondary Ab) and CD62-L (L-selectin) (+ PE-conjugated secondary Ab).
From CD45RO+ cells, central memory T cells (TCM) were determined by further gating on CCR7+/L-
selectin+ and effector memory T cells (TEM) were determined by further gating on CCR7- cells; both
populations are shown as percentage of live cells in supplementary figure 3.
Supplementary Figure 2 | Gating strategy for regulatory T cells and effector memory 
phenotype. (a) The population of regulatory T cells was determined by selecting CD25+ CD127- cells 
and subsequently gating on the FoxP3+ population. The populations are shown as percentage of live 
cells in figure 4a. Dead cells were excluded on the basis of the forward-sideward scatter. (b) Central 
and effector memory T cells were determined on the basis of surface staining of CD45RO (APC), CD197 
(CCR7) (+ A488-conjugated secondary Ab) and CD62-L (L-select n) (+ PE- onjugated secondary Ab). 
From CD45RO+ cells, central memory T cells (TCM) were determined by further gating on CCR7
+/L- 
selectin+ and effector memory T cells (TEM) were determined by further gating on CCR7
- cells; both 
populations are show  as percentage of live cells in supplementary figure 3.
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Supplementary Figure 3: Human DC subsets induce an effector memory phenotype in naive CD4+
T cells Human blood DCs were incubated with the indicated stimuli. The next day, allogeneic naive
CD4 + T cells were added to the DCs together with a low concentration of the superantigen SEB (10
pg/ml) and cultured until resting (11-13 days). The memory phenotype (n=5) was investigated using
flow cytometry. The bar graphs show the mean percentage ± SEM of effector (a) and central (b)
memory CD4 + T cells gated from live cells (TEM: CD45RO + CCR7 - and TCM: CD45RO+ CCR7 + L-
selectin +). Significance was determined by Kruskal-Wallis test followed by Dunns testing comparing
the different conditions of the same subset.
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Supplementary Figure 4: IL-17 production of re-stimulated CD4+ T cells after co-culture with the
DCs Human blood DCs were incubated with the indicated stimuli. The next day, allogeneic naive CD4
+ T cells were added to the DCs together with a low concentration of the superantigen SEB (10
pg/ml) and cultured until resting (11-13 days). These CD4+ T cells were re-stimulated for 24 hrs with
anti-CD3/CD28-beads. Supernatants were analyzed for IL-17 by sandwich ELISA (n=6 for CD1c+ mDCs
and pDCs; n=1-4 for CD141+ mDCs). The graph shows mean cytokine production. Each symbol
represents one donor (also across the subsets).
Supplementary Figure 3 | Human DC subsets induce an effector memory phenotype in naive 
CD4+ T cells Human blood DCs were incubated with the indicated stimuli. The next day, allogeneic 
naive CD4+ T cells were added to the DCs together with a low concentration of the superantigen SEB 
(10 pg/ml) and cultured until resting (11-13 days). The memory phenotype (n=5) was investigated 
using flow cytometry. The bar graphs show the mean percentage ± SEM of effector (a) and central (b) 
memory CD4+ T cells gated from live cells (TEM: CD45RO+ CCR7- and TCM: CD45RO
+ CCR7+ Lselectin+). 
Significance was determined by Kruskal-Wallis test followed by Dunns testing comparing the different 
conditions of the same subset.
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Supplementary Figure 3: Human DC subsets induce an effector memory phenotype in naive CD4+
T cells Human blood DCs were incubated with the indicated stimuli. The next day, allogeneic naive
CD4 + T cells were added to the DCs together with a low concentration of the superantigen SEB (10
pg/ml) and cultured until resting (11-13 days). The memory phenotype (n=5) was investigated using
flow cytometry. The bar graphs show the mean percentage ± SEM of effector (a) and central (b)
memory CD4 + T cells gated from live cells (TEM: CD45RO + CCR7 - and TCM: CD45RO+ CCR7 + L-
selectin +). Significance was determined by Kruskal-Wallis test followed by Dunns testing comparing
the different conditions of the same subset.
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Supplementary Figure 4: IL-17 production of re-stimulated CD4+ T cells after co-culture with the
DCs Human blood DCs were incubated with the indicated stimuli. The next day, allogeneic naive CD4
+ T cells were added to the DCs together with a low concentration of the superantigen SEB (10
pg/ml) and cultured until resting (11-13 days). These CD4+ T cells were re-stimulated for 24 hrs with
anti-CD3/CD28-beads. Supernatants were analyzed for IL-17 by sandwich ELISA (n=6 for CD1c+ mDCs
and pDCs; n=1-4 for CD141+ mDCs). The graph shows mean cytokine production. Each symbol
represents one donor (also across the subsets).
Supplementary Figure 4 | IL-17 production of re-stimulat d CD4+ T cells after co-culture 
with the DCs Human blood DCs were incubated with the indicated stimuli. The next day, allogeneic 
naive CD4 + T cells were added to the DCs together with a low concentration of the superantigen SEB 
(10 pg/ml) and cultured until resting (11-13 days). These CD4+ T cells were re-stimulated for 24 hrs 
with anti-CD3/CD28-beads. Supernatants were analyzed for IL-17 by sandwich ELISA (n=6 for CD1c+ 
mDCs and pDCs; n=1-4 for CD141+ mDCs). The graph shows mean cytokine production. Each symbol 
represents one donor (also across the subsets).
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ABSTRACT 
In human peripheral blood, four populations of DCs can be distinguished, plasmacytoid 
DCs (pDCs) and CD16+, CD1c+, and BDCA-3+ myeloid DCs (mDCs), each with distinct 
functional characteristics. DCs have the unique capacity to cross-present exogenously 
encountered Ags to CD8+ T cells. Here we studied the ability of all four blood DC 
subsets to take up, process and present tumor Ags to T cells. Although pDCs take up 
less Ags than CD1c+ and BDCA3+ mDCs, pDCs induce potent Ag-specific CD4+ and CD8+ 
T cells responses. We show that pDCs can preserve Ags for prolonged periods of time 
and upon stimulation show strong induction of both MHC class I and II, which explains 
their efficient activation of both CD4+ and CD8+ T cells. Furthermore, pDCs cross-
present soluble and cell-associated tumor Ags to cytotoxic T lymphocytes equally well 
as BDCA3+ mDCs. These findings, and the fact that pDCs outnumber BDCA3+ mDCs, 
both in peripheral blood and lymph nodes, together with their potent IFN-I production, 
known to activate both components of the innate and adaptive immune system, put 
human pDCs forward as potent activators of CD8+ T cells in anti-tumor responses. 
Our findings may therefore have important consequences for the development of anti-
tumor immunotherapy.
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INTRODUCTION
Dendritic cells (DCs) are the professional antigen presenting cells (APCs) of the immune 
system with the unique capacity to attract and activate naïve CD4+ and CD8+ T-cells 
[1]. Following infection or inflammation, DCs undergo a complex maturation process 
and migrate into lymph nodes where they present Ags to T cells. The DC family is 
very heterogeneous and consists of different DC subsets, each with distinct functional 
characteristics. In human peripheral blood, at least two main populations of DCs can be 
distinguished: CD11c positive myeloid DCs (mDCs) and CD11c negative plasmacytoid 
DCs (pDCs). Myeloid DCs can be further subdivided based on the expression of CD16, 
CD1c, and BDCA3 [2]. Transcriptional profiling revealed significant differences between 
the human blood DC subsets [3], likely reflecting differences in their Ag presenting-
capacities. Furthermore, mDCs and pDCs show clearly different responses to products 
derived from pathogens, as a result of their distinct Toll-like receptor (TLR) expression 
profiles [4]. Myeloid DCs have the capacity to produce IL-12 in response to microbial 
stimuli through TLRs and, thereby, induce Th1 responses [5, 6]. Plasmacytoid DCs, in 
contrast, are the key effectors in innate immunity because of their capacity to produce 
large amounts of type I IFNs in response to bacterial or viral infections [7]. Like mDC-
derived IL-12, pDC-derived type I IFNs also participate in T-cell priming as Th1-inducing 
cytokines [8]. 
In addition to directing CD4+ Th responses, DCs are also important for the generation of 
CD8+ cytotoxic T cell responses against viruses and tumors. As professional APCs, DCs 
have the unique capacity to take up, process and present exogenously encountered 
Ags for cross-presentation via MHC class I molecules to CD8+ T cells. Numerous studies 
have been performed in order to comprehend this cross-presentation process, and 
these have revealed two major pathways: 1) The ‘canonical’ proteasome dependent 
cytosolic pathway, 2) the TAP- and proteasome independent pathway [9-12]. Many 
studies however, made use of murine DCs to study cross-presentation capacities and 
mechanisms utilized by different DC subsets. There is ample evidence that identified 
the CD8α+ DC as the superior cross-presenting DC subset in mice [13, 14]. Recently, a 
lot of effort has been put towards finding the human counterpart of the murine cross-
presenting CD8α+ DC subset. Despite basic similarities between human and mouse 
DCs, direct comparison is difficult due to large differences in cell-surface marker and 
TLR expression, in particular also for pDCs, which in contrast to mice are the sole TLR9 
expressing subtype of DC in man [15]. Recent findings suggest, however, that the 
human BDCA3+ (XCR-1+, CLEC9A+) mDC subset represents the human homologue of 
the murine cross-presenting CD8α+ DC subset [16-19]. In these studies comparative 
analysis of the different blood DC subsets suggested that the BDCA3+ mDC subset, like 
its murine counterpart, was the superior human cross-presenting DC subset, although 
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also CD1c+ mDCs demonstrated to have cross-presenting abilities [20, 21].
In contrast to their myeloid counterparts, which efficiently endocytose extracellular 
particulates, pDCs are considered to primarily present endogenous Ags and are thought 
to minimally participate in the uptake and presentation of Ags from the extracellular 
environment [22]. However, we and others recently showed that human pDCs can 
take up, process and present particulate Ags [23]. Furthermore, it was demonstrated 
that pDCs can cross-present exogenous Ags to CD8+ T cells in the context of viral 
infection [10, 24, 25]. Cross-presentation of endocytosed tumor Ags to cytotoxic CD8+ 
T cells is also essential for the induction of antitumor immunity. In the present study 
we assessed the capacity of all four described human blood DC subsets; CD1c+ mDCs, 
CD16+ mDCs, BDCA3+ mDCs and pDCs, to present tumor Ags to T cells by studying 
1) the uptake, 2) processing, and 3) cross-presentation of extracellular tumor Ags to 
cytotoxic CD8+ T cells. We show that, although they take up less Ags than myeloid 
dendritic cell subsets, human pDCs are also very well capable of cross-presenting 
soluble and cell-associated tumor Ags and should therefore be considered as potential 
inducers of anti-tumor immunity.
MATERIALS & METHODS
Cells
DCs were isolated from buffy coats obtained from healthy volunteers after written 
informed consent and according to institutional guidelines. Peripheral Blood 
Mononuclear Cells (PBMCs) were purified from buffy coats via ficoll density gradient 
centrifugation (Lucron Bioproducts, Sint Martens-Latem, Belgium). To obtain peripheral 
blood leukocytes (PBLs), monocytes were depleted from PBMCs via adherence to plastic 
culture flasks. CD1c+ mDCs and CD16+ mDCs were isolated from PBMCs with a CD1c+ 
DC isolation kit and CD16+ monocyte isolation kit, respectively. BDCA3 myeloid DCs 
were isolated from PBLs by selection for BDCA3+ cells with a CD141 (BDCA3) isolation 
kit. Plasmacytoid DCs were purified from PBLs by positive selection using anti–BDCA-
4–conjugated magnetic microbeads (all Miltenyi Biotec, Bergisch Gladback, Germany). 
As described previously, DC purity was assessed by double staining CD11c+/CD1c+ 
for CD1c-mDCs (>95%), CD11c+/CD16+ for CD16-mDCs (>90%), CD11c+/BDCA3+ for 
BDCA3+ mDCs (>95%), and BDCA2/CD123 for pDCs (>95%) (all Miltenyi Biotec) [26, 
27]. The yield from one buffycoat (~500x106 PBMC) was approximately 0.15x106 for 
BDCA3+ mDCs, 5x106 for CD1c+ mDCs, 10x106 for CD16+ mDCs, and 0.7x106 for pDCs. 
DCs were cultured in X-VIVO-15 medium (Cambrex, Verviers, Belgium) supplemented 
with 2% human serum. DC were stimulated with the following TLR ligands: 4 μg/
ml R848 (Axxora, San Diego, CA) for pDCs and 4 μg/ml R848 and 2 μg/ml poly(I:C) 
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(Sigma) for mDCs. If no activation stimuli were added, pDCs were cultured with 10 ng/
ml IL-3 as a survival stimulus.
Microparticle preparation
PLGA microparticle formulations containing Atto647, DQ-BSA, or gp100272-300 peptide 
were prepared by double emulsion method as described [23]. Particle size and 
polydispersity of the microparticles were measured by dynamic light scattering as 
described [23]. Microparticles of 2 μm and with a relatively monodisperse diameter 
were produced.
Uptake of FITC-gp100272-300
Gp100272-300 long peptide was labeled with FITC through linking via a Lys-Lys cathepsin-
like cleavage site as described previously [28]. DC were cultured for 0.5, 1, 4, and 18 h in 
the presence of 5, 10 or 50 μM FITC-gp100272-300. Uptake of gp100272-300 was determined 
by flow cytometry using FACS Calibur. Extracellularly bound, non-internalized Ag was 
quenched by the addition of Trypan blue.
Uptake of PLGA particles
DC were incubated for 16 h with 250 μg/ml PLGA particles encapsulating Atto647. 
Uptake of Atto647-containing PLGA particles was analyzed by flow cytometry and 
confirmed by confocal microscopy. For confocal microscopy, cells were fixed on poly-L-
lysine coated glass slides and stained with anti-human MHC class II Ab (clone Q5/13), 
followed by a secondary goat–anti-mouse IgG Alexa 488 mAb (Molecular Probes, 
Carlsbad, CA). Imaging was performed on a Olympus FV1000 confocal laser scanning 
microscope with a 60x 1.35 NA oil immersion objective. Images were processed with 
NIH ImageJ Version 1.46j software (rsb.info.nih.gov/ij).
Ag processing
Ag processing was measured with DQ-BSA, a protein strongly labeled with a 
fluorescent BODIPY dye (Molecular Probes, Leiden, the Netherlands). DQ-BSA-
containing microparticles [23] (250 μg/ml) or soluble DQ-BSA (0.5 μg/ml) were added 
to pDCs, BDCA3+ mDCs, BDCA1+ mDCs or CD16+ mDCs (105) in the presence or 
absence of TLR ligands. Cells were cultured at 37°C and fluorescence was measured 
spectrophotometrically in a CytoFluor II.
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Ag presentation to CD4+ T cells
PBLs from healthy donors were cultured for 8–10 d with TT830–844 peptide (3 μg/ml) 
and IL-2 (50 EU/ml) to increase the number of TT-responsive cells. Autologous pDCs, 
BDCA3+ mDCs, BDCA1+ mDCs or CD16+ mDCs (104) were incubated overnight at 
37°C with PLGA particles containing TT830–844 peptide (0.25 mg/ml) or equal amounts of 
soluble FITC-TT in the presence of absence of TLR ligands in threefold. After washing, 
prestimulated PBLs were added to the DCs at a ratio of 1:10. After 4 d, proliferative 
responses were determined by adding tritiated thymidine (1 μCi [0.037 MBq]/well; MP 
Biomedicals, Amsterdam, The Netherlands) to the cell cultures. Tritiated thymidine 
incorporation was measured after 16 h in a scintillation counter.
Gp100-specific activation of CD8+ T cells 
pDCs and mDCs from a HLA-A2.1+ donors were loaded with different concentrations of 
specific peptide (gp100280-288), irrelevant peptide (either gp100154-167 or tyrosinase369-376), 
gp100 long peptide (gp100272-300), or necrotic BLM cells transfected with full length 
gp100 or tyrosinase in 96 well round bottom plates (7x103 per well). Necrotic BLM cells 
were generated by three subsequent snap freeze-thaw cycles in liquid nitrogen. After 
approximately 1 h, CD8+ gp100280-288-specific T cells (5x10
4 per well) [29, 30] and TLR 
ligands were added. After overnight incubation, CD69 expression on the CD8+ gp100280-
288-specific T cells was measured by flow cytometry using PeCy5-conjugated mouse 
anti-human CD69 (Pharmingen), and IFNg production was measured using a standard 
sandwich ELISA (Pierce Endogen). Proliferation was measured after 4 days of culturing 
by adding [3H] thymidine and measuring incorporation with a scintillation counter.
Statistical analysis
Data were analyzed with either paired student t-test or with one-way ANOVA followed 
by Newman-Keuls test using Prism (GraphPad Software). Statistical significance was 
defined as <0.05.
RESULTS 
Ag uptake by human circulating DC subsets
In order to present exogenous Ags to T cells, Ags need to be taken up from the 
extracellular environment, processed into peptides, and loaded onto MHC molecules. 
To study the ability of circulating DC subsets to take up soluble Ags, the uptake of 
fluorescently labeled Ag was analyzed by flow cytometry. As Ag we used short and long 
(which requires Ag processing) peptide fragments of gp100, a melanoma-associated 
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tumor Ag that is commonly used as target Ag in immunotherapy against melanoma. 
The uptake of soluble gp100 long peptide by freshly isolated DC subsets was already 
detectable as early as 30 minutes after addition of the Ag (Fig. 1A,B).
Figure 1 | Ag uptake by human circulating DC subsets. (A+B) Uptake of soluble Ags. Human 
CD1c+ mDCs, CD16+ mDCs, BDCA3+ mDCs and pDCs were incubated with 5 μM (n), 10 μM (▲), or 50 
μM (▼) of FITC-labeled gp100272-300 long peptide. Ag uptake was measured by flow cytometry after 0.5, 
1, and 4 h (A) and 18 h (B). Extracellularly bound, non-internalized Ag was quenched by the addition 
of Trypan blue. The figures show mean MFI ± SEM of three independent experiments performed in 
duplicate. (C+D) Uptake of particulate Ags. Human CD1c+ mDCs, CD16+ mDCs, BDCA3+ mDCs and 
pDCs were incubated with Atto647-encapsulating PGLA microparticles for 16 h. Uptake was analyzed by 
flow cytometry (C,D) and confocal microscopy (E). (C) The graph shows the mean MFI ± SEM of three 
independent experiments. Depicted in (E) are the merged pictures of the fluorescence of Atto647-
containing PGLA particles (red) and surface MHC class II staining (green), magnification 60x. (D,E) The 
figures show the result from one representative experiment.
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Interestingly, CD16+ mDCs and pDCs showed only modest uptake at the highest Ag 
concentration, whereas CD1c+ mDCs and especially BDCA3+ mDCs in contrast displayed 
high uptake of soluble Ag after 4 hours (Fig. 1A). This became even more evident after 
18 hours of incubation, when the fluorescence of CD16+ mDCs and pDCs indicated a 
3-5 times lower Ag uptake compared to CD1c+ mDCs and BDCA3+ mDCs (Fig. 1B).
Receptor independent uptake of soluble antigens from the extracellular environment 
occurs via the non-specific incorporation of extracellular fluid in a process called 
pinocytosis or “cell drinking”. To engulf larger particulates such as synthetic microspheres, 
bacteria or cellular debris, DCs however exploit the mechanistically different process 
of phagocytosis. To also study the capacity of freshly isolated DC subsets to take up 
particulate Ags, the DCs were incubated overnight with PLGA microparticles containing 
a fluorescent dye. Flow cytometric analysis indicated that all DC subsets engulfed 
PLGA microparticles after overnight incubation (Fig. 1C), which was confirmed by 
confocal microscopy (Fig 1D). Z-stack analysis confirmed that the detected fluorescent 
signal was located intracellulary (data not shown). Interestingly, both flow cytometry 
and confocal analysis suggest that the CD1c+ mDCs are more efficient in engulfing 
exogenous particulate Ags through phagocytosis than the CD16+ mDCs and BDCA3+ 
mDCs, as in these cells we detected the strongest fluorescent signal. These findings 
support our current hypothesis that CD1c+ mDCs share key features with monocyte-
derived DCs (moDCs), such as the capacity to engulf large amounts of particulate Ags. 
In accordance with our previous findings also human pDCs were able to phagocytose 
PLGA microparticles (Fig. 1C) [23], albeit a lesser extent than the mDC subsets. Taken 
together, our data suggest that all DC subsets can clearly take up soluble as well as 
particulate Ags, but their uptake capacity differs greatly amongst the DC subsets. 
Ag processing by human circulating DC subsets
To study the ability of human DC subsets to process soluble and particulate Ags, the 
model protein BSA, labeled with a fluorescent BODIPY dye (DQ-BSA), was used. DQ-
BSA is labeled to such a high degree that the fluorescence is self-quenched. Quenching 
is relieved on processing of the Ag into fluorescent peptides by cellular proteases. 
Antigen degradation could only be monitored for maximally up to 4 days due to the 
limited lifespan of these rather fragile natural human DC subsets in vitro. As expected, 
almost no Ag degradation was detected when soluble or particulate DQ-BSA were 
incubated in culture medium in the absence of DCs. Moreover, DCs incubated in culture 
medium, without soluble or particulate DQ-BSA, displayed minimal auto-fluorescence 
(Fig. 2). Although we observed that all DC subsets have the ability to take up soluble 
Ags (Fig. 1A, B), in our hands only the CD1c+ mDCs and to some extend also the pDCs 
displayed the ability to process soluble DQ-BSA (Fig. 2A). 
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Particulate DQ-BSA in contrast was efficiently degraded by CD1c+ mDCs, BDCA3+ mDCs 
and pDCs (Fig. 2B). Interestingly, in spite of the significant uptake of particulates by 
the CD16+ mDCs, this DC subset showed only minimal antigen degradation of both 
soluble and particulate Ags (Fig.2B).
Pathogens or infected cells display TLR ligands that are known to affect DC antigen 
processing and presentation. Therefore we next analyzed the processing of exogenous 
Ags in the presence of TLR ligands known to activate the tested subsets: R848 alone 
(pDCs) or a combination of R848 and Poly I:C (mDCs). Previously we demonstrated 
that in pDCs TLR9-induced activation diminishes processing of exogenous Ags [23, 
31]. Similarly, in CD1c+ and BDCA3+ mDCs R848 and Poly I:C-induced activation 
strongly diminished processing of soluble or particulate DQ-BSA by CD1c+ and BDCA3+ 
mDCs, although residual processing above background levels could still be observed 
(Fig. 2A,B). In pDCs R848-induced activation, however, did not hamper the uptake 
and processing of particulate Ag (Fig. 2B). Together, our findings unambiguously 
demonstrate that human CD1c+ mDCs, BDCA3+ mDCs and also pDCs can process 
ingested particulate Ags.
MHC molecule surface expression on human blood DCs
An effective anti-tumor immune response requires both MHC class I-restricted CD8+ 
and MHC class II-restricted CD4+ T cell responses. APCs present the Ags to T cells 
via MHC peptide complexes on their cell surface. Therefore we compared the surface 
expression of MHC class I and MHC class II molecules. All blood circulating DC subsets 
express both MHC class I and MHC class II at their cell surface. However, figure 3 
illustrates that freshly isolated BDCA3+ mDCs express high levels of both MHC class I 
and MHC class II molecules when compared to other subsets. Freshly isolated CD1c+ 
mDCs, CD16+ mDCs and pDCs expressed lower but comparable levels of MHC class I 
(Fig. 3A), whereas expression of MHC class II was exceptionally low on freshly isolated 
CD16+ mDCs (Fig. 3B). Plasmacytoid DCs and CD1c+ mDCs expressed high levels of 
MHC class II. After overnight TLR-stimulation, pDCs exhibited a significant upregulation 
of both MHC class I and MHC class II molecules (Fig. 3B), which was modest for CD1c+ 
and BDCA3+ mDCs. On CD16+ mDCs in contrast, expression of MHC molecules was 
not altered. Thus, steady state human blood DC subsets differentially express MHC 
molecules and also variably regulate their expression of MHC molecules in response to 
TLR activation. The upregulation of MHC class I by pDCs may be linked to their role 
in viral defense, but may also indicate their importance for the cross-presentation of 
extracellular Ags.
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Figure 3 | Expression of MHC class I and MHC class II. Expression of (A) MHC class I (HLA-ABC) 
and (B) MHC class II (HLA-DR) was measured by flow cytometry on freshly isolated human CD1c+ 
mDCs, CD16+ mDCs, BDCA3+ mDCs and pDCs and DC stimulated overnight with TLR ligands (4 μg/
ml R848 for pDCs, 4 μg/ml R848 and 2 μg/ml poly(I:C) for mDC subsets). The graphs show the mean 
± SEM of the mean fluorescence intensity of at least four independent experiments. Significance was 
determined by unpaired Student’s t-test. *p < 0.05.
Figure 4 | Ag-specific CD4+ T cell activation. Human CD1c+ mDCs, CD16+ mDCs, BDCA3+ mDCs 
and pDCs were incubated overnight with soluble TT peptide or with PLGA particles containing TT peptide 
in the presence of TLR ligands (4 μg/ml R848 for pDCs, 4 μg/ml R848 and 2 μg/ml poly(I:C) for mDC 
subsets). Subsequently, autologous TT-responsive PBLs were added. After 4 days, T cell proliferation 
was measured by [3H]-thymidine incorporation. Data are mean values ± SEM of one representative 
experiment performed in triplicate. Significance was determined by ANOVA and Newman-Keuls testing. 
*p < 0.05; **p < 0.01; ***p < 0.001, compared to PBLs only.
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Human CD1c+ and BDCA-3+ mDCs and pDCs present soluble and 
particulate Ag to CD4+ T cells
To determine if pDCs could stimulate CD4+ T cells we next investigated the capacity 
of the blood DC subsets to induce tetanus toxoid (TT)-specific CD4+ T cell responses. 
Freshly isolated DCs, incubated with either soluble TT or with PLGA particles containing 
TT, induced higher proliferation of autologous TT-responsive T cells compared to 
unstimulated T cells (data not shown), indicating that the subsets processed and 
presented soluble and particulate Ags to CD4+ T cells, and were able to trigger 
an Ag-specific proliferative recall responses. The addition of TLR agonists strongly 
enhanced the ability of BDCA3+ mDCs but also pDCs to induce Ag specific proliferative 
recall responses (Fig. 4), whereas only slightly and non-significantly increased T cell 
proliferation induced by CD16+ mDCs was observed. These findings are in line with 
results shown in Fig. 2A, where CD1c+ mDCs, BDCA3+ mDCs and pDCs, but not CD16+ 
mDCs, effectively processed particulate DQ-BSA. Taken together, our data suggest 
that the efficiency of Ag presentation by DC subsets is directly related to their ability 
to process incoming Ags and is for each subset differentially regulated by maturation.
Human circulating pDCs cross-present soluble and cell-associated Ags 
to CD8+ T cells
Cross-presentation of ingested Ags to cytotoxic CD8+ T cells is essential for the 
induction of anti-tumor immunity [32]. In literature, there is a common census that 
BDCA3+ mDCs cross-present Ags derived from different sources. However, it remains 
controversial whether also the other DC subsets have the capacity to cross-present 
Ags to CD8+ T cells [10, 16-21, 24, 25]. Therefore, we next studied the capacity of all 
four blood DC subsets to cross-present soluble long gp100272-300 peptide that requires 
intracellular processing to release the T cell cognate epitope gp100280-288. To control for 
MHC levels and DC activation we also assessed direct presentation of the short gp100280-
288 peptide that does not require intracellular processing but directly binds extracellular 
HLA-A2 molecules. As expected, all blood DC subsets effectively presented the short 
gp100280-288 peptide to gp100280-288-specific CD8
+ T cells in a dose-dependent manner, 
based on both the expression of the early activation marker CD69 (Fig. 5A) and the 
secretion of IFNγ (Fig. 5B). In accordance with previous studies, we observed that the 
use of TLR agonists strongly enhanced the ability of the blood DCs to specifically prime 
IFNγ secreting CD8+ T cells (Fig. 5 A,B) [16, 19, 33]. Intriguingly, CD1c+ mDCs, BDCA3+ 
mDCs as well as pDCs effectively cross-presented soluble long gp100272-300 peptide, in a 
dose-dependent manner in two different titration experiments (Fig. 5A,B). In contrast, 
CD16+ mDCs displayed only minimal ability to activate gp100280-288-specific CD8
+ T cells 
after incubation with the gp100272-300 long peptide, even in the presence of TLR ligands. 
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Figure 6 | Cross-presentation of extracellular Ags to CD8+ T cells. Human CD1c+ mDCs, CD16+ 
mDCs, BDCA3+ mDCs and pDCs were incubated with 10μM irrelevant peptide (tyrosinase369-376), 10 μM 
gp100 short peptide (gp100280-288), 25 μM gp100 long peptide (gp100272-300) (A+B), or 50 μg/mL necrotic 
BLM cells expressing gp100 or tyrosinase (C+D). Next, DCs were cocultured overnight with allogeneic 
CD8+ T cells expressing gp100280-288-specific TCR in the presence of 4 μg/mL R848 and 2 μg/mL poly 
I:C (mDCs) or 4 μg/mL R848 only (pDC). Ag specific T-cell activation was assessed by analysis of CD69 
expression (A, C) and IFN-γ production (B, D). IFNγ production is shown relative to irrelevant peptide. 
For (A, B) the graphs show the mean ± SEM of CD1c+ mDCs (n=5), CD16+ mDCs (n=4), BDCA3+ mDCs 
(n=6), pDCs (n=12) and for (C, D) the graphs show CD1c+ mDCs (n=2), CD16+ mDCs (n=2), BDCA3+ 
mDCs (n=2), pDCs (n=9) experiments with different donors. (A,B) Significance was determined by 
ANOVA and Newman-Keuls testing. *p < 0.05; **p < 0.01; ***p < 0.001, compared to irrelevant 
peptide; (D) Significance was determined by a paired Student´s t-test.
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The ability of CD1c+ mDCs, BDCA3+ mDCs and pDCs to cross-present was robust as it 
was found over a large number of different donors and T cell preparations (Fig 6 and 
Supplementary Fig 1). Thus, human pDCs can be regarded as efficient as CD1c+ mDCs 
and BDCA3+ mDCs in the cross-presentation of soluble long gp100 peptides and the 
subsequent cross-priming of CD8+ T cells.
So far literature suggests that the human BDCA3+ mDCs are superior in cross-presenting 
particulate Ags, such as cell-associated Ags [16, 17, 19]. To investigate the ability of the 
blood DC subsets to cross-present cell associated Ags, we next compared the capacity 
of the DC subsets to cross-present the gp100280-288-epitope derived from whole gp100 
protein-expressing BLM melanoma cell lysates, which were generated through three 
freeze-thaw cycles. Lysates of BLM melanoma cells expressing the irrelevant Tyrosinase 
protein were used as control. Obviously, the release of the gp100280-288 epitope from 
whole gp100 expressing cell lysate is much more demanding on the cell’s Ag uptake 
and processing machinery than for long peptides, also since the latter were offered in 
pure form and higher concentrations. Nonetheless we detected small but reproducible 
increases in the expression of CD69 on gp100280-288-specific CD8
+ T cells, incubated 
with BDCA3+ mDCs and pDCs that had ingested BLM cells expressing gp100 protein, 
but not in T cells incubated with CD1c+ mDCs and CD16+ mDCs (Fig. 6C). Interestingly, 
only pDCs also effectively and significantly induced IFNγ secretion by gp100280-288-
specific CD8+ T cells upon exposure to tumor lysates (Fig 6D). Thus, our data suggest, 
pDCs at least share but may even outcompete the capacity of BDCA3+ mDCs to cross-
present tumor cell-derived antigens to cytotoxic CD8+ T lymphocytes, also because 
their number circulating in the peripheral blood and lymph nodes is much higher [34].
DISCUSSION
The cross presentation of exogenous antigens (Ags) on MHC class I is essential for the 
initiation of an effective adaptive immune response against tumors. Therefore over 
the past decade cross-presentation has been extensively studied and the cell type and 
conditions best facilitating cross-presentation has become the holy grail of (tumor) 
immunology. Here we investigated not only the capacity of all four natural circulating 
DC subsets to cross-present exogenous Ags from various sources in combination with 
TLR agonists as adjuvants, but also their ability to take up and process different Ags 
both in soluble as particulate form. We show that, although human pDCs take up 
significantly less Ags than their myeloid counterparts, pDCs effectively cross-present 
and cross-prime soluble and cell-associated tumor Ags to CD8+ T cells. 
The use of different Ags and Ag sources like proteins, cell lysates, peptides, and virus 
infected apoptotic cells, in combination with small comparative studies has made it 
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hard to compare the cross-presenting capacities of human blood DC subsets [10, 16-
21, 24, 25]. The balance of different signaling pathways stimulated by the various 
pathogens may result in the initiation of the cross-presentation program, but currently, 
many aspects of this programming have not been elucidated. The identification of the 
dents on the keys that will kick-start each desired Ag-presentation pathway should lead 
to more efficient knowledge-based vaccine and adjuvant development. The stimulation 
of cross-presentation by specific adjuvants has been established using many different 
TLR-ligands and on many different DCs [16, 19, 33, 35]. The Ag-presenting capacities 
of each individual DC subset may vary with the stimulatory agents used in the different 
studies. Thus far, only Bachem et al. directly compared the four known human DC 
subsets in their capacity to cross-present Ag [17]. However, in that study the capacity to 
cross-present Ag was executed solemnly without the use of TLR agonists as adjuvants. 
Furthermore, DCs encounter Ags in many different shapes and sizes, derived from 
various sources, such as soluble peptides, particulates, immune complexes, etc. The 
ability of DCs to handle all these different types of Ags is largely determined by the 
repertoire of Ag uptake receptors, and the ability to engulf Ags through phagocytosis 
or receptor independent processes, such as (micro) pinocytosis. The current paradigm 
of superior cross-presentation by human BDCA-3+ mDCs is mainly derived from the 
preferential use of specific types of Ags such as cell-associated Ags, a restricted number 
of soluble model Ags or bead-bound Ags. Dendritic cells exploit endocytic receptors, 
such as DEC-205, to transport Ags into endosomes in which subsequently the cross-
presentation machinery will be recruited. Previously, Bachem et al. showed that human 
BDCA3+ mDCs induced strong T cell activation upon internalization of soluble protein, 
indicative for a potent cross-presenting machinery, whereas pDCs hardly induced T 
cell activation [17]. Nonetheless, the finding that pDCs did not cross-present whole 
protein is not surprising because previously we demonstrated that pDCs inefficiently 
take up soluble whole proteins in a receptor independent fashion. However, human 
pDCs very efficiently internalized and presented Ags from immune complexed proteins 
[36]. Obviously, the capacity of blood DC subsets to cross-present antigens largely 
depends on their ability to exploit Ag uptake receptors to take up encountered Ags. 
This notion is supported by the study from Klechevsky et al. where they demonstrated 
that all DC subsets tested cross-presented Ags when targeted trough the C-type lectin 
receptor DCIR [37]. Hence, when analyzing the cross-presenting capacities of DCs, the 
capacity to handle different types of antigens should be carefully taken into account.
We here show that, although human pDCs take up less Ags than their myeloid 
counterparts, pDCs effectively cross-present and cross-prime soluble and cell-associated 
tumor Ags to CD8+ T cells. This is in contrast to previous reports in mice where it was 
suggested that steady state spleen-derived pDCs do not cross-present cell-associated 
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Ags [38], or soluble OVA and peptide-coated beads [35]. In contrast, activation of 
murine pDCs by R848 and to a lesser extent CpG led to efficient cross-presentation 
of soluble and Ag-coated beads [35], emphasizing the significance and strength of 
specific stimulation of distinct DC subsets to induce the cross-presenting capacity. 
However, cross-presentation is not only dependent on Ag uptake and on adjuvants 
such as TLR agonists. Also Ag processing, intracellular routing of the Ag (containment 
in early endosomal compartments/entry into cross-presentation pathway), and loading 
onto MHC class I molecules are indispensable. Although pDCs take up less exogenous 
material when compared to other DC subsets, they may, because of lower oxidative 
enzymes, preserve antigen for a prolonged period of time and efficiently transfer Ags 
into the cross-presentation pathway. We show that pDCs have developed a mechanism 
of efficient preserving and processing exogenous Ags. The Ags are present for 
prolonged periods of time within the cell and upon stimulation strong induction of both 
MHC class I and II occurs, which explains their efficient activation of both CD4+ and 
CD8+ T cells.  An in depth comparative proteomic analysis on the four subsets suggest 
that human pDCs express a specific set of Ag derivative enzymes or transporters that 
could facilitate epitope generation and the transfer of Ags to the cytosol (unpublished 
results). Despite their lower Ag uptake potential, pDCs might specifically exploit these 
enzymes and transporters leading to more efficient Ag cross-presentation to equal 
levels induced by CD1c+ and BDCA-3+ mDCs despite lower antigen uptake. 
Although human pDCs generally reside in the peripheral blood they also infiltrate solid 
tumors, such as breast cancer, head and neck cancer and ovarian cancer [39]. Soluble 
factors, secreted by the tumor and necrotic tumor material prevent differentiation 
and activation of tumor infiltrating pDCs (TIpDCs). In an inactivated tolerogenic 
state TIpDCs help to maintain the immunosupressive environment, which has been 
correlated with poor prognosis [39-41]. In contrast to their suppressive counterparts, 
properly activated TIpDCs are able to directly lyse cancer cells or may take up the 
released tumor-associated Ags and present them to both CD4+ and CD8+ T cells [42, 
43]. Furthermore, by their ability to secrete large amounts of type I IFN upon activation, 
pDCs were already shown to mediate cross-talk with other immune cells, such as NK 
cells or T cells leading to superior anti-tumor immunity [44, 45]. Therefore, TIpDCs 
are interesting targets when opting for the targeted delivery of Ags and TLR ligands to 
switch the balance from tolerance to immunity for the eradication of tumors. Our study 
thus underscores that pDC can also generate CD8+ antitumor responses.
The important role for DCs in inducing immunity is the rationale for DC-based 
immunotherapy, in which DCs loaded with tumor antigens are injected into cancer 
patients to stimulate T cells to eradicate tumors [46, 47]. Because of the limited 
number of naturally circulating DCs, virtually all vaccination studies so far have used 
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DCs differentiated ex vivo from monocytes or CD34+ progenitors [48-50]. Although, 
clinical efficacy has been observed in a fraction of patients treated with these DCs [48, 
49], it has been postulated that moDCs might be less effective than naturally occuring 
DC subsets [30]. The data presented here, in combination with other studies, urges for 
the re-evaluation of the role for human pDCs as professional APCs able to effectively 
induce both CD4+ and CD8+ T cells responses in addition to a high IFN-a production. 
Just recently, the worlds’ first clinical study carried out in man (submitted) confirms 
the potency of vaccinating cancer patients with activated pDCs as it led to significant 
extension of patient survival. 
CONCLUSION
The efficiency of Ag presentation is determined by several critical steps that are 
involved in this process: 1) presence of adjuvants, 2) Ag uptake, 3) processing, 4) 
loading onto MHC class I , and 5) presentation and cross-priming of CD8+ T cells. We 
here analyzed all these different steps involved and found that, although pDCs take 
up less tumor Ags than their myeloid counterparts, they can activate CD8+ T cells to a 
similar extend. Our findings thus have important consequences for the development of 
anti-tumor immunotherapy. All together, these findings underscore that human pDCs 
are indispensable and should be considered as potent activators of CD8+ T cells in anti-
tumor responses, not only because of their capacity to efficiently present exogenous 
antigens, but also because of their potent IFN I production which potentiates both 
components of the innate and adaptive immune system.  
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ABSTRACT
Dendritic cells are key regulators of immune responses by shaping specific CD4+ and 
CD8+ T cell responses. In peripheral blood, there are at least three primary DC subsets, 
namely CD1c+ and CD141+ myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). Limited 
knowledge is available about the functional specialization of these subsets, although 
differences in e.g. their transcriptional profile suggest specialized functions. Here, we 
studied the role of indoleamine 2,3-dioxygenase 1 (IDO) in human primary blood DC 
subsets. IDO can be expressed by DCs and is known for its immunoinhibitory effects 
on T cells. IDO enzymatically converts L-tryptophan in L-kynurenine. Decreases in 
tryptophan and increases of tryptophan metabolites inhibit T cell proliferation, induce 
anergy and apoptosis and drive naïve CD4+ T cells towards differentiation into regulatory 
T cells. We report a striking difference in expression and functionality of IDO in human 
blood DC subsets. In steady state, IDO is expressed by CD141+ mDCs, but not CD1c+ 
mDCs or pDCs. IFN-γ or TLR ligation further increase the expression levels in CD141+ 
mDCs and induce low expression in CD1c+ mDCs, but not in pDCs. The enzyme is 
functionally active in CD141+ mDCs and to a lesser extend in CD1c+ mDCs as measured 
by kynurenine production, closely reflecting expression levels. Interestingly, although 
IDO activity in CD141+ mDCs inhibits T cell proliferation, it boosts cross-presentation, 
potentially via starvation-induced autophagy. Our findings thus provide new insights 
into the functional specialization of human blood DCs and uncover a new link between 
expression of IDO – an enzyme known for its immune-suppressive function – and a 
possible boosting effect of cross-presentation by human CD141+ mDCs.
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INTRODUCTION
Dendritic cells are professional Ag-presenting cells that possess the unique capacity 
to activate and prime CD4+ and CD8+ T cells. Indoleamine 2,3-dioxygenase 1 (IDO) is 
known for its immunoinhibitory effects on T cells when expressed by DCs. IDO can be 
induced in different cell types by IFNγ [1] and is an intracellular enzyme that controls 
the first, rate-limiting step in kynurenine pathway - the conversion of L-tryptophan 
to N-formylkynurenine. This is in turn quickly catabolized into L-kynurenine, the first 
stable catabolite of tryptophan. Tryptophan is an essential amino acid and is used 
in protein synthesis or in the synthesis of serotonin and melatonin. There is two 
other known enzymes capable of converting tryptophan into kynurenine, namely 
tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase 2 (IDO2). TDO 
is predominantly expressed in the liver, regulates dietary levels of tryptophan which 
in return the expression of TDO [2].  The role of IDO2 in tryptophan catabolism is 
uncertain. However, differing expression profiles for IDO and IDO2 suggest specialized 
functions [3,4]. IDO2 activity can inhibit T cell proliferation [5], but the functional 
relevance of this finding is not clear, since IDO2 has a much lower affinity and conversion 
rate for tryptophan than IDO [6]. 
In the immune system, IDO activity and therefore catabolism of tryptophan is mainly 
known for its immunoinhibitory effects on T cells when expressed by DCs or by tumors. 
IDO contributes in two ways to the inhibition of T cells. The proliferation of T cells is 
very sensitive to decreases in tryptophan levels [7–9]. So by depleting tryptophan in 
the immediate surroundings of the DC producing it, IDO can hinder the proliferation 
of T cells by depriving them of tryptophan. Secondly, T cells are also sensitive to the 
increases in levels metabolites of tryptophan, which can have a toxic effect or induce 
apoptosis as well as anergy in T cells [9–11]. Furthermore, IDO activity induces new 
formation of regulatory T cells (Tregs) from naïve CD4+ T cells and activation and 
expansion of mature Tregs [12,13]. 
Little is known about the function of IDO in human DC subsets. In peripheral blood, 
at least two major types of DCs can be distinguished, namely myeloid DCs and pDCs 
[14]. Myeloid DCs express high levels of CD11c and can further be subdivided based 
on the differential expression of either CD1c (BDCA1) or CD141 (BDCA3). Differences 
in their transcriptional profile, their repertoire of Toll-like receptors and cytokines 
produced upon stimulation suggest specialized functions [15–18]. For both pDCs and 
mDCs it has been shown that they induce T cell proliferation in an allogeneic setting 
and that they can both activate CD4+ T cells and cross-present exogenous antigens 
to prime CD8+ T cells [19–21]. RNA expression profiling for mouse and human DC 
subsets revealed a difference in IDO expression between mouse and human pDCs 
[15,22]. While it is present in steady-state mouse pDCs, IDO is absent in human pDCs. 
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Interestingly, the RNA profiling furthermore revealed high IDO expression for human 
steady-state CD141+ mDCs, similar to their likely mouse counterpart – CD8α+ DCs 
[15,22]. Proteomics analysis of steady-state human dendritic subsets recently revealed 
IDO protein to be uniquely expressed by CD141+ mDCs, while the signal was below 
the detection limit for both CD1c+ mDCs and pDCs (Buschow et al. - manuscript in 
preparation). Here, we studied and compared the expression and activity of IDO in 
human peripheral blood DCs and studied the functional effects on T cell proliferation 
and antigen cross-presentation. 
MATERIAL AND METHODS
Cells and reagents
Human primary blood DCs were isolated from buffy coats (Sanquin) obtained from 
healthy volunteers after written informed consent and according to institutional 
guidelines. Peripheral Blood Mononuclear Cells (PBMCs) were obtained from buffy 
coats via ficoll density gradient centrifugation (Lymphoprep by Axis-Shield). DCs were 
isolated by fluorescence-activated cell sorting (FACS). Prior to antibody labeling, DCs 
were enriched by depletion of T cells, B cells, monocytes/ macrophages, granulocytes, 
NK cells and erythrocytes from PBMCs with Dynabeads Human DC enrichment kit 
(Invitrogen by Life Technologies). The remaining cells were incubated with the following 
antibodies: FITC-conjugated anti-Lin1 (BD Biosciences), PE-Cy7-conjugated anti-HLA-
DR (BD Biosciences), BV421-conjugated anti-CD1c (Biolegend), APC-conjugated anti-
CD141 (Miltenyi Biotec), and PE-conjugated anti-BDCA4 (Miltenyi Biotec). The cells 
were sorted from lineage negative, HLR-DR+/high cells into three different populations, 
based on the expression of CD1c, CD141 or BDCA4 to obtain CD1c+ mDCs, CD141+ 
mDCs or pDCs, respectively. Cell sorting was performed on a BD Aria and flow cytometry 
on a BD Calibur. The flow cytometry data was analyzed by FlowJo software. In some 
experiments as indiciated, CD1c+ mDCs were isolated from PBMCs and CD141+ mDCs 
and pDCs were isolated from PBLs with magnetic microbeads by MACS sorting (Miltenyi 
Biotec). To obtain peripheral blood leukocytes (PBLs), monocytes were depleted from 
PBMCs via adherence to plastic culture flasks. 
Cells were cultured in either X-VIVO 15 medium (Lonza) supplemented with 2 % 
human serum (Sigma-Aldrich) or in custom-made tryptophan-free RPMI 1640 (Gibco) 
supplemented with 1% ultraglutamine (Lonza), 1% antibiotic-antimycotic (Gibco), 
10% human serum albumin (Sanquin) and the indicated concentration of L-tryptophan 
(Merck). The DCs were incubated with different stimuli as indicated in the figures: 
4 μg/ml resiquimod (R848) (Axxora), 20 μg/ml polyinosinic:polycytidylic acid (pI:C) 
(Enzo Life Sciences),  450 U/ml GM-CSF (Cellgenix), 5 μg/ml CpG oligodeoxynucleotide 
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class C (CpG-C) (Enzo Life Sciences) or 10 ng/ml IFN-γ (Thermo Scientific). If no 
activation stimulus was added, pDCs were cultured in medium supplemented with 10 
ng/ml recombinant human IL-3 (Cellgenix) to ensure pDC survival [23].
Flow cytometry analysis of IDO
The DCs were isolated by MACS sorting and cultured overnight in X-VIVO 15 medium 
(Lonza) supplemented with 2 % human serum (Sigma-Aldrich) with the stimuli as 
indicated. The next day, cells were harvested and stained extracellularly with APC-
conjugated anti-CD11c (Miltenyi Biotec) for mDCs or APC-conjugated anti-BDCA2 
(Miltenyi Biotec) for pDCs. Then cells were fixed and permeabilized and stained 
intracellularly with A488-conjugated anti-IDO (Monoclonal Mouse IgG1 Clone # 
700838; R&D systems). Dead cells were excluded on the basis of the forward-sideward 
scatter and IDO expression analyzed for the CD11c+ or BDCA2+ populations of isolated 
cells, respectively. Graphs show the geometric mean fluorescence intensity (MFI) of 
IDO expression after deduction of the isotype signal. 
Kynurenine quantification  
The DCs were isolated by FACS sorting and cultured for 24 hours in X-VIVO 15 medium 
(Lonza) supplemented with 2 % human serum (Sigma-Aldrich) with the stimuli as 
indicated. For each condition, 80x103 DCs were cultured at 5x105 cells/ml; for this, DCs 
from three different donors were pooled at the same ratio for each subset to obtain 
a sufficient number of cells and to even out donor variation. Conditioned media were 
analyzed for L-kynurenine by high-pressure liquid chromatography (HPLC). Kynurenine 
is the first stable catabolite downstream of IDO. Since kynurenine can be further 
metabolized to downstream products, it is not entirely quantitative, but can provide a 
relative indication of IDO activity.
Samples are pretreated with perchloric acid to precipitate proteins. Samples were 
pretreated (5:1) with 20% formic acid. 200 µL of samples was mixed well with 200 µl 
buffer (0.77 g/L NH4Ac, 100 mg/L Na2-EDTA, 375 mg/L NaCl, 37.5 ml/L MeOH; 
pH 5.35). As a calibrator, pure kynurenine (Sigma Aldrich) was used. Samples were 
injected onto an Acquity Ultra Performance Liquid Chromatography (UPLC) system 
(Waters), consisting of an autosampler, injector, column (Acquity UPLC HSS T3 1.8 µm; 
2.1x100mm) and UV detector (Waters) at 360 nm. Chromatographic separation was 
performed at an elution rate of 0.3 ml/min buffer.
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T cell proliferation assays
For the proliferation assay with conditioned medium, DCs were isolated by FACS sorting 
and 2,5-3x104 DCs cultured for 48 hours in 100 µl tryptophan-free RPMI supplemented 
with 10 µM L-tryptophan (Merck) and with the stimuli as indicated. DCs from three 
different donors were pooled at the same ratio for each subset to obtain a sufficient 
number of cells and to even out donor variation. After 48 hours, supernatants were 
harvested and 75 µl of this conditioned medium was added to 75 µl tryptophan-free 
RPMI containing 1.5x105 PBLs and 3x104 anti-CD3 and anti-CD28 beads (Dynabeads 
Gibco by Life Technologies). After 3 days, proliferation was assessed by adding 1 μCi 
[0.037 MBq]/well of 3H (MP Biomedicals) to the cells. 3H incorporation over a time 
course of 16 hours was measured in counts per minute (CPM) with a scintillation 
counter. All experiments were performed in triplicate for CD1c+ mDCs and pDCs and in 
duplicate for CD141+ mDCs.
For classical mixed leukocyte reactions, DCs were isolated by FACS sorting and 2.5-
4x104 DCs (always same across subsets) cultured for 16 hrs in 100 µl tryptophan-free 
RPMI supplemented with 10 µM L-tryptophan (Merck) and with the stimuli as indicated. 
1.5x105 PBLs were added and incubated with the DCs for three days. Proliferation was 
assessed by adding 1 μCi [0.037 MBq]/well of tritiated thymidine (3H) (MP Biomedicals) 
over a time course of 16 hours and 3H incorporation was measured in counts per 
minute (CPM) with a scintillation counter. All experiments were performed in triplicate 
for CD1c+ mDCs and pDCs and in duplicate for CD141+ mDCs.
Antigen cross-presentation assay
Jurkat T cells transduced with CD8 and the α and β chains of a T cell receptor (TCR) 
specific for the HLA-A2.1-restricted gp100(280-288) peptide (JE6.1 fl296) and described 
previously [24], were maintained in RPMI supplemented with 0.5% antibiotic-
antimycotic (Gibco), 2 mM ultra-glutamine (Lonza) and 10% FBS (Greiner Bio One). 
The percentage of Jurkat T cells positive for the gp100-specific TCR was regularly 
monitored by flow cytometry with PE-conjugated anti-TCR-V-β14 monoclonal antibody 
(Immunotools). The population was enriched for TCR positive cells when needed by 
labeling with PE-conjugated anti-TCR-V-β14 and anti-PE microbeads (Miltenyi Biotec). 
The DCs were isolated by and cultured for 16 hrs in RPMI containing 10 µM L-tryptophan 
(Merck) and with the stimuli as indicated. 
10x103 FACS sorted DCs from a HLA-A2.1+ donor were loaded with 1 µM gp100(154-162) 
peptide (irrelevant peptide), 1 µM gp100(280-288) (short peptide) or 50 µM gp100(272-
300) peptide (long peptide) (all JPT peptide technologies) in duplicate and incubated 
with or without 10 µM specific IDO inhibitor INCB024360 (Selleck Chemicals), 5 mM 
3-methyladenine (Invivogen), 50 nM rapamycin (Selleck Chemicals). The tryptophan-
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free RPMI was supplemented with either 1 µM or 10 µM tryptophan. Additionally, pDCs 
were matured with R848 and mDCs with R848 as well as pI:C. After overnight culture, 
5x104 JE6.1 fl296 T cells (ratio 1:5) were added and incubated with the DCs for another 
24 hours. The cells where harvested and labeled with FITC-conjugated anti–CD3 (BD 
Pharmingen), APC-conjugated CD69–APC (eBioscience) and fixable viability dye eFluor 
780 (eBioscience) to determine the percentage of the CD69high population among live 
CD3+ T cells. 
RESULTS
Steady state CD141+ mDCs express high levels of functionally active IDO 
High expression of IDO by human CD141+ mDCs compared to CD1c+ mDCs and 
pDCs was first shown on RNA level by Crozat et al. [22] in a dataset generated by 
Lindstedt et al. (RNA array chip by Affimetrix) [15]. Protein expression analysis in 
steady-state human blood DC subsets performed in our laboratory revealed that IDO 
was uniquely expressed by CD141+ mDCs, while the signal was below the detection 
limit for both CD1c+ mDCs and pDCs (Buschow et al. - manuscript in preparation). 
Analysis of steady-state blood DCs by flow cytometry showed significantly higher 
IDO expression by CD141+ mDCs compared to CD1c+ mDCs and pDCs (Figure 1A). 
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Figure 1: Steady-state CD141+ mDCs, but not CD1c+ mDCs and pDCs, express functionally active IDO. (A) IDO
protein expression was analyzed by flow cytometry in DCs cultured overnight; the graph shows the geometric
mean fluorescent intensity (MFI) of IDO expression subtracted by the MFI of the isotype control  SD (n ≥ 7).
(B) IDO activity was measured by analyzing the conversion of L-tryptophan to L-kynurenine. Equal numbers of
DCs were cultured for 24 hrs and L-kynurenine was measured by HPLC in the supernatants. The graph shows
the L-kynurenine concentration for three donors (pooled supernatants). Significance was tested with a 1-way-
ANOVA followed by Benferroni testing (* P<.05; ** P<.01; *** P<.001).
Figure 1: Steady-state CD141+ mDCs, but not CD1c+ mDCs and pDCs, express functionally 
active IDO. (A) IDO protein expression was analyzed by flow cytometry in DCs cultured overnight; 
the graph shows the geometric mean fluorescent intensity (MFI) of IDO expression subtracted by the 
MFI of the isotype control ± SD (n ≥ 7). (B) IDO activity was measured by analyzing the conversion of 
L-tryptophan to L-kynurenine. Equal numbers of DCs were cultured for 24 hrs and L-kynurenine was 
measured by HPLC in the supernatants. The graph shows the L-kynurenine concentration for three 
donors (pooled superna ants). Significance was tested with a 1-way-ANOVA followed by Benferroni 
testing (* P<.05; ** P<.01; *** P<.001).
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The activity of IDO was then tested by the measurement of L-kynurenine in supernatants 
from 24-hour cultures of DCs by high-performance liquid chromatography (HPLC). 
CD141+ mDC converted at least 1 µM tryptophan into kynurenine, whereas the same 
number of pDCs and CD1c+ mDCs converted less than 0.1 µM kynurenine (Figure 
1B). Taken together, steady-state human peripheral blood CD141+ mDCs express 
functionally active IDO at significantly higher levels than pDCs and CD1c+ mDCs.
IDO expression and activity are induced in CD1c+ mDCs by TLR ligation 
or IFNγ and maintained in CD141+ mDCs 
Since it is activated DCs that will migrate to lymph nodes and instruct T cells, we extended 
our analysis to TLR-matured DCs. Furthermore, as IFNγ is a potent inducer of IDO [1], 
IFN-γ stimulation was also included in the analysis. Different DC subsets were cultured 
overnight with the indicated stimuli and IDO protein expression was analyzed by flow 
cytometry (Fig. 2A) and IDO enzyme activity by determining kynurenine production in 
supernatants by HPLC (Fig. 2B). Importantly, while steady state CD1c+ mDCs showed 
only minimal levels of IDO expression and activity, stimulation with IFNγ and also 
polyinosinic:polycytidylic acid (pI:C)  or the combination of pI:C and resiquimod (R848), 
induced significant increases in both protein expression and enzyme activity. CD141+ 
mDCs stimulated with IFNγ or the combination of pI:C and R848, maintained protein 
expression and enzyme activity. On the other hand, we found overall low levels and no 
significant increase in either protein expression or enzyme activity for pDCs stimulated 
with IFNγ, R848 or CpG oligodeoxynucleotide class C (CpG-C). So, both activated 
or IFN-γ stimulated CD1c+ and CD141+ mDCs, but not pDCs, express active IDO.
IDO activity in CD141+ and CD1c+ mDCs inhibits T cell proliferation 
Especially mDCs and to a lesser extend also pDCs express high levels of stimulatory 
molecules upon maturation and are known for their T cell stimulatory capacity [17,19–
21]. However, IDO activity can inhibit T cell proliferation by limiting access to the 
essential amino acid tryptophan. To test whether IDO expressed by human blood DCs 
affects T cell proliferation,  PBLs were stimulated with anti-CD3/anti-CD28 antibody-
coated beads in DC-conditioned medium of differentially stimulated DCs. Proliferation 
was assessed by tritiated thymidine incorporation. T cell proliferation was significantly 
inhibited by supernatant of CD141+ mDCs matured with the combination of pI:C and 
R848 (mean -36 % compared to no DCs; Fig. 3A); 75 % of this inhibition could be 
rescued by specifically blocking IDO activity in the DCs (mean -9 %). Proliferation 
was also significantly boosted by IDO inhibition of CD1c+ mDCs stimulated with a 
combination of pI:C and R848. Although not significantly, IDO inhibition also boosted 
proliferation of T cells cultured with conditioned medium of IFNγ stimulated CD1c+ as 
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well as CD141+ mDCs. Inhibiting IDO activity in pDCs did not show an effect on T cell 
proliferation. These findings are in accordance with the expression and activity data 
shown in figure 2 and proof functional relevance of this IDO activity on T cell proliferation.
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Figure 2: IDO expression and activity among stimulated primary blood DCs. IDO expression was analyzed by
flow cytometry in DCs cultured overnight with different stimuli. (A) The histograms show isotype control
(solid grey line) and the IDO expression for no stimulus (dashed line), either IFNγ or CpG-C stimulation (solid
line) for mDCs or pDCs, respectively. Histograms from a representative donor are shown. (B) The figure shows
the geometric mean fluorescent intensity (MFI) of IDO expression subtracted by the MFI of the isotype
control  SEM (n ≥ 4). Significance was determined with a Mann Whitney test (* P<.05; ** P<.01; *** P<.001)
comparing each condition to unstimulated CD1c+ mDCs. (C) The activity of the IDO enzyme was determined
by measuring the conversion of L-tryptophan to L-kynurenine. Equal numbers of DCs were cultured for 24 hrs
with the different stimuli and L-kynurenine was measured by HPLC in the supernatants. The graph shows the
L-kynurenine concentration for three donors (pooled supernatants).
Figure 2: IDO expression and activity among stimulated primary blood DCs. IDO expression 
was analyzed by flow cytometry in DCs cultured overnight with different stimuli. (A) The histograms 
show isotype control (solid grey line) and the IDO expression for no stimulus (dashed line), either IFNγ 
or CpG-C stimulation (solid line) for mDCs or pDCs, respectively. Histograms from a representative 
donor are shown. (B) The figure shows the geometric mean fluorescent intensity (MFI) of IDO 
expression subtracted by the MFI of the isotype control ± SEM (n ≥ 4). Significance was determined 
with a Mann Whitney test (* P<.05; ** P<.01; *** P<.001) comparing each condition to unstimulated 
CD1c+ mDCs. (C) The activity of the IDO enzyme was determined by measuring the conversion of 
L-tryptophan to L-kynurenine. Equal numbers of DCs were cultured for 24 hrs with the different stimuli 
and L-kynurenine was measured by HPLC in the superna ants. The graph shows t e L-kynurenine 
concentration for three donors (po led supernatants). 
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Figure 3: Functional inhibition of T cell proliferation mediated by IDO. The different DC subsets were
stimulated with the indicated stimulus and/or inhibitor in medium containing 10 µM tryptophan. (A)
Supernatants were harvested after culturing for 48 hrs. PBLs were then added to these supernatants and
stimulated with anti-CD3/CD28-beads. Proliferation was measured after another three days by determining
tritiated thymidine incorporation. The graph shows the mean proliferation  SEM in counts per minute [cpm]
relative to no cells-control of same stimulus (n = 3). Significance was tested with a 2 way ANOVA followed by
Dunn’s testing comparing no inhibitor vs IDO inhibitor and a paired t-test for each subset comparing the
different stimuli to the no cells-control. (B) PBLs were added directly to the cells after overnight stimulation
and proliferation was measured after another three days by determining tritiated thymidine incorporation.
The graph shows the mean proliferation  SEM in counts per minute [cpm] (n ≥ 3). Significance was tested
with a 2 way ANOVA followed by Dunn’s testing (* P<.05; ** P<.01; *** P<.001). Each experiment was
performed in triplicate for CD1c+ mDCs and pDCs and in duplicate for CD141+ mDCs.
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Figure 3: Functional inhibition of T cell proliferation mediated by IDO. The different DC 
subsets were stimulated with the indicated stimulus and/or inhibitor in medium containing 10 µM 
tryptophan. (A) Supernatants were harvested after culturing for 48 hrs. PBLs were then added to these 
supernatants and stimulated with anti-CD3/CD28-beads. Proliferation was measured after another 
three days by determining tritiated thymidine incorporation. The graph shows the mean proliferation 
± SEM in counts per minute [cpm] relative to no cells-control of same stimulus (n = 3). Significance 
was tested with a 2 way ANOVA followed by Dunn’s testing comparing no inhibitor vs IDO inhibitor and 
a paired t-test for each subset comparing the different stimuli to the no cells-control. (B) PBLs were 
added directly to the cells after overnight stimulation and proliferation was measured after another 
three days by determining tritiated thymidine incorporation. The graph shows the mean proliferation 
± SEM in counts per minute [cpm] (n ≥ 3). Significance was tested with a 2 way ANOVA followed by 
Dunn’s testing (* P<.05; ** P<.01; *** P<.001). Each experi ent was performed in triplicate for 
CD1c+ mDCs and pDCs and in duplicate for CD141+ mDCs. 
The effect of IDO on DC-induced T cell proliferation was further studied in a classical 
mixed lymphocyte reaction, in which PBLs from an independent donor were added 
directly to differentially stimulated DCs and proliferation was assessed again by tritiated 
thymidine incorporation. Inhibition of IDO did not have an effect on the induction 
of T cell proliferation by pDCs (Fig. 3B). Inhibition of IDO did also not affect T cell 
proliferation induced by CD141+ mDCs, probably indicting that IDO activity has only 
limited inhibitory effect on T cell proliferation when the T cells directly interact with 
CD141+ mDCs. In contrast, IDO inhibition did boost T cell proliferation induced by 
unstimulated and IFN-γ stimulated CD1c+ mDCs. For IFN-γ stimulation, this corresponds 
to the highest activity of IDO observed with this stimulus, while for unstimulated CD1c+ 
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mDCs this finding is somewhat unexpected and probably reflects the complex interplay 
of inhibitory and stimulatory molecules expressed by DCs in T cell activation.
IDO activity boosts cross-presentation of CD141+ mDCs potentially by a 
pathway involving autophagy
An important ability of human blood DCs is to present exogenous antigens on MHC class I 
molecules to cross-prime CD8+ T cells [19–21]. A link between autophagy and increased 
cross-presentation has recently been described [25–27]. Tryptophan depletion by IDO 
activity can activate the nutrient sensor GCN2 and thereby induce autophagy [12,28]. 
Hence, we postulated that the selective high activity of IDO by CD141+ mDCs could 
contribute to their excellent cross-presenting capacity by possible activation of GCN2 
kinase after tryptophan depletion and subsequent initiation of autophagy. Therefore, 
we studied the capacity of the DC subsets to cross-present exogenous soluble antigens 
in the absence or presence of IDO inhibitor, or in presence of an excess of tryptophan 
to prevent amino acid starvation. We tested the capacity of HLA-A2.1+ DCs to cross-
present soluble gp100(272-300) peptide, which requires intracellular processing in order 
to release the HLA-A2.1 restricted gp100(280-288) epitope, to T cells transduced with a 
TCR specific for the gp100(280-288) peptide. In line with our expectations, all subsets 
effectively cross-presented soluble gp100(272-300) peptide to the T cells  (Figure 4). 
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Figure 4: IDO activity boosts cross-presentation of CD141+ mDCs. Dendritic cells from HLA-A2.1+ donors were
loaded with gp100(154-162) peptide (irrelevant short peptide), gp100(280-288) (short peptide) or gp100(272-300)
peptide (long peptide) and incubated with or without IDO inhibitor, 3-methyladenine (3-MA) or rapamycin.
The DCs were matured with R848 or a combination of R848 and pI:C for pDCs and mDCs, respectively. After
overnight culture, 5x104 JE6.1 fl296 T cells expressing the T cell receptor recognizing gp100(280-288) in the
context of HLA-A2.1 were added for 24 hours. Flow cytometry analysis revealed the percentage  SEM of the
CD69high population among live CD3+ T cells (n ≥ 4). Significance was determined with a paired t-test (* P<.05;
** P<.01; *** P<.001).
Figure 4: IDO activity boosts cross-presentation of CD141+ mDCs. Dendritic cells from 
HLA-A2.1+ donors were loaded with gp100(154-162) peptide (irrelevant short peptide),  gp100(280-288) 
(short peptide) or gp100(272-300) peptide (long peptide) and incubated with or without IDO inhibitor, 
3-methyladenine (3-MA) or rapamycin. The DCs were matured with R848 or a combination of R848 
and pI:C for pDCs and mDCs, respectively. After overnight culture, 5x104 JE6.1 fl296 T cells expressing 
the T cell receptor recognizing gp100(280-288) in the context of HLA-A2.1 were added for 24 hours. Flow 
cytometry analysis revealed the percentage ± SEM of the CD69high population among live CD3+ T cells 
(n ≥ 4). Significance was determined with a paired t-test (* P<.05; ** P<.01; *** P<.001).
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However, IDO inhibition only significantly inhibited cross-presentation by CD141+ mDCs 
and not by CD1c+ mDCs and pDCs, suggesting that IDO activity can boost cross-
presentation by CD141+ mDCs. Addition of an excess of tryptophan, which prevents 
starvation-induced autophagy, also inhibited cross-presentation, further substantiating 
the hypothesis that starvation-induced autophagy can boost cross-presentation by 
CD141+ mDCs. Certainly autophagy plays a role in cross-presentation of both mDC 
subsets, as autophagy inhibition by 3-methyladenine [29] significantly reduced cross-
presentation, whereas induction of autophagy by rapamycin [30] significantly increased 
it. Together this suggests that IDO activity can support cross-presentation in CD141+ 
mDCs probably via a pathway inducing autophagy.
DISCUSSION
Human blood DCs are all capable to induce T cell proliferation, activate CD4+ T cells 
and cross-present exogenous antigens to prime CD8+ T cells [19–21]. However, 
differences in their transcriptional profile, their repertoire of Toll-like receptors and 
cytokines produced upon stimulation suggest specialized functions [15–18]. Despite 
the individual characteristics, the specialized roles of human DC subsets are not clearly 
defined. Especially the functional differences between CD1c+ and CD141+ mDCs are 
less sharply demarcated than in mouse DCs. We describe here a functional role for IDO 
in especially CD141+ mDCs and to a lesser extend also in CD1c+ mDCs.
The RNA expression profiling of steady-state human DC subsets [15,22] showed unique 
expression of IDO by CD141+ mDCs. We expand this data and describe unique IDO 
protein expression and activity in steady-state CD141+ mDCs; this was maintained and 
increased upon incubation with IFN-γ or stimulation with the combination of pI:C and 
R848. CD1c+ mDCs have been shown to express enzymatically active IDO in response 
to prostaglandin E2, LPS, Escherichia coli and to a lesser extend also to pI:C [36,37]. We 
observed IDO expression and activity in CD1c+ mDCs activated with IFN-γ, pI:C and the 
combination of pI:C and R848. In contrast to pDCs, IDO had a functional impact on T cell 
proliferation induced by both mDCs subsets. Both in a classical MLR and a proliferation 
assay with DC-conditioned medium, IDO inhibition boosted T cell proliferation induced 
by CD1c+ mDCs. However, the proliferation assay with the conditioned medium showed 
that only CD141+ mDCs can inhibit T cell proliferation by a mechanism dependent 
on IDO and independent of cell-cell contact, probably by depleting tryptophan and/
or enriching T cell inhibitory breakdown products of tryptophan. Stimulatory cell-cell 
contact between CD141+ mDCs and T cells in a classical MLR, seem to overpower 
this inhibition, as IDO inhibition does not boost T cell proliferation induced by CD141+ 
mDCs in this setting.
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The activity of the immune-inhibitory enzyme IDO in CD141+ mDCs seems 
counterintuitive, as they are handled as homologues of mouse CD8α+ DCs - professional 
antigen cross-presenters that can trigger strong antiviral and anti-tumor responses. 
However, in peripheral tissues, CD141 expressing DCs show potential signs of immune-
inhibition. One study of lung DCs and another with monocyte derived DCs (moDCs) 
showed that expression of the molecule CD141 is associated with a tolerogenic function 
of DCs [38,39]. Human lung CD141+ mDCs were also shown to induce Th2 cytokines 
IL-4 and IL-13 slightly more than CD1c+ mDCs [40]. 
On the other hand, CD141+ mDCs show many immune-stimulatory characteristics. They 
highly express co-stimulatory molecules in steady-state and upon maturation [41,42]. 
Furthermore, several genes involved in MHC class I processing and presentation are 
expressed at even higher levels in CD141+ mDCs as compared with CD1c+ mDCs [22]. 
CD141+ mDCs induce proliferation of naïve CD4+ T cells and can cross-prime CD8+ T 
cells  [19–21,40]. Also, we could show in earlier study that CD141+ mDCs do not induce 
a higher proportion of Tregs than CD1c+ mDCs or pDCs under tryptophan rich conditions 
[43]. Additionally, human CD141+ mDCs selectively express high levels of TLR3 and 
can be effectively stimulated via this TLR [17], producing anti-viral effectors IL-12 and 
IFN-λ [44], pointing to a specialization in anti-viral responses. Taken together, this 
suggests that CD141+ mDCs may function as professional cross-presenting DCs that 
induce efficient CD8+ T cell responses against intracellular pathogens and cancer, but 
promote tolerance for controlling auto-immune responses in steady-state. However, 
active IDO was not only found at steady-state, but also for CD141+ mDCs stimulated 
either by IFN-γ or the combination of pI:C and R848. 
Interestingly, IDO activity in CD141+ mDCs might not serve to inhibit immune responses, 
as IDO activity seems to have a boosting effect cross-presentation in CD141+ mDCs 
and we also observed no inhibitory effect of IDO activity in an MLR setting. It is known 
that tryptophan depletion by IDO activity can activate the nutrient sensor GCN2 and 
induce autophagy [12,28]. A link between autophagy and increased cross-presentation 
has recently been described [25,27]. Furthermore, Ravindran et al. showed that 
activity of the nutrient sensor GCN2 kinase in human moDCs initiates autophagy and 
thereby enhances antigen cross-presenting abilities [26]. We speculated that the 
selective high activity of IDO by CD141+ mDCs could contribute to their excellent cross-
presenting capacity by possible activation of GCN2 kinase after tryptophan depletion 
and subsequent initiation of autophagy. One argument for the role of starvation 
induced autophagy in cross-presentation of CD141+ mDCs is the inhibitory effect of the 
addition of extra tryptophan - preventing starvation-induced autophagy. Furthermore, 
autophagy inhibition hampered cross-presentation, while autophagy induction boosted 
it. This was also true for CD1c+ mDCs, pointing to a role of autophagy in cross-
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presentation of this subset, too. The boosting effect by IDO activity however, was only 
significant for CD141+ mDCs, fitting the higher activity levels in this subset. While it is 
certain that all three human blood DC subsets can cross-present antigens [20,21,42], 
some publications show superior cross-presentation capacity of CD141+ mDCs and 
put them forward as the human counterparts of mouse CD8α+ DCs [41,45–48]. IDO 
activity could possibly contribute to this superior cross-presenting ability.
In contrast to mouse pDCs, human pDCs showed no or very low IDO expression and 
activity in steady-state. This is in accordance with RNA expression profiling of steady-
state mouse and human DC subsets [15,22]. We also find very low expression and 
activity in pDCs stimulated with CpG-C, R848 or IFN-γ. Expression of IDO in human 
pDCs has been described in rheumatoid arthritis synovial tissues and peripheral blood 
of HIV as well as melanoma patients [31–35]. Manches et al. detected induction of 
IDO by R848 by western blot, and showed regulatory T cell (Treg) induction for R848 
and HIV matured pDCs [32]. Prostaglandin E2 did not induce IDO in pDCs, while it did 
so in CD1c+ mDCs [36]. Our data do not exclude a role for IDO in pDCs, however the 
expression levels and activity were much lower as compared to mDCs. Furthermore, 
we did not find a functional role for IDO in pDCs with regard to T cell proliferation or 
antigen cross-presentation. Therefore, although IDO seems to play a role in mouse 
pDCs and in in some human diseases, its functional weight in human pDCs compared 
to especially CD141+ mDCs seems to be limited. 
With our findings, we add to the knowledge of functional specialization of human blood 
DCs and describe a unique IDO phenotype of CD141+ mDC. It remains to be proven 
in further studies whether CD141+ mDCs are tolerogenic in steady-state and immune-
stimulatory when activated and whether IDO activity in CD141+ mDCs functions to 
inhibit T cell function, boost cross-presentation, acts as a negative feedback loop or 
any combination of the above. Like for other DC subsets, plasticity of DC function 
enables CD141+ mDC to respond to environmental factors and adjust their function in 
order to induce the appropriate immune response. Therefore, the role of CD141+ mDC 
may vary among tissues and activation status and should be studied for each setting.
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ABSTRACT 
Plasmacytoid dendritic cells (pDCs) play a crucial role in initiating immune responses 
by secreting large amounts of type I interferons. Currently, the role for human pDCs as 
professional APCs in the cross-presentation of exogenous antigens is being re-evaluated. 
Human pDCs are equipped with a broad repertoire of antigen uptake receptors and an 
efficient antigen processing machinery. Here, we set out to investigate which receptor 
can best be deployed to deliver antigen to pDCs for antigen (cross-) presentation. 
We show that targeting nanoparticles to pDCs via the C-type lectins DEC-205, DCIR, 
BDCA-2 or the Fc receptor CD32 led to uptake, processing and (cross-) presentation of 
encapsulated antigen to both CD4+ and CD8+ T cells. This makes these receptors good 
candidates for potential in vivo targeting of pDCs by nanocarriers. Notably, the co-
encapsulated TLR7 agonist R848 efficiently activated pDCs, resulting in phenotypical 
maturation as well as robust IFNα and TNFα production. Taken together, their cross-
presentation capacity and type I IFN production to further activate components of both 
the innate and adaptive immune system, mark pDCs as inducers of potent anti-tumor 
responses. These findings pave the way to actively recruit human pDCs for cellular 
cancer immunotherapy.
Targeting uptake receptors on human pDCs triggers Ag cross-presentation  | 
129
6
INTRODUCTION
Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferons (IFNα/β) 
in response to viral or bacterial stimuli [1]. Type I interferons are essential in initiating 
immune responses by stimulating NK cell functions, T helper 1 responses and DC 
maturation for efficient cross-priming of CD8+ T cells [2, 3]. Non-stimulated pDCs on 
the other hand are involved in the induction of regulatory responses and tolerance [4]. 
Human pDCs exploit a repertoire of different pattern recognition receptors such as Toll-
like receptors (TLRs) or C-type lectin receptors (CLRs) for the detection of pathogens 
and the uptake of antigens (Ags) for subsequent processing and presentation to T cells 
[5]. Previous studies showed that the delivery of antibody-coupled Ags to the CLRs 
DEC-205, DCIR and BDCA-2 or to the Fc receptor CD32 (FcγRIIa) leads to Ag specific 
CD4+ T cell activation [6-8]. However, for a potent anti-tumor response both CD4+ 
and CD8+ T cell activation is essential. Although human pDCs were previously thought 
to poorly cross-present exogenous Ag to CD8+ T cells, accumulating evidence now 
suggests that human pDCs are endowed with an efficient cross-presenting machinery 
[9-14]. Just recently, we could demonstrate the potency of pDCs in a small cohort 
of metastatic melanoma patients, in which vaccination with activated pDCs induced 
favorable immune responses and significantly extended overall survival [15]. This 
puts human pDCs forward as potent activators of anti-tumor responses that efficiently 
present exogenous Ags to T cells in combination with a high type I IFN production to 
further activate components of both the innate and adaptive immune system. 
Harnessing pDCs for DC-based immunotherapy by direct targeting of pDCs in vivo 
is an attractive opportunity; it allows the delivery of Ags without extensive handling 
and ex vivo culturing [16, 17]. The potency of harnessing pDCs in vivo was already 
demonstrated in mice, where targeting the murine pDC specific receptor Siglec-H 
induced the priming of Ag specific CD8+ T cells upon Ag uptake via this receptor 
[18]. Moreover, targeting murine pDCs via BST2 induced Ag specific CD4+ and CD8+ 
T cell responses [18, 19]. Human pDCs, however, do not express Siglec-H [20] and 
expression of BST2 – while a possible target – is not restricted to human pDCs, but 
is also found on B cells and upregulated by IFNα on a range of other cell types [21]. 
In this study, we investigated which receptor can best be harnessed to deliver Ags for 
Ag (cross-) presentation to human pDCs. For this purpose poly(lactic-coglycolic acid) 
(PLGA) nanoparticles (NPs) were used that were decorated with antibodies against 
either DEC-205, DCIR, BDCA-2 or CD32 and that encapsulated peptide Ags along with 
the TLR7 agonist R848 (Fig. 1). PLGA is a biocompatible polymer that is already widely 
used as a vaccine carrier [22]. Furthermore, the use of these nanocarriers allows 
the co-delivery of several components, such as Ag and adjuvant, circumventing the 
need for systemic TLR administration and all the therewith associated side-effects. 
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We demonstrate that targeting PLGA NPs via DEC-205, DCIR, BDCA-2 or CD32 to 
human pDCs led to receptor-specific uptake and processing of the particulate Ag. The 
processed peptides were loaded in MHC class I and II and (cross-) presented to CD8+ 
and CD4+ T cells, respectively. Importantly, the co-encapsulated TLR7 agonist R848 
efficiently activated pDCs resulting in phenotypical maturation and cytokine production. 
Figure 1 
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Figure 1: Schematic depiction of nanoparticle. The core of the particle consists of poly(lactic-co-
glycolic acid) and comprises variable content, such as an antigen and TLR agonist as depicted here. The 
particles are shielded by a lipid-poly(ethylene glycol) layer. Biotinylated antibodies specific for different 
antigen uptake receptors are coupled to the particles via streptavidin. 
MATERIALS AND METHODS
Cells
Cells were obtained from buffy coats of healthy individuals in accordance to 
institutional guidelines. Peripheral blood mononuclear cells were obtained by Ficoll 
density centrifugation and monocytes were removed by plastic adherence. Peripheral 
blood leukocytes were used for pDC isolation by positive selection using anti-BDCA-
4-conjugated magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Plasmacytoid DC purity was routinely 95% or higher as analyzed by flow cytometry by 
double staining with CD123 and BDCA-2. Plasmacytoid DCs were cultured in X-VIVO-15 
medium (Cambrex, Verviers, Belgium), supplemented with 2% human serum (Sigma, 
St. Louis, Missouri, USA) and activated as indicated. 
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PLGA nanoparticles
Nanoparticles were generated using the copolymer poly(lactic-co-glycolic acid) as 
described previously [23]. Gp100272-300 peptide, tetanus-toxoid830-844 peptide (TT), TLR-
ligand R848 (Axxora, San Diego, CA, USA) and DQ-BSA (Molecular Probes, Leiden, 
the Netherlands) were encapsulated by addition to the NPs (Table I). Encapsulation 
efficiency was determined by reverse phase high-performance liquid chromatography, 
as described before [24, 25]. Nanoparticles were coated with lipid-PEG and streptavidin, 
and subsequently coupled to the following biotinylated antibodies as described by Cruz 
et al. [25] α-DCIR (Dendritics), α-DEC-205 (eBioscience), α-BDCA-2 (Miltenyi Biotec), 
α-CD32 (AbD Serotec) and α-DC-SIGN.
Particle binding and uptake
To study particle binding 3x104 pDCs were incubated with 20 µg/ml NPs encapsulating 
fluorescein isothiocyanat (FITC) labeled TT (FITC-TT) (and R848) for different time 
periods at 4°C. Cells were washed and fluorescence intensity of FITC was analyzed 
by flow cytometry while constantly keeping the cells on ice to avoid internalization of 
particles. Particle uptake was studied by incubating pDCs for different time periods at 
37°C with 20 µg/ml NPs encapsulating FITC-TT (and R848) and determining changes 
in cell-associated fluorescence of FITC on a FACSCalibur (BD Biosciences, San Jose, CA, 
USA); data was analyzed  by Cell Quest (BD Bioscience, San Jose, CA, USA). As a pH 
sensitive fluorophore, FITC loses intensity at lower pH values as present in endosomes 
and lysosomes [19]. This could account for the seemingly low percentage of positive 
cells for DEC-205, DCIR and CD32 targeted NPs after overnight culture. Also, the PLGA 
surrounding the fluorescent antigen can shield the FITC signal as supported by the 
observation that upon in vitro degradation of PLGA, thereby releasing its fluorescent 
content, fluorescence levels increased 150-fold [23].
Confocal microscopy
Particle uptake after overnight incubation was confirmed by confocal analysis of 
intracellular FITC signal of the FITC-TT-containing NPs. Cells were fixed on poly-L-lysine 
coated glass slides and stained with anti-human HLA-DR/DP (Q5/13) antibody, followed 
by a secondary goat-anti-mouse IgG Alexa 647 antibody (Molecular Probes, Carlsbad, 
CA, USA). Cells were imaged with a Bio-Rad MRC 1024 confocal system operating on a 
Nikon Optiphot microscope and a Nikon 60x planApo 1.4 oil immersion lens. 
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Antigen degradation
2.5x104 pDCs were cultured in 100 µl phenol red free X-VIVO 15 medium supplemented 
with 2% human serum in the presence of 0.5 µg soluble DQ-BSA (bovine serum albumin 
labeled with a auto-quenching fluorescent BODIPY dye) or DQ-BSA encapsulated in 
antibody-coated NPs. After 4 hours at 37°C, the excessive NPs were washed away and 
cells were cultured at 37°C up to 72 hours. The fluorescence released within pDCs 
was measured (excitation: 485 nm; emission: 530 nm) with a CytoFluor II (Applied 
Biosystems, USA) at various time points. Antigen degradation kinetics was determined 
as described previously [23]. 
Phenotype
The phenotype of pDCs was determined by flow cytometry after overnight stimulation 
with 20 µg/mL NPs containing R848 (and either FITC-TT or gp100272-300), 10 ng/ml 
rhIL-3 (Cellgenix Freiburg, Germany) or 4 µg/ml soluble R848 at 37°C. The following 
monoclonal antibodies with appropriate isotype controls were used for staining: mIgG1-
FITC, mIgG1-PE, mIgG1-allophycocyanin, anti-CD80-PE, anti-CD86-allophycocyanin, 
anti-MHCI-PE, anti-MHCII-FITC, anti-CD83-PE, anti-PDL-1-PE, anti-ICOS-L-ALexa488, 
anti-CCR7-PE (BD Bioscience Pharmingen, San Diego, CA) and anti-CD40-PE (Beckman 
Coulter, Mijdrecht, The Netherlands). Flow cytometry analysis was performed on a 
FACSCalibur (BD Bioscience); the mean fluorescence intensity (MFI) and percentage of 
positive cells were determined from live cell population based on FSC and SSC using 
Cell Quest (BD Bioscience).
Antigen presentation to CD4+ T cells
Peripheral blood leukocytes from healthy donors were cultured for 8-10 days with 
TT peptide (3 μg/ml) and IL-2 (50 EU/ml) to increase the pool of TT-specific T cells. 
Autologous plasmacytoid DCs were cultured overnight at 37°C either with 20 µg/ml 
NPs containing FITC-TT and R848 or with 4 µg/ml soluble R848 together with soluble 
TT peptide. The pDCs were then added to the pre-stimulated PBLs in a ratio of 1:10. 
After 4 days 1 μCi [0.037 MBq]/well [3H] thymidine (MP Biomedicals, Amsterdam, The 
Netherlands) was added to measure proliferation. [3H] thymidine incorporation was 
measured with a betacounter. 
Gp100-specific activation of CD8+ T cells 
Plasmacytoid DCs from HLA-A2.1+ donors were loaded with different concentrations 
of soluble gp100280-288 short peptide, irrelevant peptide (either gp100154-167 or 
tyrosinase369-376), or gp100272-300 long peptide in 96-well round bottom plates (7x10
3 
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cells per well). After approximately 1 hour, allogeneic CD8+ gp100280-288-specific T cells 
[26, 27] (5x104 cells per well) and 4 µg/mL R848 (where applicable) were added. 
After overnight incubation, CD69 expression by the CD8+ gp100280-288-specific T cells 
was measured by flow cytometry using PeCy5-conjugated mouse anti-human-CD69 
(Pharmingen); IFNg production was measured using a standard sandwich ELISA 
(Pierce Endogen). 
Furthermore, pDCs (1x104 cells per well) from HLA-A2.1+ donors were pre-cultured for 
two hours with either 6,6 μM gp100280-288 short peptide and 4 µg/mL R848, 16,6 μM 
gp100272-300 long peptide and 4 µg/ml R848, or with 20 µg/ml NPs containing gp100272-
300 and R848. Gp100280-288 specific CD8
+ T cells (5x104 cells per well) were added to the 
pre-stimulated pDCs and cultured overnight. CD69 expression by the CD8+ gp100280-
288-specific T cells was measured by flow cytometry using the following antibodies: 
mIgG1-PE, mIgG1-allophycocyanin, anti-CD8-allophycocyanin and anti-CD69-PE (BD 
Bioscience Pharmingen, San Diego, CA). Proliferation was measured after 4 days of 
culturing by adding [3H] thymidine and measuring incorporation with a scintillation 
counter.
Cytokine Detection
Plasmacytoid DCs were stimulated with 20 µg/ml R848 containing NPs, 10 ng/ml rhIL-3 
or 4 µg/ml R848 overnight at 37°C at a concentration of 1x106 pDCs/ml in a 96-well 
round-bottom plate. After 16 hours of activation supernatant was collected and IFNα 
and IL-6 production was analyzed by ELISA using murine monoclonal capture and 
HRP-conjugated anti-IFNα detection antibodies (Bender MedSystems, Vienna, Austira) 
and anti-IL-6 antibodies (Sanquin, Amsterdam, The Netherlands) respectively. TNFα 
production was measured using a human TNFα ELISA kit according to manufacturer’s 
protocols (BD). 
The cytokine profile was analyzed by incubating 1x104 pre-stimulated pDCs with 1x105 
TT-stimulated PBLs and collecting supernatant after 3 days. Production of the cytokines 
IL-5, IL-6, IL-10, TNFα and IFNγ was analyzed with a human Th1/Th2 Multiplex kit 
(BenderMed System) according to manufacturer’s instructions. 
Cytokine production by pDCs targeted in PBMCs: 3x106 PBMCs were stimulated with 
20 µg/ml NPs containing R848 and FITC and incubated at 37°C. After 6 hours, BFA 
(Sigma) was added to the PBMCs at 2 µg/ml and cells further cultured at 37°C. The 
next day, cells were harvested, surface receptors and subsequently intracellular IFNα 
and TNFα (BD Bioscience Pharmingen, San Diego, CA) were stained and analyzed by 
flow cytometry.
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Statistics
All data are expressed as the mean ± SEM. The data were analyzed by one-way ANOVA 
followed by either Newman-Keuls multiple comparisons test or Dunnett’s multiple 
comparisons test.
RESULTS
Nanoparticles targeted to different receptors are specifically taken up 
and degraded by pDCs
Human pDCs express the receptors DEC-205, DCIR, BDCA-2 and CD32 but not DC-
SIGN [7, 8]. We investigated whether receptors expressed by pDCs can be used for 
receptor-specific delivery of nanocarriers and whether pDCs bind, take up and process 
antigens targeted to these receptors. To this end, pDCs were incubated with antibody-
coated PLGA nanoparticles (NPs) (Fig. 1) encapsulating either FITC-labeled tetanus 
toxoid (TT) or DQ-BSA (Table I). After incubation for 1 hour with FITC-TT containing 
NPs at 4°C, pDCs specifically bound DEC-205-NPs as well as BDCA-2-NPs, but only 
minimally bound DCIR-NPs and CD32-NPs compared to control DC-SIGN-NPs (Fig. 
2A). The targeted NPs were taken up by pDCs after overnight incubation at 37°C, 
as demonstrated by the percentage of FITC+ cells, which even reached statistical 
significance for BDCA-2-NPs (Fig. 2B). We also performed a kinetic analysis of binding 
and uptake ranging from 1hr to overnight incubation. We observed that the binding 
(4°C) of the different NPs over a time course of 16 hours was low (Suppl. Fig. 1A). 
However, we did observe that the DC-SIGN coated particles bound at a lower rate 
compared to the NPs targeted to receptors expressed by pDCs. For the uptake (37°C) 
of the different NPs, pDCs incubated with BDCA-2-NPs showed a high total percentage 
of FITC+ pDCs, while for the other receptors the percentage of FITC+ pDCs increased 
at a lower rate. The lowest percentage of FITC+ pDCs was observed for the negative 
control DC-SIGN-NPs (Suppl. Fig. 1B). The relatively low percentage of FITC+ cells could 
potentially be attributed to quenching of FITC in endosomal compartments as FITC is 
a pH sensitive dye or by shielding by the PLGA surrounding the fluorescent antigen. 
This notion was supported by the observation that upon in vitro degradation of PLGA, 
thereby releasing its fluorescent content, fluorescence levels increased 150-fold(23).
Additional evidence for NP internalization was obtained by confocal microscopy. In line 
with the results obtained by flow cytometry, pDCs targeted via DEC-205, DCIR, BDCA-
2 and CD32 had all taken up FITC-TT containing PLGA NPs (Fig. 2C). Z-stack analysis 
confirmed that the FITC signal was located within the pDCs (data not shown). These 
data demonstrate that pDCs can bind and take up NPs coated with antibodies specific 
for DEC-205, DCIR, BDCA-2 and CD32. 
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Figure 2 | Nanoparticles targeted to different receptors are specifically taken up and 
degraded by pDCs. (A) Human pDCs were incubated with NPs containing FITC-labeled TT (FITC-TT) 
for 1h at 4°C, washed and analyzed by flow cytometry to determine binding of NPs. Figures show the 
percentage of FITC positive cells and the mean fluorescence intensity (MFI) of the FITC signal. Data 
show the means ± SEM of six independent experiments. (B) pDCs were incubated overnight at 37°C 
with NPs containing FITC-TT or with soluble IL-3. Uptake by pDCs was then analyzed by flow cytometry. 
Data represent at least 4 independent experiments with means ± SEM. (C) Uptake of encapsulated 
FITC-TT was further confirmed by confocal microscopy. Pictures show merged signal from encapsulated 
FITC-TT (green) and MHC class II (red) of pDCs incubated with the different NPs. (D) pDCs were 
incubated with antibody-coated NPs encapsulating the self-quenching model protein DQ-BSA. After 4 
hours, the excessive NPs were washed away and fluorescence was measured spectrophotometrically at 
various time points during 72 hours. The fluorescent signal is depicted as the percentage of fluorescence 
relative to the total amount that could theoretically be generated upon full degradation of the ingested 
DQ-BSA. Data represent the mean value ± SEM from two independent experiments performed in 
quadruplicate. Statistical significance (A+B) was determined by one-way ANOVA followed by Dunnett’s 
Multiple Comparison Test. *p < 0.05; **p < 0.01; ***p < 0.001. 
Table I | Characteristics of PLGA nanoparticles 
Samples Antigens  (µg/mg PLGA)
R848  
(µg/mg PLGA)
size ± S.D. 
(nm) PDI ± S.D.
Zeta potential 
± S.D. (mV)
NP (DQ-BSA) 18.8 ± 3.2 - 245.6 ± 16.7 0.178 ± 0.116 -21.5 ± 2.4
NP (FITC-TT + R848) 8.2 ± 3.6 1.90 ± 0.5 267.5 ± 12.6 0.183 ± 0.136 -22.7 ± 1.6
NP( gp100 + R848) 10.4 ± 2.9 1.82 ± 0.4 249.8 ± 14.6 0.123 ± 0.086 -23.5 ± 1.9
PDI: polydispersity index
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To investigate whether human pDCs are able to process particulate Ag delivered via 
surface receptors, we made use of the model protein BSA labeled with a fluorescent 
BODIPY dye (DQ-BSA). DQ-BSA is self-quenched; quenching is relieved upon release 
of DQ-BSA from the NPs within the cell and subsequent processing into fluorescent 
peptides by cellular proteases. Incubation of pDCs with DQ-BSA-containing PLGA NPs 
showed an increase in fluorescence over time as measured by spectrophotometry (Fig. 
2D). We did not observe, however, a difference of Ag degradation by pDCs targeted 
via the different receptors, nor with the control DC-SIGN-NPs.  Notwithstanding, these 
findings demonstrate that pDCs process particulate Ags upon receptor-specific delivery.
Receptor targeting delivers particulate R848 to TLR7 containing 
endosomes 
Activation of pDCs is essential for the induction of optimal immune responses and T cell 
activation. Therefore, we investigated whether the encapsulated TLR7 agonist R848 is 
able to induce full pDC activation by studying surface receptor expression and cytokine 
production by pDCs. As expected and in line with our previous study [24], pDCs cultured 
with IL-3 were minimally activated, in contrast to pDCs stimulated with soluble R848 
(Fig. 3A). An interesting observation made throughout our experiments is that a large 
proportion of pDCs died in vitro when cultured with DC-SIGN-NPs compared to the use 
of either soluble IL-3 or other receptor targeted NPs (Suppl. Fig. 2A).  Plasmacytoid DCs 
targeted via DEC-205, DCIR, BDCA-2 and CD32 showed significant increased expression 
of the co-stimulatory molecules CD40, CD80, and CD86, while pDCs incubated with DC-
SIGN-NPs did not (Fig. 3A). Remarkably, targeting of R848-containing PLGA NPs via 
DEC-205, DCIR, BDCA-2 and CD32 induced pDC activation to a similar degree as soluble 
R848, even though the concentration of particulate R848 is about one hundred times 
lower than the concentration of soluble R848. Furthermore, the targeted delivery of 
NPs induced a trend towards upregulation of CD83, MHC class I, MHC class II, inducible 
co-stimulator ligand (ICOS-L), co-inhibitory molecule programmed cell death ligand 1 
(PD-L1) and C-C chemokine receptor type 7 (CCR7); however, these levels did not 
reach statistical significance compared to levels induced by control DC-SIGN-NPs (Fig. 
3A and data not shown). The notion that encapsulated R848 induces full activation of 
pDCs is further supported by the production of inflammatory cytokines. Encapsulated 
R848 delivered via DEC-205, DCIR, BDCA-2 and CD32 induced significant production 
of IL-6, TNFα and IFNα compared to the production induced by DC-SIGN-NPs (Fig. 3B, 
Table II). Surprisingly, upon targeting pDCs with R848-containing antibody-coated NPs, 
they secreted comparable amounts of cytokines as pDCs activated with soluble R848. 
Next, we investigated whether we can also deliver the contents of the particles to pDCs 
in bulk PBMC cultures. To this end, we incubated PBMCs overnight with the different 
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NPs. Interestingly, a clear population of pDCs could only be detected when the NPs 
could deliver their contents to pDCs via receptors they express (Suppl. Fig. 2B), but 
not for DC-SIGN-NPs. This indicates that the survival of  pDCs in bulk culture – like in 
isolated pDC cultures – depends on the acquisition of specific stimuli. This finding is in 
accordance with previous studies demonstrating that pDCs need a stimulus to survive. 
Similar to the experiments with isolated pDCs, also in total PBMCs pDCs only produced 
the cytokines TNFα and IFNα when targeted through DEC-205, DCIR, BDCA-2 or CD32 
(Suppl. Fig 3). Thus, particulate R848 can reach TLR7 containing endosomes in pDCs, 
both isolated and in bulk, thereby inducing full pDC activation without affecting TLR-
induced cytokine secretion.
Table II | Production of IL-6, TNFα and IFNα by human pDCs after overnight incubation 
with IL-3, R848 or the different antibody-coated NPs. Data are shown as mean ± SEM.
IL-6
(pg/ml)
TNFα
(pg/ml)
IFNα
(pg/ml)
IL-3 447 ± 69 564 ± 124 11 ± 4
R848 5999 ± 2857 4287 ± 1358 773 ± 295
αDC-SIGN-NP 1514 ± 605 860 ± 336 332 ± 167
αDEC-205-NP 2948 ± 585 4036 ± 1541 736 ± 276
αDCIR-NP 3270 ± 904 3429 ± 1220 661 ± 275
αBDCA-2-NP 4276 ± 1612 3776 ± 1137 712 ± 285
αCD32-NP 5186 ± 2012 3824 ± 1034 721 ± 279
Receptor targeting induces antigen specific CD4+ T cell activation and 
IFNγ production
Next we investigated the capacity of pDCs to induce TT specific CD4+ T cell responses 
after targeted delivery of antigen encapsulated in antibody-coated PLGA NPs. 
Plasmacytoid DCs pre-incubated with soluble TT and soluble R848 induced significantly 
higher proliferation of autologous TT-responsive T cells compared to unstimulated T 
cells (PBLs only) (Fig. 4A). This indicates that pDCs efficiently process and present 
soluble TT to CD4+ T cells, resulting in an Ag-specific proliferative recall responses. 
Importantly, pDCs incubated with DEC205-, DCIR-, BDCA2-, or CD32-targeted PLGA 
NPs containing both TT and R848, also induced significantly higher proliferation of 
autologous TT-responsive T cells compared to unstimulated T cells or T cells co-cultured 
with DC-SIGN-NP-targeted pDCs (Fig. 4A). Notably, the recall response after targeted 
delivery of particulate TT and R848 is higher than after delivery of soluble antigens, 
even though a substantial lower amount of both Ag and TLR ligand is comprised in the 
NPs. Cytokine analysis of IFNγ, TNFα, IL-10, IL-6, and IL-5 revealed that TT-specific 
CD4+ T cells co-cultured with NP-targeted pDCs predominantly produced large amounts 
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of IFNγ (Fig. 4B). Taken together, pDCs incubated with NPs targeted to the receptors 
DEC-205, DCIR, BDCA-2 or CD32, are able to process and present the particulate Ag 
to CD4+ T cells, inducing proliferation of Ag-specific CD4+ T cells that predominantly 
produce IFNγ. 
Figure 4 | Targeted antigen delivery to pDC surface receptors induces antigen specific 
CD4+ T cell activation and IFNγ production. pDCs were incubated overnight with NPs containing 
FITC-TT and R848 or a combination of soluble R848 and TT peptide as a control. Subsequently, 
autologous TT-responsive PBLs were added. Four days later, T cell proliferation was measured by 
[3H]-thymidine incorporation (A) and cytokine production was determined in supernatants (B). Data 
show mean values ± SEM of three independent experiments. Statistical significance was determined 
by one-way ANOVA followed by Newman-Keuls Multiple Comparison Test. *p < 0.05; ***p < 0.0001.
pDCs cross-present soluble and receptor targeted antigens
Cross-presentation of exogenous Ags to cytotoxic CD8+ T cells is essential for the 
induction of anti-tumor immunity [28]. We studied the capacity of human pDCs to 
cross-present tumor Ags derived from soluble and particulate gp100 peptide. Gp100 
is a melanoma-associated tumor antigen that is commonly used as target antigen in 
immunotherapy of melanoma. Plasmacytoid DCs presented the soluble short gp100280-
288 peptide, which directly binds extracellular HLA-A2 molecules, to gp100280-288-specific 
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Figure 5 | Plasmacytoid DCs cross-present soluble Ag and receptor targeted particulate 
antigen to CD8+ T cells. (A + B) Specific CD8+ T cell activation with soluble gp100 Ag. Plasmacytoid 
DCs were incubated with 10 μM irrelevant peptide (gp100154-167 or tyrosinase369-376), 10 μM gp100 short 
peptide (gp100280-288), or with 10 μM or 25 μM gp100 long peptide (gp100272-300). Next, DCs were co-
cultured overnight with allogeneic CD8+ T cells expressing a gp100280-288-specific T cell receptor in 
the presence of 4 μg/mL R848. Antigen specific T cell activation was assessed by analysis of CD69 
expression (A) and IFNγ production (B). Data show mean values ± SEM of at least 4 independent 
experiments. (C + D) Specific CD8+ T cell activation with gp100 long peptide containing NPs. Human 
pDCs were pre-incubated with NPs containing long gp100272-300 and R848 for 1 hour. Gp100280-288 specific 
CD8+ T cells were added to the pre-stimulated pDCs and cultured overnight. Antigen specific T-cell 
activation was assessed by analysis of CD69 expression (C); proliferation was measured after 4 days 
by [3H] thymidine incorporation (D). Data were collected from at least 3 independent experiments 
and means ± SEM are shown. Statistical significance was determined by one-way ANOVA followed by 
Newman-Keuls Multiple Comparison Test. **p < 0.01; ***p < 0.0001.
CD8+ T cells, as shown by the expression of the early T cell activation marker CD69 (Fig. 
5A) and the secretion of IFNγ (Fig. 5B). Moreover, pDCs effectively cross-presented the 
soluble long gp100272-300  peptide, which needs to be taken up and processed before it 
can be loaded onto MHC class I molecules. In accordance with previous studies [14, 
29], we observed that the TLR7 agonist R848 enhanced the ability of the pDCs to 
specifically prime IFNγ-secreting CD8+ T cells (Fig. 5B). To determine which uptake 
receptor could be harnessed for facilitating optimal Ag cross-presentation and cross-
priming of CD8+ T cells by pDCs, we used antibody-coated PLGA NPs with encapsulated 
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gp100272-300 peptide and R848. Figure 5 illustrates that pDCs incubated with gp100272-300 
containing DC-SIGN-NPs only induced minimal CD8+ T cell activation. Interestingly, 
gp100272-300 containing NPs targeted to pDCs via DEC-205, DCIR, BDCA-2 or CD32, 
significantly increased gp100-specific T cell activation (Fig. 5C) and proliferation (Fig. 
5D) even though the concentration of particulate gp100272-300 is about 120 times lower 
than the concentration of soluble gp100272-300. These data reveal that DEC-205, DCIR, 
BDCA-2 and CD32 are all possible targets for the delivery of Ags to human pDCs and 
that Ags delivered via these receptors are cross-presented by pDCs and lead to the 
priming of antigen specific CD8+ T cells.
DISCUSSION 
In this study we set out to investigate which uptake receptor expressed by human 
pDCs can best be targeted for the delivery of Ag for (cross-) presentation. We showed 
that targeting DEC-205, DCIR, BDCA-2 and CD32 successfully delivered the content 
of NPs to pDCs, leading to specific activation, cytokine production as well as (cross-) 
presentation of particulate Ag to both CD4+ and CD8+ T cells. Our findings further 
support the notion that human pDCs can cross-present exogenous Ag [9-11, 13, 
14], a process essential for the induction of anti-tumor immunity [28]. Here, pDCs 
cross-presented gp100272-300 peptide either in soluble form or encapsulated in NPs that 
were targeted to uptake receptors DEC-205, DCIR, BDCA-2 and CD32. Together, this 
puts human pDCs forward as interesting targets for the induction of potent adaptive 
immune responses against tumors. This is further underlined by our recent findings, 
where vaccination with activated pDCs induced favorable immune responses and a 
significantly prolonged overall survival in a small cohort of melanoma patients [15].
After encountering soluble TLR ligands human pDCs down-regulate their surface 
expression of DCIR and BDCA-2, thereby reducing the internalization of Ags [6, 
30]. Although CD32 expression remains unchanged upon TLR-induced activation, 
Ag internalization via this receptor is impaired [6]. In contrast, DEC-205 expression 
increases upon pDC activation and still efficiently captures Ags for subsequent processing 
and presentation [8]. However, the delivery of Ag without TLR ligands as adjuvants 
would likely induce tolerogenic responses, since immature pDCs minimally express co-
stimulatory molecules that are needed for T cell activation [31, 32]. Furthermore, our 
data support the importance of TLR ligands as adjuvants in the functional activation 
of CD8+ T cells, as pDCs pulsed with Ag alone did not induce IFNγ secreting T cells. 
Therefore, the simultaneous delivery of both Ags and TLR ligands is critical for the 
successful induction of Ag specific immune responses via uptake receptors in vivo. 
In accordance with earlier findings in monocytes-derived DCs, we found that the 
simultaneous delivery of co-encapsulated Ags and TLR ligands is effective to achieve 
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successful pDC activation as well as Ag (cross-) presentation and T cells activation 
[33-35].
Previously, we and others have shown that the cross-linking of uptake receptors 
modulated TLR-induced signaling. In those studies, the secretion of cytokines was 
determined after the cross-linking of receptors followed by the addition of soluble TLR 
ligands. Cross-linking CD32 on human pDCs did not inhibit TLR-induced IFNα secretion 
[6, 36, 37], however, cross-linking DEC-205, DCIR or BDCA-2 impaired TLR7- and/or 
TLR9-induced IFNα secretion and cross-linking DCIR and BCDA-2 also impaired TLR7- 
and/or TLR9-induced TNFα production [7, 8, 38]. The amplitude of cytokine secretion 
in response to TLR ligands can be regulated by signaling of the uptake receptors 
through immunoreceptor tyrosine-based activating or inhibiting motifs (ITAMs or 
ITIMs). Receptors that signal through ITAMs usually activate cells, whereas ITIM-
bearing receptors inhibit cell activation. For the regulation of cytokine production by 
pDCs, this principle does not always hold true (reviewed in [39]). For example, BDCA-
2-induced signaling through the ITAM motif inhibited type I IFN secretion by pDCs [38, 
40], as did DCIR-induced signaling through the ITIM motif [7]. Interestingly, we did not 
observe such an inhibition of TNFα or IFNα secretion when R848 was delivered to pDCs 
via DEC-205, DCIR, BDCA-2 or CD32 in PGLA NPs. This might indicate that the timing of 
signaling through these receptors and the slow release of TLR ligands from NPs in the 
TLR7 containing endosomes, circumvent the negative modulatory effect of receptor 
cross-linking. Furthermore, also the mode of entry of the TLR ligand, soluble versus 
particulate and targeted, is an important factor that deserves further investigation. 
Delivery of NPs to pDCs via either DEC-205, DCIR, BDCA-2 or CD32, resulted in 
comparable functional outcomes in our experiments. When opting for exclusive in 
vivo targeting of human pDCs, BDCA-2 would serve as an interesting receptor as it 
is exclusively expressed by human pDCs. DEC-205 and CD32 on the other hand are 
expressed by a wider range of immune cells [41, 42], and therefore would be suited 
for a more general approach of Ag delivery. Additionally, we showed here that NPs can 
deliver Ag to pDCs via DCIR resulting in Ag cross-presentation. Recently, Klechevsky 
et al. showed that targeting DCIR with fusion constructs specifically delivered Ags to 
various cell types including myeloid DCs, resulting in cross-presentation and cross-
priming of CD8+ T cells [43]. In accordance with their study we also observed that the 
addition of soluble R848 enhanced the capacity of pDCs to cross-prime CD8+ T cells. 
However, in contrast to their and other studies we now used nanocarriers that enabled 
us to simultaneously deliver TLR agonists and Ags to human pDCs. This circumvents 
the need for systemic TLR agonist administration and the therewith associated side 
effects [44-46]. We believe that exploiting NPs that target such Ag uptake receptors 
that are expressed by both pDCs and myeloid DCs, has great potential, as they interact 
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synergistically, thereby increasing Ag-specific immune responses induced by these cells 
[47-50]. Furthermore, we believe that nanocarriers, such as the here described PLGA 
particles, pose a powerful and versatile tool, as they can be decorated with different 
antibodies for targeting of different cell populations. Moreover, these nanocarriers 
allow the incorporation of different substances, such as adjuvants for cell activation 
and fluorophores or radioactive labels for cell tracking purposes. Additionally, the 
encapsulation of different forms of antigens, e.g. peptides, proteins or glycolipids 
ensures the activation of antigen specific CD4+ and CD8+ T cells as well as NKT cells.
In conclusion, the CLRs DEC-205, DCIR and BDCA-2 as well as the Fc receptor CD32 
- with their distinct properties regarding expression by different immune cells - are all 
potential targets for the delivery of NPs to pDCs in vivo. Our data indicate that PLGA NPs 
might be a promising tool to efficiently load pDCs with tumor Ag and simultaneously 
activate them by co-encapsulated TLR ligands, resulting in fully activated pDCs capable 
of stimulating anti-tumor responses via both production of IFNα and direct induction of 
Ag-specific CD4+ and CD8+ T cell responses. These exciting findings pave the way to 
actively recruit human pDCs for cellular in vivo immunotherapeutic strategies.
DISCLOSURE OF CONFLICT OF INTEREST
The authors declare no competing financial interests.
ACKNOWLEDGEMENTS
This work was supported by grants from the Dutch Cancer Society (KUN2006-3699, 
KUN2009-4402), the EU (ENCITE HEALTH-F5-2008-201842; ERC-2010-AdG-269019; 
Pharmachild FP7-HEALTH-2010-260353), The Netherlands Organization for Scientific 
Research (NWO-Vidi-917.76.363), the NOTK (Nijmeegs Offensief tegen Kanker) 
foundation, the Netherlands Institute for Regenerative Medicine (NIRM, grant No. 
FES0908) and a Radboud University Nijmegen Medical Centre PhD grant. CF received 
the NWO Spinoza award.
|  Chapter 6
144
REFERENCES
1. Cella, M.; Jarrossay, D.; Facchetti, F.; Alebardi, O.; Nakajima, H.; Lanzavecchia, A.; Colonna, M. 
Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type i 
interferon. Nat Med 1999, 5, 919-923.
2 .Kadowaki, N.; Antonenko, S.; Liu, Y.J. Distinct cpg DNA and polyinosinic-polycytidylic acid double-
stranded rna, respectively, stimulate cd11c- type 2 dendritic cell precursors and cd11c+ dendritic 
cells to produce type i ifn. J Immunol 2001, 166, 2291-2295.
3. Le Bon, A.; Etchart, N.; Rossmann, C.; Ashton, M.; Hou, S.; Gewert, D.; Borrow, P.; Tough, D.F. 
Cross-priming of cd8+ t cells stimulated by virus-induced type i interferon. Nature immunology 
2003, 4, 1009-1015.
4. Ito, T.; Hanabuchi, S.; Wang, Y.H.; Park, W.R.; Arima, K.; Bover, L.; Qin, F.X.; Gilliet, M.; Liu, Y.J. Two 
functional subsets of foxp3+ regulatory t cells in human thymus and periphery. Immunity 2008, 
28, 870-880.
5. Schreibelt, G.; Tel, J.; Sliepen, K.H.; Benitez-Ribas, D.; Figdor, C.G.; Adema, G.J.; de Vries, I.J. Toll-
like receptor expression and function in human dendritic cell subsets: Implications for dendritic 
cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010, 59, 1573-1582.
6. Benitez-Ribas, D.; Tacken, P.; Punt, C.J.A.; de Vries, I.J.M.; Figdor, C.G. Activation of human 
plasmacytoid dendritic cells by tlr9 impairs fc gamma rii-mediated uptake of immune complexes 
and presentation by mhc class ii. Journal of Immunology 2008, 181, 5219-5224.
7. Meyer-Wentrup, F.; Benitez-Ribas, D.; Tacken, P.J.; Punt, C.J.A.; Figdor, C.G.; de Vries, I.J.M.; 
Adema, G.J. Targeting dcir on human plasmacytoid dendritic cells results in antigen presentation 
and inhibits ifn-{alpha} production. Blood 2008, 111, 4245-4253.
8. Tel, J.; Benitez-Ribas, D.; Hoosemans, S.; Cambi, A.; Adema, G.J.; Figdor, C.G.; Tacken, P.J.; de 
Vries, I.J. Dec-205 mediates antigen uptake and presentation by both resting and activated human 
plasmacytoid dendritic cells. European journal of immunology 2011, 41, 1014-1023.
9. Hoeffel, G.; Ripoche, A.C.; Matheoud, D.; Nascimbeni, M.; Escriou, N.; Lebon, P.; Heshmati, F.; Guillet, 
J.G.; Gannage, M.; Caillat-Zucman, S., et al. Antigen crosspresentation by human plasmacytoid 
dendritic cells. Immunity 2007, 27, 481-492.
10. Di Pucchio, T.; Chatterjee, B.; Smed-Sorensen, A.; Clayton, S.; Palazzo, A.; Montes, M.; Xue, Y.; 
Mellman, I.; Banchereau, J.; Connolly, J.E. Direct proteasome-independent cross-presentation of 
viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class i. Nature 
immunology 2008, 9, 551-557.
11. Lui, G.; Manches, O.; Angel, J.; Molens, J.P.; Chaperot, L.; Plumas, J. Plasmacytoid dendritic cells 
capture and cross-present viral antigens from influenza-virus exposed cells. PLoS One 2009, 4, 
e7111.
12. Schnurr, M.; Chen, Q.; Shin, A.; Chen, W.; Toy, T.; Jenderek, C.; Green, S.; Miloradovic, L.; Drane, 
D.; Davis, I.D., et al. Tumor antigen processing and presentation depend critically on dendritic cell 
type and the mode of antigen delivery. Blood 2005, 105, 2465-2472.
13. Mittag, D.; Proietto, A.I.; Loudovaris, T.; Mannering, S.I.; Vremec, D.; Shortman, K.; Wu, L.; 
Harrison, L.C. Human dendritic cell subsets from spleen and blood are similar in phenotype and 
function but modified by donor health status. J Immunol 2011, 186, 6207-6217.
14. Tel, J.; Schreibelt, G.; Sittig, S.P.; Mathan, T.S.M.; Buschow, S.I.; Cruz, L.J.; Lambeck, A.J.; Figdor, 
C.G.; De Vries, I.J.M. Human plasmacytoid dendritic cells efficiently cross-present exogenous ags to 
cd8+ t-cells, despite lower ag uptake than myeloid dendritic cell subsets. Blood 2012.
15. Tel, J.; Aarntzen, E.H.; Baba, T.; Schreibelt, G.; Schulte, B.M.; Benitez-Ribas, D.; Boerman, O.C.; 
Croockewit, S.; Oyen, W.J.; van Rossum, M., et al. Natural human plasmacytoid dendritic cells 
induce antigen-specific t-cell responses in melanoma patients. Cancer Res 2013, 73, 1063-1075.
16. Tacken, P.J.; de Vries, I.J.; Torensma, R.; Figdor, C.G. Dendritic-cell immunotherapy: From ex vivo 
loading to in vivo targeting. Nat Rev Immunol 2007, 7, 790-802.
17. Tel, J.; van der Leun, A.M.; Figdor, C.G.; Torensma, R.; de Vries, I.J. Harnessing human plasmacytoid 
dendritic cells as professional apcs. Cancer Immunol Immunother 2012, 61, 1279-1288.
18. Zhang, J.; Raper, A.; Sugita, N.; Hingorani, R.; Salio, M.; Palmowski, M.J.; Cerundolo, V.; Crocker, 
P.R. Characterization of siglec-h as a novel endocytic receptor expressed on murine plasmacytoid 
dendritic cell precursors. Blood 2006, 107, 3600-3608.
Targeting uptake receptors on human pDCs triggers Ag cross-presentation  | 
145
6
19. Loschko, J.; Schlitzer, A.; Dudziak, D.; Drexler, I.; Sandholzer, N.; Bourquin, C.; Reindl, W.; Krug, 
A.B. Antigen delivery to plasmacytoid dendritic cells via bst2 induces protective t cell-mediated 
immunity. J Immunol 2011, 186, 6718-6725.
20. Fitzgerald-Bocarsly, P.; Jacobs, E.S. Plasmacytoid dendritic cells in hiv infection: Striking a delicate 
balance. J Leukoc Biol 2011, 87, 609-620.
21. Blasius, A.L.; Giurisato, E.; Cella, M.; Schreiber, R.D.; Shaw, A.S.; Colonna, M. Bone marrow stromal 
cell antigen 2 is a specific marker of type i ifn-producing cells in the naive mouse, but a promiscuous 
cell surface antigen following ifn stimulation. J Immunol 2006, 177, 3260-3265.
22. Hamdy, S.; Haddadi, A.; Hung, R.W.; Lavasanifar, A. Targeting dendritic cells with nano-particulate 
plga cancer vaccine formulations. Advanced drug delivery reviews 2011, 63, 943-955.
23. Cruz, L.J.; Tacken, P.J.; Fokkink, R.; Joosten, B.; Stuart, M.C.; Albericio, F.; Torensma, R.; Figdor, 
C.G. Targeted plga nano- but not microparticles specifically deliver antigen to human dendritic cells 
via dc-sign in vitro. J Control Release 2011, 144, 118-126.
24. Tel, J.; Lambeck, A.J.; Cruz, L.J.; Tacken, P.J.; de Vries, I.J.; Figdor, C.G. Human plasmacytoid 
dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol 2010, 
184, 4276-4283.
25. Cruz, L.J.; Tacken, P.J.; Pots, J.M.; Torensma, R.; Buschow, S.I.; Figdor, C.G. Comparison of 
antibodies and carbohydrates to target vaccines to human dendritic cells via dc-sign. Biomaterials 
2012, 33, 4229-4239.
26. Schaft, N.; Dörrie, J.; Müller, I.; Beck, V.; Baumann, S.; Schunder, T.; Kämpgen, E.; Schuler, G. 
A new way to generate cytolytic tumor-specific t cells: Electroporation of rna coding for a t cell 
receptor into t lymphocytes. Cancer Immunology, Immunotherapy 2006, 55, 1132-1141.
27. Schreibelt, G.; Benitez-Ribas, D.; Schuurhuis, D.; Lambeck, A.J.; van Hout-Kuijer, M.; Schaft, N.; 
Punt, C.J.; Figdor, C.G.; Adema, G.J.; de Vries, I.J. Commonly used prophylactic vaccines as an 
alternative for synthetically produced tlr ligands to mature monocyte-derived dendritic cells. Blood 
2010, 116, 564-574.
28. Kurts, C.; Robinson, B.W.; Knolle, P.A. Cross-priming in health and disease. Nat Rev Immunol 2010, 
10, 403-414.
29. Kool, M.; Geurtsvankessel, C.; Muskens, F.; Madeira, F.B.; van Nimwegen, M.; Kuipers, H.; 
Thielemans, K.; Hoogsteden, H.C.; Hammad, H.; Lambrecht, B.N. Facilitated antigen uptake and 
timed exposure to tlr ligands dictate the antigen-presenting potential of plasmacytoid dcs. J Leukoc 
Biol 2011, 90, 1177-1190.
30. Wu, P.; Wu, J.; Liu, S.; Han, X.; Lu, J.; Shi, Y.; Wang, J.; Lu, L.; Cao, X. Tlr9/tlr7-triggered 
downregulation of bdca2 expression on human plasmacytoid dendritic cells from healthy individuals 
and lupus patients. Clinical immunology (Orlando, Fla 2008, 129, 40-48.
31. Krug, A.; Veeraswamy, R.; Pekosz, A.; Kanagawa, O.; Unanue, E.R.; Colonna, M.; Cella, M. 
Interferon-producing cells fail to induce proliferation of naive t cells but can promote expansion and 
t helper 1 differentiation of antigen-experienced unpolarized t cells. The Journal of experimental 
medicine 2003, 197, 899-906.
32. Boonstra, A.; Asselin-Paturel, C.; Gilliet, M.; Crain, C.; Trinchieri, G.; Liu, Y.J.; O’Garra, A. Flexibility 
of mouse classical and plasmacytoid-derived dendritic cells in directing t helper type 1 and 2 cell 
development: Dependency on antigen dose and differential toll-like receptor ligation. The Journal 
of experimental medicine 2003, 197, 101-109.
33. Tacken, P.J.; Torensma, R.; Figdor, C.G. Targeting antigens to dendritic cells in vivo. Immunobiology 
2006, 211, 599-608.
34. Schlosser, E.; Mueller, M.; Fischer, S.; Basta, S.; Busch, D.H.; Gander, B.; Groettrup, M. Tlr ligands 
and antigen need to be coencapsulated into the same biodegradable microsphere for the generation 
of potent cytotoxic t lymphocyte responses. Vaccine 2008, 26, 1626-1637.
35. Heit, A.; Schmitz, F.; O’Keeffe, M.; Staib, C.; Busch, D.H.; Wagner, H.; Huster, K.M. Protective cd8 
t cell immunity triggered by cpg-protein conjugates competes with the efficacy of live vaccines. J 
Immunol 2005, 174, 4373-4380.
36. Tel, J.; Beenhakker, N.; Koopman, G.; Hart, B.; Mudde, G.C.; de Vries, I.J. Targeted delivery of 
cpg odn to cd32 on human and monkey plasmacytoid dendritic cells augments ifnalpha secretion. 
Immunobiology 2012, 217, 1017-1024.
|  Chapter 6
146
37. Bave, U.; Magnusson, M.; Eloranta, M.L.; Perers, A.; Alm, G.V.; Ronnblom, L. Fc gamma riia is 
expressed on natural ifn-alpha-producing cells (plasmacytoid dendritic cells) and is required for the 
ifn-alpha production induced by apoptotic cells combined with lupus igg. J Immunol 2003, 171, 
3296-3302.
38. Cao, W.; Zhang, L.; Rosen, D.B.; Bover, L.; Watanabe, G.; Bao, M.; Lanier, L.L.; Liu, Y.J. Bdca2/
fc epsilon ri gamma complex signals through a novel bcr-like pathway in human plasmacytoid 
dendritic cells. PLoS biology 2007, 5, e248.
39. Swiecki, M.; Colonna, M. Unraveling the functions of plasmacytoid dendritic cells during viral 
infections, autoimmunity, and tolerance. Immunological reviews 2010, 234, 142-162.
40. Dzionek, A.; Sohma, Y.; Nagafune, J.; Cella, M.; Colonna, M.; Facchetti, F.; Gunther, G.; Johnston, 
I.; Lanzavecchia, A.; Nagasaka, T., et al. Bdca-2, a novel plasmacytoid dendritic cell-specific type ii 
c-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. 
The Journal of experimental medicine 2001, 194, 1823-1834.
41. Kato, M.; McDonald, K.J.; Khan, S.; Ross, I.L.; Vuckovic, S.; Chen, K.; Munster, D.; MacDonald, K.P.; 
Hart, D.N. Expression of human dec-205 (cd205) multilectin receptor on leukocytes. Int Immunol 
2006, 18, 857-869.
42. Fanger, N.A.; Wardwell, K.; Shen, L.; Tedder, T.F.; Guyre, P.M. Type i (cd64) and type ii (cd32) fc 
gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 1996, 157, 
541-548.
43. Klechevsky, E.; Flamar, A.L.; Cao, Y.; Blanck, J.P.; Liu, M.; O’Bar, A.; Agouna-Deciat, O.; Klucar, 
P.; Thompson-Snipes, L.; Zurawski, S., et al. Cross-priming cd8+ t cells by targeting antigens to 
human dendritic cells through dcir. Blood 2011, 116, 1685-1697.
44. Jensen, T.O.; Schmidt, H.; Moller, H.J.; Donskov, F.; Hoyer, M.; Sjoegren, P.; Christensen, I.J.; 
Steiniche, T. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and 
are associated with pstat3 expression in ajcc stage i/ii melanoma. Cancer 2012, 118, 2476-2485.
45. Tacken, P.J.; Zeelenberg, I.S.; Cruz, L.J.; van Hout-Kuijer, M.A.; van de Glind, G.; Fokkink, R.G.; 
Lambeck, A.J.; Figdor, C.G. Targeted delivery of tlr ligands to human and mouse dendritic cells 
strongly enhances adjuvanticity. Blood 2011, 118, 6836-6844.
46. Pockros, P.J.; Guyader, D.; Patton, H.; Tong, M.J.; Wright, T.; McHutchison, J.G.; Meng, T.C. Oral 
resiquimod in chronic hcv infection: Safety and efficacy in 2 placebo-controlled, double-blind phase 
iia studies. Journal of hepatology 2007, 47, 174-182.
47. Piccioli, D.; Sammicheli, C.; Tavarini, S.; Nuti, S.; Frigimelica, E.; Manetti, A.G.O.; Nuccitelli, A.; 
Aprea, S.; Valentini, S.; Borgogni, E., et al. Human plasmacytoid dendritic cells are unresponsive 
to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for 
maturation. Blood 2009, 113, 4232-4239.
48. Nierkens, S.; den Brok, M.H.; Garcia, Z.; Togher, S.; Wagenaars, J.; Wassink, M.; Boon, L.; Ruers, 
T.J.; Figdor, C.G.; Schoenberger, S.P., et al. Immune adjuvant efficacy of cpg oligonucleotide in 
cancer treatment is founded specifically upon tlr9 function in plasmacytoid dendritic cells. Cancer 
Res 2011, 71, 6428-6437.
49. Kramer, M.; Schulte, B.M.; Eleveld-Trancikova, D.; van Hout-Kuijer, M.; Toonen, L.W.; Tel, J.; de 
Vries, I.J.; van Kuppeveld, F.J.; Jansen, B.J.; Adema, G.J. Cross-talk between human dendritic cell 
subsets influences expression of rna sensors and inhibits picornavirus infection. J Innate Immun 
2010, 2, 360-370.
50. Lou, Y.; Liu, C.; Kim, G.J.; Liu, Y.J.; Hwu, P.; Wang, G. Plasmacytoid dendritic cells synergize with 
myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 
2007, 178, 1534-1541.
Targeting uptake receptors on human pDCs triggers Ag cross-presentation  | 
147
6
SUPPLEMENTARY FIGURES
 
 
 
Supplemental Figure 1: Kinetics of binding and uptake of nanoparticles by pDCs. Human 
pDCs were incubated with NPs containing FITC-labeled TT (FITC-TT) for different time 
periods up to 16 hours at either 4°C or 37°C, washed and analyzed by flow cytometry to 
determine binding (A) and uptake (B) of NPs, respectively. Figures show the percentage of FITC 
positive cells; IL-3 condition was deducted as background from the other samples of the same 
time point. Data show the means ± SEM. 
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pDCs were incubated with NPs containing FITC-labeled TT (FITC-TT) for different time periods up to 
16 hours at either 4°C or 37°C, washed and analyzed by flow cytometry to determine binding (A) and 
uptake (B) of NPs, respectively. Figures show the percentage of FITC positive cells; IL-3 condition was 
deducted as background from the other samples of the same time point. Data show the means ± SEM.
 
 
 
Supplemental Figure 2: Nanoparticles coated with DC-SIGN-antibodies do not confer 
survival stimulus to pDCs. (A) Isolated pDCs were cultured 24 hrs at 37°C with soluble IL-3 or 
antibody-coated NPs containing R848 (and FITC-TT). The forward x sideward scatter 
demonstrates that pDCs survive with IL-3 or when targeted through DEC-205, DCIR, BDCA-2 
or CD32, but a large portion of pDCs dies when DC-SIGN-NPs are added. (B) PBMCs were 
cultured overnight at 37°C in medium with or without antibody-coated NPs containing R848 
(and FITC-TT). A population of pDCs is only detectable for conditions with particles targeted 
through DEC-205, DCIR, BDCA-2 or CD32, but not for DC-SIGN-NPs or medium only.  
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antibody-coated NPs containing R848 (and FITC-TT). The forward x sideward scatter demonstrates 
that pDCs survive with IL-3 or when targeted through DEC-205, DCIR, BDCA-2 or CD32, but a large 
portion of pDCs die when DC-SIGN-NPs are added. (B) PBMCs were cultured overnight at 37°C in 
medium with or without antibody-coated NPs containing R848 (and FITC-TT). A population of pDCs is 
only detectable for conditions with particles targeted through DEC-205, DCIR, BDCA-2 or CD32, but not 
for DC-SIGN-NPs or medium only.
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Supplemental Figure 3: Intracellular cytokine production by blood pDCs incubated with 
nanoparticles in whole PBMCs. Human PBMCs were incubated with NPs containing R848 and 
FITC-TT overnight at 37°C. The next day, cells were washed, stained and analyzed  by flow 
cytometry to determine intracellular IFNα and TNFα in pDCs. 
Supplemental Figure 3 | Intracellular cytokine production by blood pDCs incubated with 
nanoparticles in whole PBMCs. Human PBMCs were incubated with NPs containing R848 and FITC-
TT overnight at 37°C. The next day, cells were washed, stained and analyzed by flow cytometry to 
determine intracellular IFNα and TNFα in pDCs.
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With the studies described in this thesis, we have gained useful insights into the 
functional specialization of human blood plasmacytoid DCs and CD1c+ and CD141+ 
myeloid DCs. Research groups around the world have studied human primary DCs 
from the blood, lymph nodes and different tissues. Due to our goal to use primary 
DCs from the blood for DC-based cancer vaccines, we strive to understand especially 
blood DCs to gain insights into how to improve the vaccines. In this thesis, I have 
therefore directly compared human blood pDCs and mDCs with regard to different 
functions important for their use as cancer vaccines including the induction of T cell 
proliferation, the polarization of naïve CD4+ T cells (chapter 3) and the capacities 
to process and (cross-)present extracellular antigens (chapter 4). We also describe 
a striking difference in the expression and functional role of the immune-inhibitory 
enzyme indoleamine 2,3-dioxygenase 1 (IDO) among the subsets (chapter 5). Finally, 
we have explored the possibility to target pDCs with nanocarriers (chapter 6) that 
could induce maturation while at the same time delivering tumor antigen to the DCs 
for (cross-)presentation and activation of T cells. In this discussion, I will place my own 
work into the context of the current knowledge on pDCs and both mDC subsets in light 
of their use as DC-based cancer vaccines.
PLASMACYTOID DCS IN THE CONTEXT OF CANCER 
IMMUNOTHERAPY
Plasmacytoid DCs are key effectors of innate immune responses due to their capacity 
to produce large amounts of type I IFNs IFN-α and IFN-β in response to bacterial or 
viral infections [1]. Plasmacytoid DCs mainly express TLR7 and TLR9 [2–5], recognizing 
ssRNA and CpG DNA, respectively. These intracellular TLRs therefore signal upon 
encounter with viral RNA, viral DNA or bacterial DNA. Both TLRs signal via MyD88 and 
induce maturation of pDCs. Plasmacytoid DCs can also be matured by ligation of CD40 
by CD40L. T cell polarization induced by pDCs can vary and depends on cues such 
as differential TLR triggering [6]. The maturation and cytokine production of pDCs 
can be induced by TLR agonists such as R848 (TLR 7/8) and different classes of CpG 
(TLR 9) [1,7]. Upon activation with TLR agonists, pDCs upregulate MHC class I and II 
as well as co-stimulatory molecules and the lymph node homing receptor CCR7 [8,9] 
(summarized in [10]). 
By now, a number of studies including our own (chapter 4) have shown that human 
pDCs can cross-present exogenous antigens to CD8+ T cells and that they even 
compare to mDCs in this capacity [9,11–15]. In chapter 4, we demonstrate that 
pDCs take up less soluble and particulate antigens than CD1c+ and CD141+ mDCs, but 
both mDC subsets as well as pDCs induce potent Ag-specific CD4+ and CD8+ T cell 
responses. Furthermore, in our experimental setup pDCs and mDCs cross-presented 
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soluble and cell-associated tumor antigens to cytotoxic T lymphocytes equally well. 
To which extend pDCs are able to phagocytose cell-derived antigens and dead cells, 
is still to be established [16]. However, overall they appear to less efficiently take up 
antigens when compared to human mDCs (chapter 4) [9,16]. Nonetheless, pDCs 
can take up soluble and particulate antigens [17] and receptors expressed by pDCs 
can be targeted (see targeting section). A recent study showed that pDCs can acquire 
membrane patches from cancer cell lines and present acquired antigens on MHC class I 
molecules; this mechanism may allow pDCs to present tumor-derived antigens, despite 
limited properties of phagocytosis [18]. 
The large amounts of type I IFNs that are produced by pDC upon activation, have 
pleiotropic effects on the immune system and initiate and facilitate innate immune 
responses and an anti-viral state, but also support adaptive anti-tumor responses. 
pDCs are able to quickly respond to viral infection with an extensive ER compartment 
that facilitates high-capacity secretion of type I IFNs as well as pre-synthesized stores 
of MHC class I and II to rapidly activate CD4+ and CD8+ T cells [12]. The type I IFNs not 
only promote their own survival as well as phenotypic and functional activation [19], 
but they also induce the upregulation of MHC class I on all cell types [20], activate 
macrophages and NK cells, and are critical for the activation and survival of both CD4+ 
and CD8+ T cells [21–24]. It has been shown in mice that type I IFNs boost cross-
priming of antigen by DCs eliciting strong CD8+ T cell responses [25]. Importantly, the 
presence of IFN-α can restore the immunogenic capacity of human tolerogenic DC 
[26] and type I IFNs also enhance the maturation of mDCs [27] (discussed below). 
Therefore, the IFNs can help skew responses towards a Th1 phenotype and are 
relevant in the context of anti-tumor responses. Figure 1 summarizes pDC functions in 
the context of cellular immunity.
The fact that pDCs are able to induce strong anti-viral responses mediated by effective 
cytotoxic CD8+ T cell responses, already makes them promising candidates for inducing 
effective anti-tumor responses. Plasmacytoid DCs can infiltrate several human tumor 
types including ovarian cancer [28], breast cancer [29], head and neck cancer [30] 
and melanoma [31]. However, the immune inhibitory microenvironment of the tumor 
inhibits pDC differentiation and maturation [32,33]. Anti-tumor responses induced by 
pDCs have been reported in animal models injecting TLR matured pDCs into tumors 
lead to effective and systemic antitumor immunity in a mouse melanoma model [24]. In 
humans, both intra-tumoral injection of CpG (basal cell carcinoma and melanoma) [34] 
or topical application of R848 (basal cell carcinoma) [35] can overcome the inhibition 
exerted by the tumor microenvironment and induce type I IFN responses as well as 
tumor regression. In mice, depletion of pDCs shows a reduction in the frequencies and 
numbers of antigen-specific CD8+ T cells [8]. Although type I IFN production was not 
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impaired and probably taken over by other cell types, involvement in T cell recruitment 
by pDCs via a soluble factor is suggested [8]. Therefore, pDCs exert relevant tasks for 
anti-tumor responses beyond the production of type I IFNs.
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Figure 1: Maturation of moDCs and primary human DCs in the context of cancer 
immunotherapy. Stimulatory signals for human primary blood DCs include PAMPs from bacteria 
and viruses, but also proinflammatory cytokines. For cancer vaccine purposes, they can be matured 
by synthetic TLR ligands imitating natural ligands of TLRs. Monocyte-derived DCs used for DC-cell 
based cancer therapy are matured by proinflammatory cytokines or TLR ligands. TLR ligands mimicking 
viral infections – such as polyI:C (TLR3), R848 (TLR7/8) and CpG (TLR9) – have been proven most 
successful in inducing potent cellular responses. They trigger TLRs and induce maturation of the DCs; 
this increases expression of MHC and co-stimulatory molecules (not depicted) which support efficient 
T cell activation by the DCs. All subsets can cross-present antigen to CD8+ T cells and will direct T 
cell responses by soluble factors. Chemoattractants for immune cells are produced by all subsets. 
Plasmacytoid DCs are potent inducers of type I IFNs, which have pleiotropic effects on many cell types 
including T cells, NK cells and mDCs (cross-talk). Monocyte-derived DCs, CD1c+ mDCs and CD141+ 
mDCs produce IL-12, supporting CD4+ T cell skewing towards a T helper type 1 (Th1) phenotype. 
Mature CD141+ mDCs also produce IFN-λ, further supporting Th1 skewing. NK cells, activated produce 
chemokine (C motif) ligand 1 (XCL1), a chemokine sensed by CD141+ mDCs expressing its receptor 
chemokine (C motif) receptor 1 (XCR1). NK cells thereby attract CD141+ mDCs that are equipped to 
take up and (cross-) present dead cell material and initiate adaptive cellular T cell responses. Together, 
these functions of mature human moDCs and blood DCs allow the induction of potent cellular anti-
tumor responses.
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Expression of the immune-inhibitory enzyme IDO in human pDCs has been described in 
rheumatoid arthritis synovial tissues and peripheral blood of HIV as well as melanoma 
patients [36–40]. Manches et al. showed Treg induction for R848 and HIV matured 
pDCs [37]. In our study on IDO and its functional relevance among human blood DCs 
(chapter 5) [41], we found that human steady-state pDCs and pDCs stimulated with 
CpG-C, R848 or IFN-γ express no or very low levels of IDO. Our finding is in accordance 
with a RNA expression profiling study of steady-state mouse and human DC subsets 
[42,43]. Furthermore, we did not find a functional role for IDO in pDCs with regard to 
T cell proliferation or antigen cross-presentation and the expression levels and activity 
are much lower as compared to mDCs (discussed below). Therefore, although IDO 
seems to be expressed by pDCs in in some human diseases, its functional weight 
compared to especially CD141+ mDCs seems to be limited. Whether there is a role of 
IDO in pDCs concerning the induction of Tregs needs to be further analyzed. 
In our ex vivo study on T cell polarization by human bood DCs (chapter 3) [44] 
we found that neither unstimulated pDCs nor pDCs stimulated with CpG-C or R848 
induced a high proportion of Tregs. However and importantly, steady-state pDCs can 
induce tolerance rather than an immune stimulatory response. The induction of T cell 
anergy and IL-10 producing Tregs by immature pDCs has been described in different 
diseases and tumors (summarized in [8]). For example, pDCs exposed to the tumor 
microenvironment of malignant human ovarian epithelial tumor cells induced IL-10-
producing Tregs rather than T cell activation, thus promoting tolerance instead of anti-
tumor immunity [28]. In 2004, it was found that pDCs mediate tolerance to harmless 
inhaled antigen by inducing Tregs that suppress the generation of effector T cells by 
DCs [45]. To prevent tolerance, it is therefore important to induce maturation of pDCs 
in DC-based cancer vaccination strategies.
MYELOID DCS IN THE CONTEXT OF CANCER IMMUNOTHERAPY
CD1c+ and CD141+ mDCs share some characteristics among which is the important 
capacity of both myeloid DC subsets to produce IL-12 upon TLR3 or TLR8 stimulation [46]. 
This enables the generation of Th1 CD4+ T cells and the priming of naïve CD8+ T cells. 
Both mDC subsets are already equipped with high immune stimulatory capacities 
without any maturation and especially express high levels of MHC molecules, but 
also co-stimulatory receptors [47–49]. While MHC expression is barely affected, TLR 
ligation with polyI:C or R848 significantly increases the expression of co-stimulatory 
molecules such as CD40, CD80, CD83 and CD86 as well as the essential lymph node 
homing receptor CCR7 (summarized in [10]) [46]. CD1c+ mDCs express TLRs 1-6, TLR 
8 and TLR10 [5,46]. TLR3 recognizes dsRNA, an intermediate of viral replication. TLR 
|  Chapter 7
156
8 (and 7) recognizes ssRNA. TLR1, 2 and 6 are triggered by bacterial lipoprotein and 
peptidoglycans, whereas TLRs 4 and 5 recognize the bacterial wall components lipid A 
of lipopolysaccharide and flagellin, respectively. TLR2 is also involved in the recognition 
of fungi. CD1c+ mDCs are therefore equipped to respond to bacterial and fungal PAMPs 
and to a lesser extend also to viral PAMPs. Upon TLR ligation, CD1c+ mDCs can produce 
a variety of cyto- and chemokines including IL-1α, IL-1β, IL-6, IL-8, IL-12, CCL3, CCL4, 
chemokine (C-C motif) ligand 5 (CCL5), chemokine (C motif) ligand 10 (CXCL10), 
TNF-α [46,47,50]. CD141+ mDCs possess a more limited repertoire of TLRs as well as 
cyto- and chemokines compared to CD1c+ mDCs. CD141+ mDCs express TLR1, TLR3, 
TLR6, TLR8 and TLR10 [42,46,48] and especially TLR3 is uniquely highly expressed as 
compared to CD1c+ mDCs and pDCs. TLR3 recognizes retroviral double-stranded RNA, 
which points to an anti-viral function of CD141+ mDCs. Upon TLR3 stimulation, CD141+ 
mDCs produce differing levels of IL-6, IL-8, IL-12, CCL5, CXCL10, TNF-α, IFN-β, and 
IFN-λ [15,46,48,51–53]. 
The chemokines expressed by both mDC subsets are able to attract and activate T 
cells. CCL5 is implicated in chemotaxis and activation of and array of immune cells 
including T cells and NK cells [24,54,55]. CXCL10 is a potent chemoattractant for 
activated T cells in mice [56]. IL-8 is a central chemoattractant stimulus for immune 
cells. Therefore, both mDC subsets play a role in recruiting and activating immune cells 
to the sight of inflammation.
In addition to TNF-α and IL-6, cytokines produced by both mDC subsets, CD1c+ 
mDCs produce two other mediators of inflammation, namely IL-1α and IL-1β. On the 
other hand, CD141+ mDCs exclusively produce IFN-λ [52], a cytokine associated with 
anti-viral effects. Furthermore, human CD141+ mDCs can produce IFN-β upon TLR3 
stimulation [46] and in a humanized mouse model, CD141+ mDCs produced significant 
levels of IFN-α [57]. This capacity to produce type I IFNs, once more underline their 
anti-viral capacities.
Importantly, IL-12 can be produced by both mDC subsets. Initially, it has been assumed 
that CD1c+ mDC produce more IL-12 than CD141+ mDCs [46]. Some studies have 
shown that in order to induce strong IL-12 responses in human and mouse DCs, both 
an innate trigger such as TLR ligation and a second trigger like ligation of CD40 by 
CD40L on T cells is needed [46,52,58]. A synergistic effect in the induction IL-12 and 
of potent Th1 responses by different combinations of TLR ligands has been described 
for mouse DCs and human moDCs [59,60]; examples include the combination of 
R848 with LPS or polyI:C. More recently, it has been shown for CD1c+ mDCs, that the 
combination of the TLR ligands R848 and LPS can trigger significant IL-12 production 
[47]. In the case of CD141+ mDCs, polyI:C stimulation of whole blood or a cocktail of 
polyI:C together with for example IFN-γ, TNF-α, IFN-α, and IL-1β for isolated cells, was 
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shown to induce significant levels of IL-12 in CD141+ mDCs [46,48,51]. In chapter 3,
we support the notion that a single stimulus is not sufficient to induce high IL-12 
production, especially for CD141+ mDCs. Similar to the findings in moDCs [59,60], we 
found that the combination of polyI:C and R848 can trigger substantially higher IL-12 
secretion by both human mDC subsets than each stimulus alone [44].
It is interesting to note that both CD1c+ and CD141+ mDCs react strongly and in a 
similar way to polyI:C, although the expression levels of TLR3 are much higher in 
CD141+ mDCs than in CD1c+ mDCs [46]. Likely, other receptors for polyI:C contribute 
to the response in one or both of the mDC subsets. The synthetic dsRNA analog is 
a ligand for multiple pathogen recognition receptors, and besides TLR3 also triggers 
cytosolic RIG-I-like receptors that are expressed by mDCs [61,62]. Perrot et al. suggest 
in a study on mDCs and NK cells that both TLR3 stimulation as well as RIG-I-like 
receptor ligation is needed for IFN-γ induction by mDCs [63].
Both blood mDC subsets can cross-present soluble and tumor lysate-derived exogenous 
antigens to CD8+ T cells. In contrast to mouse DC subsets, in which CD8α+ DC seem to 
be clearly superior cross-presenters as compared to CD8α- DCs, for human mDCs the 
situation is less clear cut. While some publications suggest that the different human 
blood DCs subsets compare in their cross-presentation capacity (chapter 4) [9,49], 
several studies show superior cross-presentation capacity of CD141+ mDCs and put 
them forward as the human counterparts of mouse CD8α+ DCs [48,64,65,53,51]. The 
type and size of the antigen as well as the compartments the antigen is targeted 
to probably underlie these differing outcomes. For example, targeting antigens to 
early endosomal compartments in CD141+ mDCs, diminishes their superior cross-
presentation capacities [49]. Importantly, CD141+ mDCs in these studies are activated 
with polyI:C, which boosts their cross-presentation capabilities. While tissue mDCs 
(tonsil, dermis) do not need maturation to cross-present [53,66,67], blood mDC cross-
present only if matured with polyI:C or a combination of polyI:C and R848 (chapter 
4) [9,46,48,51,53,67]. 
Just as for pDCs, the response mDCs will induce depends on the cues they receive from 
their environment. As an example, an immunoregulatory phenotype and function was 
demonstrated for CD1c+ mDCs after bacterial stimulation with E. coli [68]. However, 
multiple studies – including our study described in chapter 3 – demonstrate that both 
matured blood CD1c+ and CD141+ mDCs are equipped to induce Th1 CD4+ T cell and 
CD8+ T cell responses [44,46–48,53,67]. Segura et al. show, that in contrast to lymph 
node resident and migratory DCs, blood DCs induced efficient Th1 polarization, but 
poor Th2 polarization [67].
In chapter 5 we report a striking difference in expression and functionality of the 
immune inhibitory molecule IDO in human blood DC subsets [41]. We found that in 
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steady state, IDO is expressed by CD141+ mDCs, but not CD1c+ mDCs or pDCs. IFN-γ 
or TLR ligation further increase the expression levels in CD141+ mDCs and induce 
lower expression in CD1c+ mDCs, but not in pDCs. The enzyme is functionally active 
in CD141+ mDCs and to a lesser extend in CD1c+ mDCs, closely reflecting expression 
levels. CD1c+ mDCs have been shown to express enzymatically active IDO in response 
to prostaglandin E2, LPS, Escherichia coli and to a lesser extend also to polyI:C 
[68,69]. We found that IDO activity in mDCs inhibits T cell proliferation. The activity 
of the immune-inhibitory enzyme IDO in CD141+ mDCs seems counterintuitive, as we 
think of them as the homologue of mouse CD8α+ DCs, professional antigen cross-
presenters that can trigger strong antiviral and anti-tumor responses. However, in 
peripheral tissues, CD141 expressing DCs show potential signs of immune-inhibition 
[70–72]. In contrast, CD141+ mDCs show many immune-stimulatory characteristics 
as their expression of co-stimulatory molecules in steady-state and upon maturation 
[48,49] and their induction of proliferation of naïve CD4+ T cells and can cross-prime 
CD8+ T cells  [9,15,66,72]. Also, we could show, that CD141+ mDCs do not induce a 
higher proportion of Tregs than CD1c+ mDCs or pDCs under tryptophan rich conditions 
(chapter 3) [44]. 
Interestingly, IDO activity in CD141+ mDCs might not serve to inhibit immune responses, 
as IDO activity seems to have a boosting effect cross-presentation in CD141+ mDCs 
(chapter 5) [41]. IDO activity could therefore possibly contribute to the superior 
cross-presenting ability of CD141+ mDCs. It will be interesting to further investigate 
the exact role of IDO in cross-presentation of especially CD141+ mDCs. Importantly the 
role of IDO in Treg induction by both mDC subsets should still be carefully addressed. 
CD141+ mDCs are well equipped to take up material from dead and necrotic cells 
for subsequent cross-presentation of derived antigens to CD8+ T cells. Like mouse 
CD8α+ DCs, they almost exclusively express the CLR CLEC9A, which is an endocytic 
receptor involved in the sensing and presentation of antigens derived from necrotic 
cells [73,74]. PolyI:C activated human CD141+ mDCs were shown to cross-present 
antigen from necrotic cells [48,51]; although both mDC take up dead cell material, only 
CD141+ mDCs could cross-present antigen efficiently to CD8+ T cells [48]. 
Another link between human CD141+ mDCs and mouse CD8α+ DCs is the chemokine 
(C motif) receptor 1 (XCR1), which is exclusively expressed by these subsets [64,65]; 
it is the receptor for the chemokine XCL1 that is produced especially by activated NK 
and CD8+ T cells. Activated NK and CD8+ T cells therefore attract the subset specialized 
in cross-presenting dead cell material [64]. XCR1 knock-out mice have decreased early 
CD8+ T cell responses to the intracellular pathogenic bacteria Listeria monocytogenes 
infection [65]. 
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In mice, CD8α+ DCs produce IL-12, excel at cross-presentation and polarize naive 
CD4+ T cells toward the Th1 cell phenotype, whereas CD8α- DCs preferentially induce 
Th2 cell responses [75]. As discussed above, comparable characteristics of CD141+ 
mDCs with mouse CD8α+ DCs suggest them to be excellent targets for DC-based 
cancer immunotherapy [51,53,64,65]. Besides Il-12, human CD141+ mDCs selectively 
produce the anti-viral effector IFN-λ [52]. Taken together, this suggests that CD141+ 
mDCs may function as professional cross-presenting DCs that induce efficient CD8+ T 
cell responses against intracellular pathogens and cancer, but promote tolerance for 
controlling auto-immune responses in steady-state. 
However, the functional division between the two human mDC subsets is not as 
outspoken as in mice. Human CD1c+ and CD141+ mDCs can both produce large 
amounts of IL-12 and are both well capable to cross-prime CD8+ T cells [15,46,47]. 
Figure 1 summarizes the functions of primary human blood DCs in the context of 
cellular immunity. Whether it is feasible to isolate the rare subset of CD141+ mDCs 
from apheresis material for ex vivo maturation and antigen loading and subsequent re-
injection into patients, remains to be shown. CD1c+ mDCs on the other hand are much 
more abundant and therefore easier accessible in sufficient numbers and have been 
used in first clinical studies (see section below).
HUMAN PRIMARY DC SUBSETS AS CANCER VACCINES
Primary DCs are hypothesized to be stronger inducers of anti-cancer responses than 
moDCs in cell-based vaccination strategies since they differentiate in vivo and require 
only short ex vivo handling, a process that might negatively affect DCs. Especially IL-4, 
required for the transition of monocytes into immature DCs may hamper their capability 
to migrate [76,77]. The first clinical studies utilizing primary blood DCs have recently 
been conducted, demonstrating the safety and efficacy of primary blood DCs in cancer 
immunotherapy. Late stage melanoma patients vaccinated with ex vivo activated 
and antigen-loaded pDCs showed remarkably improved overall survival compared to 
matched control patients treated with standard chemotherapy as first-line treatment 
[78]. Due to limited availability of clinical grade TLR ligands that activate pDCs, the 
pDCs in this trial were matured with FSME, a preventive vaccine against the tick-borne 
encephalitis virus. PDCs matured with FSME demonstrate a mature phenotype and 
produce large amounts of type I interferons [79,80].
By now, two trials have been conducted with CD1c+ mDCs. Prue et al. vaccinated 
prostate cancer patients with immature, tumor-antigen loaded CD1c+ mDCs [81]. 
Although the administration was safe, no tumor specific immunological responses were 
reported. In another recent trial by our group using CD1c+ mDCs, three out of 14 
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vaccinated metastatic melanoma patients showed functional tumor-specific T cells in 
peripheral blood and post-treatment skin tests, coinciding with improved progression-
free survival and objective clinical responses [82]. In this trial, the CD1c+ mDCs were 
cultured with GM-CSF; a stronger maturation stimulus such as a TLR3 ligand polyI:C 
or TLR7/8 ligand R848 would likely even increase the number and magnitude of 
responses. Since clinical-grade TLR ligands are difficult to obtain [79,83], we recently 
characterized RNA stabilized in a formulation with protamine as a possible clinical 
grade TLR ligand, which induced a mature phenotype and secretion of type I IFNs and 
IL-12 by pDCs and CD1c+ mDCs, respectively [84]. Clinical studies utilizing protamine-
mRNA matured pDCs and CD1c+ mDCs are currently ongoing in patients with prostate 
cancer and melanoma.
For proper CD8+ T cell activation and memory formation, type I IFNs, IL-12 and IFN-γ 
are important players [85]. Matured CD1c+ and CD141+ mDCs can produce IL-12 and 
matured pDCs produce the highest amounts of type I IFNs, and all three subsets can 
induce IFN-γ production by Th1 and other cells. Therefore, simultaneous activation of 
several DC subsets would probably more efficiently raise a strong cytotoxic anti-tumor 
response. Interestingly, pDCs and mDCs can interact with each other and synergize 
via bi-directional cross-talk and this cross-talk is instrumental in increasing anti-tumor 
immune responses (summarized in [86]). Examples include the upregulation of co-
stimulatory molecules on mDCs after selective pDC activation [27] or the recruitment 
and important role of mDCs in pDC mediated anti-tumor responses [24]. Therefore, 
co-administration of properly matured pDCs and CD1c+ mDCs may induce even more 
potent anti-tumor responses than pDCs or mDCs alone. As protamine-RNA complexes 
efficiently mature both pDCs and CD1c+ mDCs, they harbor the potential for the 
combined maturation and use of these subsets, thereby exploiting their functions 
simultaneously. Considering the excellent capacities of mature CD141+ mDCs to prime 
CD8+ T cell responses and their similarity to mouse CD8α+ DCs, utilizing also this subset 
strongly recommends itself.
INDUCING MATURATION OF DC SUBSETS BY IN VIVO TARGETING
To avoid ex vivo handling and its possible negative effects on the cells and also to move 
towards an off-the-shelf approach for activating anti-tumor immunotherapy, several 
research groups pursued the idea to target DCs in vivo. Besides the delivery of antigen, 
the co-administration of maturing agents is pivotal in the context of therapeutic DC-
based vaccinations, as mouse models have shown that the lack of a maturation factor or 
an adjuvant can induce tolerance or a humoral response rather than the desired CD8+ T 
cells response [87,88]. Systemic administration of adjuvants in mice have shown anti-
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tumor effects and acts at least partially via DC maturation [89]. However, this systemic 
administration can cause severe side-effects, and co-localization of target antigen and 
adjuvant drastically improve anti-tumor responses [90]. Approaches for targeted co-
delivery of antigen and maturation agent include coupling antigen to adjuvant and 
possibly to an antibody or co-encapsulation in degradable particles. Particles are very 
versatile and can carry antibodies on the surface to target specific cell subsets and 
several components that become released continuously after intake and digestion by 
the target cell. 
Initial efforts strived to target DEC-205 [91] and by now, the efficacy of targeting DCs 
via DEC-205 is shown in numerous mouse and human ex vivo models (summarized in 
[92]). Since then, many other options have been explored for DC targeting. Particles 
co-delivering antigen and adjuvant have been successfully targeted to mouse and 
human DCs; the co-delivery of TLR ligands herein strongly enhanced adjuvanticity 
[93]. Cargo is often targeted to uptake receptors, deploying their capacity to deliver 
their ligands into the cell. Cohn et al. give an overview of endocytic receptors that have 
been studied in primary human DC subsets, indicating the intracellular compartment 
they target and their ability to deliver antigen to MHC class I and/or MHC class II 
pathways [94]. These receptors with varying cell type specificity are CD11c, CD32 
(FcγIIa), CD40, CD205 (DEC-205), CD206, CD207 (Langerin), CD209 (DC-SIGN), 
CD303 (BDCA-2) [95], CLEC4A (DCIR), CLEC9A (DNGR1) and Dectin-1. In chapter 
6, we investigated which receptor can best be deployed to deliver Ag to pDCs for Ag 
(cross-) presentation [95]. We could show that targeting nanoparticles to pDCs via 
DEC-205, DCIR, CD303, or CD32 led to uptake, processing, and (cross-)presentation 
of encapsulated antigen to both CD4+ and CD8+ T cells. The co-encapsulated TLR7 
agonist R848 efficiently activated pDCs, resulting in phenotypical maturation as well 
as robust IFN-α and TNF-α production. This is noteworthy, since we and others have 
shown that the cross-linking of uptake receptors can modulate TLR-induced signaling 
and cross-linking DEC-205, DCIR, or CD303 can impair TLR triggered  IFN-α  and/or 
TNF-α production [96–98].
Depending on the receptor, a certain subset or group of cells will be targeted. A 
combination of several targets would simultaneously make use of specific characteristic 
of the targeted subsets. Also depending on the targeted receptor, the cargo such as 
antigen and a possible maturation factor, will be enriched in certain compartments 
of the cell. This can affect the availability of the antigen to MHC class I presentation 
pathways and the maturation agent to its cognate receptor. Some receptors route their 
cargo to early endosomes in which antigen is slowly digested, leading to prolonged 
MHC class I presentation to CD8+ T cells [49,99,100]. In CD141+ mDCs, targeting 
late endosomal compartments via DEC-205 however favors cross-presentation, while 
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targeting early endosomal compartments via CD11c or CD40 diminishes their superior 
cross-presentation capacities compared to other human DC subsets [49]. This hints to 
a more efficient escape of antigens from late endosomes into the cytosol in CD141+ 
mDCs.
Nanoparticles containing antigen and adjuvant and covered with antibodies that bind 
different uptake receptors (DEC-205, DCIR, CD303 and Dectin-1) or the Fcγ receptor 
CD32, can all be delivered to pDCs inducing maturation, cytokine production and 
delivering the antigen to MHC I and II pathways [95,101] Fcγ receptors can also be 
targeted on CD1c+ as well as CD141+ mDC. While antigen is more efficiently taken up 
by CD1c+ mDCs, only CD141+ mDCs show improved cross-presentation by Fcγ receptor 
targeting [102]. Targeting antigen to mouse CD205 and simultaneously maturing 
DCs protected against a subsequent challenge with tumor cells [103]. Furthermore, 
vaccination with the same strategy after establishment of a tumor could inhibit further 
outgrowth of the tumor. Two mouse model studies underline the importance of CD8α+ 
DCs - and therefore CD141+ mDCs - as powerful targets for DC-based vaccination 
strategies. Targeting CD8α+ DCs via XCR1 (fusion protein of influenza A antigen and 
the XCR1 ligand XCL1), induced CD8+ T cell responses, Th1 CD4+ T cell responses and 
importantly protected mice against a lethal challenge with influenza A virus [104]. XCR1 
is exclusively expressed on mouse CD8α+ DCs and human CD141+ mDCs. Importantly, 
targeting CLEC9A on CD8α+ DCs efficiently induced CD8+ T cell responses [105,106] 
and when combined with an adjuvant could both prevent the development as well 
as mediate the eradication of B16 melanoma lesions. Antigen targeted to CLEC9A on 
human CD141+ mDCs is presented to both CD4+ and CD8+ T cells and induces a strong 
IFN-γ response when combined with a maturation agent [107]. The plasticity of mDC 
and the importance for the use of adjuvants was nicely demonstrated in a mouse study 
in which CLEC9A was targeted either with antigen alone or combined with different 
adjuvants. Antigen delivery alone induced Tregs, whereas curdlan induced Th17 cells 
and polyI:C strong IL-12 dependent Th1 response [108].
ACHIEVEMENTS OF THIS THESIS 
In this thesis, I have gained valuable insights into the functional specialization of 
plasmacytoid DCs and CD1c+ and CD141+ myeloid DCs. By directly comparing the 
subsets side-by-side, earlier findings have been put into a new perspective. Examples 
include the polarizing capacities and regulatory T cell (Treg) induction (chapter 3), 
antigen uptake, processing and cross-presentation capacities (chapter 4) as well as 
the expression and functional relevance of IDO (chapter 5) among the subsets – a 
process that had not been studied in human DC subsets to date. In chapter 3, we 
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describe a new combination of triggers for CD141+ mDCs that can induce efficient IL-12 
production. This finding is relevant, since IL-12 is such a key player in the induction of 
Th1 immune responses. The notion that two separate triggers are needed for efficient 
IL-12 production had already been described for moDCs and CD1c+ mDCs, but not for 
CD141+ mDCs. 
In my opinion, the notion that none of the three subsets induced a relevant proportion of 
Tregs is of high importance for their application in DC-based cancer vaccines (chapter 
3). As the possible induction of Tregs is relevant to DC-based vaccines, it is important 
to further investigate the possible induction of these cells in low tryptophan conditions. 
Our comparing study that found low levels of Tregs for all subsets was performed in 
tryptophan rich medium (chapter 3), reflecting levels in peripheral blood. In tissues 
however, the concentration of tryptophan could be locally lowered by IDO activity 
by the subsets - especially CD141+ mDCs and to a lesser extend also CD1c+ mDCs. 
Therefore, we need to further study Treg induction mediated by IDO in low tryptophan 
environments that could be present in lymph nodes. Although IDO activity has been 
described for pDCs in other studies, we find that this activity is much lower than for the 
mDC subsets and seems to be less functionally relevant in this subset (chapter 5). In 
this study on IDO, we further lay a new link between the expression of this enzyme 
known for its immune-suppressive function and a possible boosting effect of cross-
presentation in CD141+ mDCs. Our studies so far point to a mechanism via starvation 
induced autophagy, but further research is needed to confirm the boosting effect on 
cross-presentation and its exact mechanism.
Our study on antigen uptake, processing and cross-presentation capacities (chapter 4) 
was one of the studies establishing the capacity of pDCs to cross-present extracellular 
antigens to CD8+ T cells, a process only attributed to mDCs in the past. We also further 
underlined the superior capacity of mDCs to take up antigens compared to pDCs. 
In our experimental setting, al subsets performed equally well in cross-presenting 
antigens. However, mDCs might be better equipped to take up antigen from dead or 
damaged cells such as cancer cells. This could only be realized in a direct comparing 
study as performed here. 
In chapter 6 [95], we could show that targeting nanoparticles to pDCs for (cross-)
presentation of encapsulated antigen is feasible. Besides delivering antigen for 
presentation to T cells, the co-encapsulated TLR7 agonist R848 efficiently activated 
pDCs, resulting in phenotypical maturation as well as robust IFN-α and TNF-α 
production. This is important, since we and others have shown that the cross-linking 
of uptake receptors can impair TLR triggered IFN-α and/or TNF-α production. Our 
findings therefore show the feasibility for targeting strategies in human DCs and a way 
to deliver antigen without hampering cytokine production. Further analysis in both mDC 
|  Chapter 7
164
subsets is called for and also in vivo distribution of nanoparticles and effectiveness will 
have to be studied in detail in the future.
FUTURE PERSPECTIVE
In the recent years, more insight has been gained about the best possible maturation 
of the subsets and their differences in terms of antigen-processing and -presentation, 
cytokine production and T cell stimulatory capacity. We know that the use of proper 
adjuvants is crucial in inducing potent T cell responses. Mouse models are a necessary 
and valuable tool to gain many insights into the functioning of vaccine mechanisms. A 
major challenge, however, remains to translate DC-based vaccine strategies developed 
in mice to humans. There are substantial differences between the mouse and human 
immune systems and the exact equivalent of each mouse DC subsets in humans is not 
yet established. For example, the use of mouse models to study and select adjuvants 
for human vaccines and targets for targeting strategies is limited because the pattern of 
expression of TLRs and various receptors per DC subset can significantly differ between 
the two species. Overall, the division of labor between human blood CD141+ DCs and 
CD1c+ mDCs appears less sharply demarcated than between CD8α+ and CD8α- DCs 
in the mouse. CD1c+ mDCs should not be easily discarded for DC-based vaccination 
strategies, since - unlike CD8α- DCs - they can produce large amounts of IL-12 and 
are well capable to cross-prime CD8+ T cells [15,46,47]. Therefore, further studies 
into the functional specializations of different DC subsets are called for and ongoing. 
As discussed above, the combination of several DC subsets would probably more 
efficiently raise a strong cytotoxic anti-tumor response, exploiting important capacities 
of each subsets and harnessing synergizing effects via bi-directional cross-talk.
Analysis of the immune response to successful human viral vaccines that induce 
potent CD8+ T cell responses could help further determine the mechanisms that 
control immune responses to vaccination and identify predictors of vaccine efficacy. 
A successful example of such an approach is a study on the yellow fever vaccine. The 
researchers found that the potent CD8+ T cell responses and protection induced by this 
vaccine are at least in part attributed to autophagy induced by the vaccine that boosts 
cross-presentation of DCs [109].
Another crucial question at present is whether targeting specific DC subsets is more 
efficient than using well-formulated protein-based or particle-based vaccines with 
potent TLR adjuvants. Future studies need to compare these approaches using 
antigens from tumors that are more physiological antigens than ovalbumin, as these 
provide greater predictive value before advancing to human studies. 
Since a kaleidoscope of factors determine the actual final outcome of a response, 
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including in vivo factors that are not present ex vivo, we will only know which choice 
of antigens, combination of adjuvants, combination of DC subsets and concomitant 
treatments such as chemotherapy, ablation therapy or agents releasing local 
immunosuppression at the tumor site is best after testing them in vivo. Antigens should 
be immunogenic and ideally only be highly expressed by the tumor. Neoantigens are 
antigens only expressed by tumor cells and are created by DNA mutations in tumor 
cells. Such antigens can induce strong immune responses, since they are recognized as 
foreign and as such T cell specific for these antigens will not be affected by tolerogenic 
mechanisms that inhibit specific T cells that recognize self-antigens. Importantly, the 
combination of DC-based cancer vaccines with agents inducing temporary tumor 
regression or releasing local immunosuppression at the tumor site holds the promise of 
making the successful induction of T cell responses strong enough to tip the balance 
towards cancer immunity [110,111]. As targeted therapies can induce rapid tumor 
regressions and a decrease in tumor-associated immunosuppression, they may afford 
a favorable window for immunotherapy to achieve more potent cellular immunity 
[112]. Checkpoint inhibitors such as ipilimumab (anti-CTLA-4 antibody), nivolumab 
(anti-programmed cell death 1 (PD-1)) or pembroluzimab (anti-PD-1 receptor) have 
already successfully entered the clinic as anti-cancer treatments. A small first study 
combining DC vaccination with ipilimumab treatment in melanoma suggests that such 
combinations can be beneficial in treating cancer patients [113]; the results of further 
combination studies with DC vaccines are eagerly awaited. 
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NEDERLANDSE SAMENVATTING 
De functie van dendritische cellen in het afweersysteem 
Dendritische cellen (DC) spelen een centrale rol in het immuunsysteem. Zij controleren 
het lichaam voortdurend op de aanwezigheid van ziekteverwekkers. Dendritische cellen 
zijn betrokken bij de eerste directe reactie tegen ziekteverwekkers via het aangeboren 
(aspecifieke) immuunsysteem en maken ook deel uit van het adaptieve (verworven) 
immuunsysteem. Adaptieve immuniteit is specifiek gericht tegen een ziekteverwekker 
en de herkenning gebeurt via kleine stukjes van de ziekteverwekker, de antigenen, 
die specifiek door cellen van het adaptieve immuunsysteem kunnen worden herkend. 
Er ontstaat immunologisch geheugen na een eerste reactie op een bepaald antigen. 
Dit proces van verworven immuniteit is de basis van vaccinatie. Dendritische cellen 
kunnen bijvoorbeeld ziekteverwekkers opnemen en celresten die afkomstig zijn van 
virus geïnfecteerde cellen of kankercellen. Na opname kunnen DC de antigenen 
van de ziekteverwekker op hun oppervlak presenteren aan cellen van het adaptieve 
immuunsysteem. Daarom worden het ook wel antigeen-presenterende cellen (APC) 
genoemd. Zodra ze een ziekteverwekker of dood celmateriaal hebben opgenomen 
worden DC geactiveerd en migreren zij via lymfevaten naar de lymfeklieren. Hier 
presenteren zij de antigenen aan CD4+ en CD8+ T lymfocyten. De T lymfocyten 
die het antigen herkennen gaan delen en rijpen uit tot actieve mediatoren van de 
immuunreactie. T cellen herkennen dus specifiek een antigen, waarbij CD4+ T 
lymfocyten een ondersteunende rol spelen en bepalen of er een humorale (gemedieerd 
door antilichamen) of een cellulaire respons gemedieerd door CD8+ T lymfocyten wordt 
opgewekt.
Dendritische cellen als kankervaccins
Door de centrale rol, die DC in het adaptieve immuun systeem spelen, zijn zij bij uitstek 
geschikt als therapeutische vaccins tegen kanker. Het doel van kanker immunotherapie 
met DC is om een antigeen specifieke cytotoxische CD8+ T cel respons op te wekken 
tegen antigenen op de tumor en door deze cellulaire immuniteit kankercellen te 
elimineren. Bij immunotherapie met DC worden hiervoor DC van een patiënt uit het 
bloed geïsoleerd, buiten het lichaam geactiveerd en beladen met stukjes van de tumor 
en vervolgens teruggegeven aan de patiënt.
Hoewel na DC vaccinatie van patiënten met kanker in verschillende studies 
immuunreacties tegen tumor antigenen konden worden aangetoond in gevaccineerde 
patiënten, is het klinisch succes van DC vaccinatie tot nu toe beperkt. Dit wordt 
gedeeltelijk veroorzaakt door de lokale onderdrukking van de immuuncellen door de 
tumor. Optimale activatie van de DC kan helpen deze lokale  onderdrukking van de 
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immuunreactie te overwinnen. Vanwege de beperkte beschikbaarheid van menselijk 
weefsel en bloed DC, is een groot deel van onze kennis afkomstig van muismodellen 
en uit monocyten gekweekte DC (moDC). Vrijwel alle klinische DC vaccinatiestudies 
zijn met ex vivo gegenereerde moDC uitgevoerd. Door de recente ontwikkeling 
van efficiënte isolatietechnieken is het gebruik van primaire humane DC uit het 
bloed voor kanker vaccins binnen bereik gekomen. Van primaire DC wordt gedacht 
dat ze sterkere anti-kanker-immuunreacties induceren dan moDC omdat ze in vivo 
differentiëren en daardoor slechts een korte ex vivo behandeling nodig is. Ook voor 
kankerimmunotherapie met primaire bloed-DC is een optimale activatie van de DC 
essentieel om voldoende robuuste en duurzame T cel reacties te induceren, die de 
lokale onderdrukking van het immuunsysteem door de tumor kunnen overwinnen en 
tot tumorregressie of zelfs totale vernietiging van de tumor kunnen leiden. Om de T 
cel activatie door vaccinatie met DC beter te kunnen manipuleren, is een betere kennis 
van de primaire humane DC subpopulaties en hun functionele specialisatie essentieel.
Humane dendritische cel subpopulaties
In humaan perifeer bloed komen twee verschillende subpopulaties van  DC voor: 
myeloïde DC en plasmacytoïde DC (figuur 1). Myeloïde DC (mDC) kunnen verder worden 
onderverdeeld op basis van de expressie van CD1c of CD141. DCs zijn zeldzaam in 
perifeer bloed. maken Slechts ~0,6% en ~0,3% uit van alle mononucleaire cellen van 
het perifere bloed bestaat uit CD1c+ mDC en pDCs . CD141+ mDC zijn nog zeldzamer 
en vertegenwoordigen slechts ~0,03% van alle mononucleaire cellen van het perifere 
bloed. Verschillen in eiwitexpressie, het repertoire van Toll-like receptoren (TLRs – 
herkennen ziekteverwekkers) en uitgescheiden cytokines (stoffen uitgescheiden door 
cellen met specifieke effecten op andere cellen), suggereren dat de DC subpopulaties 
gespecialiseerde functies hebben in het immuunsysteem. Myeloïde DC produceren 
bijvoorbeeld na activatie het cytokine interleukine-12, een belangrijke stof in de inductie 
van cellulaire immuniteit. Plasmacytoïde DC produceren na activatie veel IFN-α, dat 
onder ander een belangrijke rol speelt in anti-virale afweerreacties (figuur 1).
Bevindingen van dit proefschrift
Onderzoeksgroepen over de hele wereld bestuderen humane primaire DC uit het 
bloed, lymfeklieren en verschillende weefsels. Omdat wij primaire DC uit het perifeer 
bloed willen gebruiken als kankervaccins, streven wij naar een beter begrip van de 
verschillende bloed DC subpopulaties om de DC vaccins verder te kunnen verbeteren. 
In dit proefschrift heb ik dan ook humane bloed pDCs en mDC direct met elkaar 
vergeleken met betrekking tot de verschillende functies die belangrijk zijn voor 
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hun gebruik als kankervaccins. Deze functies omvatten onder andere de polarisatie 
en activatie van CD4+ en CD8+ T lymfocyten (hoofdstuk 3) en de capaciteit om 
antigenen op te nemen, te verwerken en te presenteren aan T lymfocyten (hoofdstuk 
4). Verder beschrijf ik een uitgesproken verschil tussen de DC subpopulaties in de 
expressie en activiteit van het tryptofaan-afbrekende en immuunsysteem-remmende 
enzym indoleamine 2,3-dioxygenase 1 (IDO) (hoofdstuk 5). Daarnaast hebben we 
onderzocht of we nanodeeltjes kunnen gebruiken om pDC te activeren en met tumor 
stukken te beladen (hoofdstuk 6). Deze nanodeeltjes zouden dan in toekomst direct 
als vaccin kunnen worden ingezet. 
TLRs 
type I IFNs 
TLRs 
IL-12 
CD141+ mDC 
TLRs 
CD1c+ mDC 
IL-12 
Plasmacytoïde dendritische cellen Myeloïde dendritische cellen 
Figure 1: Humane dendritische cel subpopulaties. In humaan perifeer bloed komen twee 
verschillende subpopulaties van  DC voor: plasmacytoïde DC en myeloïde DC. Myeloïde DC (mDC) 
kunnen verder worden onderverdeeld op basis van de expressie van CD1c of CD141 en worden CD1c+ 
en CD141+ mDC genoemd.
In dit proefschrift heb ik nuttige inzichten verkregen in de functionele specialisatie van 
humane bloed DC subpopulaties. In hoofdstuk 3 beschrijf ik een nieuwe combinatie van 
stimulatiefactoren die efficiënte IL-12 productie door CD141+ mDC kan induceren. Dit 
is relevant, aangezien IL-12 een centrale speler in de inductie van cellulaire immuniteit 
is. Het idee dat twee afzonderlijke triggers nodig zijn voor efficiënte IL-12 productie 
was reeds beschreven voor moDC en CD1c+ mDC, maar niet voor CD141+ mDC. 
Verder heb ik in hoofdstuk 3 laten zien, dat geen van de drie DC subpopulaties een 
relevante populatie regulatoire T cellen (Treg) induceert. Omdat Treg immuunreacties 
kunnen remmen, is deze bevinding van groot belang voor de toepassing van DC als 
kankervaccins. De lage inductie van Treg, die ik in hoofdstuk 3 voor alle subpopulaties 
heb beschreven, werd gevonden in experimenten met tryptofaan-rijk medium dat een 
concentratie tryptofaan bevat die vergelijkbaar is met de concentratie in perifeer bloed. 
In weefsels en lymfeklieren zou de concentratie tryptofaan lokaal echter verlaagd 
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kunnen worden door activiteit van IDO in de DC. Omdat de mogelijke inductie van Treg 
een grote invloed heeft op de door DC-geïnduceerde immuunreacties, is het belangrijk 
om de mogelijke inductie van Treg onder tryptofaan-arme omstandigheden verder te 
onderzoeken. Hoewel IDO activiteit voor pDC was beschreven in andere studies, vinden 
we dat IDO activiteit veel lager is in pDC dan in mDC – vooral CD141+ mDC – en dat IDO 
functioneel minder relevant lijkt te zijn in pDC (hoofdstuk 5). Terwijl dit op het eerste 
oog op een immuunsuppressieve activiteit van mDC lijkt te wijzen – IDO staat eigenlijk 
bekend om zijn immuunsuppressieve functie – heb ik in immunologisch functionele 
experimenten geen immuunsuppressieve werking van de mDC aangetoond. Ik leg in 
deze studie naar de rol van IDO in DC subsets juist een nieuw verband tussen de 
expressie van dit enzym en een mogelijke simulerend effect op antigen presentatie in 
CD141+ mDC. Mijn onderzoek wijst tot nu toe op een mechanisme via autofagie, maar 
verdere analyses zijn nodig om het stimulerende effect van IDO op antigen presentatie 
en het mechanisme ervan te bevestigen. Onze vergelijkende studie over de capaciteit 
van de DC subpopulaties om extracellulair antigen op te nemen, te verwerken en 
te presenteren aan CD8+ T lymfocyten (hoofdstuk 4), was één van de studies, die 
het vermogen van pDC voor deze presentatie aan CD8+ T lymfocyten heeft kunnen 
aantonen - een proces dat in het verleden alleen toegeschreven werd aan mDC. We 
hebben ook kunnen bevestigen dat mDC beter zijn in het opnemen antigenen dan pDC. 
In hoofdstuk 6 hebben we laten zien dat het mogelijk is, om voor de activatie van 
pDC en het beladen van pDC met tumor antigenen nanodeeltjes te gebruiken. Hierbij 
hebben we geen nadelige effecten geconstateerd van de nanodeeltjes op de pDC en 
blijven belangrijke functies van de pDC intact. 
De bevindingen van dit proefschrift bevestigen de geschiktheid van primaire humane 
bloed DC als  kankervaccins. De verworven kennis zal helpen, de functies van de 
verschillende DC subpopulaties beter te begrijpen. Door de directe vergelijking van de 
subpopulaties, werden niet alleen nieuwe inzichten verkregen, maar zijn bestaande 
inzichten ook bevestigd, uitgebreid of in een nieuw perspectief geplaatst. Dit zal helpen 
deze cellen in toekomstige klinische studies toe te passen.
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